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Prostate cancer (PCa) is the most common cancer among men in Western developed 
countries. While the majority of PCa diagnosed by PSA screening are indolent, advanced 
and metastatic disease has a significant mortality and morbidity. Bone metastases are 
extremely common in PCa and identification of bone metastasis associated genes may 
provide insights into PCa progression and assist in finding new drug targets. However, 
the genetic study of bone metastases is very limited due to the difficulty of sampling.  
We performed genome-wide analysis of six fresh frozen PCa bone metastases. We 
found several alterations commonly present in advanced PCa, including gains at: 1q32.1, 
broad gains of 8q (MYC, NCOA2), 9q33.2-34.3, 11q13.1-14.1 (CCND1), 12q24.23-
24.31, 16p13.3, 16p12.1-11.2 and Xq12-13.1 (AR) as well as losses at: 5q11.1-22.1, 
5q14.3-23.1, 6q14.1-22, 8p23.2-p21, 13q13.2-31.1 (RB1), 17p13.1-12 (TP53) and 
18q11.1-22.3. Two cases also showed PTEN loss and one sample had deletion 
indicative of TMPRSS2-ERG fusion.  
For downstream analysis we concentrated on CCND1 oncogene at 11q13 and FBXL4 
at 6q16 as potential drivers of these genomic changes. Using fluorescence in situ 
hybridisation we found common CCND1 gain and FBXL4 loss in PCa bone metastases 
(54.5%, 12/22 and 47.8%, 11/23, respectively), much less frequent in primary tumours 
(7%, 10/142 and 13.8%, 20/145, respectively) and absent in BPH cases (0/55). The 
expression levels of cyclin D1 protein, coded by CCND1 correlated with CCND1 copy 
number gain (p < 0.0001) and were higher in metastatic tumours than in primary PCa (p 
= 0.015), confirming cyclin D1 involvement in advanced PCa.  
Presence of FBXL4 loss in early stage primary PCa strongly correlated with current PCa 
prognostic markers and with worse patient survival. Therefore, we propose that FBXL4 
may be a tumour suppressor gene in prostate, whose loss in early PCa could be 
indicative of more aggressive disease. Using in vitro experiments we demonstrated that 
FBXL4 regulates cells motility and invasion. We confirmed that ERLEC1, an ER lectin 
involved in ER stress response pathway is a degradation target of FBXL4. As activation 
of ER stress response pathway is linked to enhanced cell migration and invasion, loss of 
FBXL4 could be one of the mechanisms by which cancer cells increase their efficiency 
to respond to stress and to escalate their metastatic potential through stabilisation of 
ERLEC1. Further studies of FBXL4 – ERLEC1 axis are necessary to establish how they 
contribute to PCa progression. This knowledge can potentially help to develop novel 
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1 Introduction and Aims 
1.1 Prostate cancer 
1.1.1 The prostate anatomy and origin of prostate cancer 
The prostate gland is size of a walnut. It surrounds the urethra just below the urinary 
bladder and can be felt during a rectal examination. Prostate produces and secretes fluid 
that nourishes and protects sperm [1]. Four basic anatomic regions can be distinguished 
in adult prostate (Figure 1). The transition zone surrounds the urethra and constitutes 
about 5-10% of the mass of the glandular prostate. Benign prostatic hyperplasia (BPH) 
develops here but also 10-15% of prostate cancers (PCa). The central zone accounts 
for 20-25% of the prostate, lies below the proximal urethral segment and contains the 
ejaculatory ducts. 15-20% of cancers develop in this zone. The peripheral zone includes 
70-75% of the prostate and surround the central zone laterally, occupying the apical 
region of the prostate. Most PCa cases (about 70%) begin in the peripheral zone [2, 3]. 
PCa often presents as multicentric lesions located in different zones of the prostate and 
typically of different grades [4, 5].  
 
FIGURE 1 DIFFERENT ANATOMICAL ZONES OF PROSTATE GLAND. Adapted from 
Crawford et al [3]. 
 
Histologically, the normal prostate consists of glandular epithelium and fibromuscular 
stroma. The glandular epithelium is composed of two cell layers: the basal layer and the 
differentiated luminal secretory layer, with rare neuroendocrine cells distributed mostly 
in the basal layer. The luminal epithelial cells express characteristic markers such as 
cytokeratins 8 and 18, as well as high levels of androgen receptor (AR). Basal cells are 
located beneath the luminal epithelium, and express p63 and the high-molecular-weight 
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cytokeratins 5 and 14, but express AR at low or undetectable levels. Finally, 
neuroendocrine cells are rare cells of unknown function that express endocrine markers 
such as chromogranin A and synaptophysin, but are AR-negative [6]. PCa starts in the 
glandular epithelium and is classified as adenocarcinoma (Figure 2). The earliest 
precursor is prostatic intraepithelial neoplasia (PIN) and high-grade PIN (HGPIN) is 
associated with concurrent PCa [7-9].  
 
 
FIGURE 2 PROGRESSION PATHWAY FOR PROSTATE CANCER. Adapted from Shen et al 
[6]. 
 
1.1.2 Prostate cancer incidence, mortality and survival 
PCa is the second most common cancer in men worldwide, accounting for 15% of the 
cancers diagnosed in men and is the fifth leading cause of death from cancer in men 
(6.6% of all cancer related-deaths in men) [10]. In western world, including Europe and 
North America, PCa is the most common male cancer and the second most frequent 
cause of cancer-related death [11, 12]. In the UK (2013) there are 47,300 new PCa cases 
a year (150 cases for every 100,000 males), accounting for 26% of all new cases of 
cancer in males, and 10,837 deaths from PCa (35 deaths for every 100,000 males), 
accounting for 13% of all cancer deaths in men [11]. PCa incidence varies more than 25-
fold worldwide, with almost 70% of the cases occurring in more developed regions. The 
highest rates are observed in Australia/New Zealand, North America and in Europe while 
the lowest are found in Asian populations [10, 13, 14]. Much of the variation reflects 
differences in the use of prostate-specific antigen (PSA) testing, followed by diagnostic 
biopsy [10, 15]. 
PSA testing has a great effect on PCa incidence but lesser on mortality, as it often leads 
to detection of early stage PCa before clinical manifestation and without changing the 
actual time of death (discussed later) [15]. PCa mortality shows about 10 fold variation 
worldwide [10]. Mortality rates are generally high in black populations (Caribbean and 
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sub-Saharan Africa), very low in Asia and intermediate in the Americas and Oceania 
[11].  
Survival from PCa strongly depends on the stage of the disease at diagnosis. In majority 
of cases, PCa develops progressively over many decades, which gives the opportunity 
for clinical therapeutic interventions e.g. strategies to prevent PCa or reduce the risk of 
developing the disease. Often PCa is an indolent, latent disease that will not result in 
clinical symptoms during the lifetime of an elderly patient. It is estimated from post-
mortem data that around half of all men in their fifties have histological evidence of cancer 
in the prostate, which rises to 80% by age 80, but only 1 in 27 men (3.8%) will die from 
this disease [16, 17]. Consequently, men are more likely to die with PCa than from it, 
which should be considered when choosing the treatment [18]. However, there is a 
subset of PCas which are more aggressive, spreading into the seminal vesicles, bladder 
and rectum, and metastasizing to lymph nodes, bone, lung and other organs [19]. At 
present, there are no good prognostic markers to distinguish aggressive from indolent 
disease for early-diagnosed cancer [11]. In England in 2010-2011 five year PCa survival 
after diagnosis was about 85%, mostly due to the detection of latent, earlier, slow-
growing tumours by PSA testing. However, if the disease is metastatic at presentation, 
five-year relative survival decreases to around 30%, which is in agreement with data 
from US [11, 12, 20].  
1.1.3 Risk factors 
The main risk factor for PCa is age and in the UK the highest incidence rates occur in 
men in their seventies [11]. A family history of PCa is one of the strongest risk factors for 
this disease. The inherited form represents only 9% of all PCas but accounts for a 
significant proportion (43%) of early-onset disease (disease onset - 55 years). The risk 
increases about two fold for men with a first-degree relative diagnosed with PCa at age 
50. If more than one relative is affected, the individual’s risk is four times the average 
[21, 22]. PCa incidence rates also differ between racial groups and are over 60% higher 
for black Americans than for white Americans while rates for Asian Americans are over 
40% lower than for white Americans [12, 20]. This differences are due to genetic as well 
as environment factors and lifestyle choices, including diet [13, 23, 24]. 
1.1.4 Role of androgen in PCa  
Androgens acting through AR are important in the development and maintenance of 
normal prostate (promote survival of the secretory epithelia and balance cell proliferation 
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and death) as well as in development and progression of PCa from early stage, through 
metastatic disease and hormonal resistance [9, 25]. Testosterone is the main circulating 
androgen in men. In the prostate and other organs, testosterone functions as a 
prohormone; it is converted to dihydrotestosterone (DHT) in the prostatic stromal and 
basal cells by 5α-reductase, an intracellular enzyme present in the prostate [3]. Inside 
the prostate cell, both testosterone and DHT bind to the cytoplasmic AR, stimulating the 
AR translocation to the nucleus where it binds to regulatory sequences of specific target 
genes, and activates their transcription promoting cell-cycle regulation, cell survival and 
lipogenesis [9]. This dependence of prostate cells on androgen for development, growth 
and survival is the base for treatment of locally advanced and metastatic cancer with 
androgen-deprivation therapy (ADT). However, patients inevitably progress and become 
resistant to ADT. Castration resistant PCa (CRPC) represents the final stage of the 
disease, with median survival of less than 2 years [26]. Despite systemic androgen 
depletion, CRPC continue to rely on AR signalling, which remains active and supports 
their survival and growth. Persistent activation of the AR signalling can occur through 
many mechanism such as AR amplification/overexpression, AR mutation or substitution 
including AR ligand binding domain mutation, AR splice variants, glucocorticoid receptor 
signalling or concentration of intratumoural androgens [27, 28]. 
1.1.5 Prostate cancer screening using PSA  
Screening for PCa involves digital rectal examination (DRE) and blood test for PSA. PSA 
is a glycoprotein secreted by prostatic epithelial cells. It functions as a serine protease 
and is excreted in the ejaculate to liquefy semen. In normal conditions, PSA can be 
detected in blood at a low level. Disruption of normal prostatic architecture by cancer, 
benign enlargement, inflammation, or trauma can lead to elevated PSA serum levels. 
Patients with high PSA levels are sent for a prostate biopsy performed together with 
transrectal ultrasound, to provide a definitive diagnosis. However, serum PSA alone has 
low specificity and cannot reliably distinguish between BPH, prostatic infection or 
inflammation, and PCa, either low or high grade [29]. In US PCa screening with PSA 
using a threshold of 4.0 ng/ml results in about 75% of men with PSA levels of 4.0 to 10.0 
ng/ml having unnecessary prostate biopsy as they do not have cancer [23, 30]. 
Introduction of annual PSA screening in US lead to dramatic increase in incidence of 
PCa but the vast majority of men are diagnosed with early stage localised disease in the 
absence of symptoms. Accounting for long natural history, PCa screening and 
subsequent treatment of early disease largely leads to unnecessary treatment of indolent 
cancers, as many patients will die with PCa rather than of the disease [29]. Recent meta-
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analysis of randomised controlled trials on PCa screening showed that PCa screening 
did not significantly decrease prostate cancer-specific mortality in most of the trials but 
indeed led to overdiagnosis and overtreatment with adverse events such as infection, 
erectile dysfunction, and incontinence [31]. Two large landmark trials: the European 
Randomized Study of Screening for Prostate Cancer (ERSPC) [32, 33] and the US-
based Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial [34] 
brought opposite results for PSA screeing impact on PCa patient mortality. The PLCO 
trial after 7-10 years follow up found 22% increase in PCa diagnosis but no significant 
reduction in mortality in screening group. However, this trial was criticised for poor 
design, with 70% contamination by PSA testing in the control group [35]. The ERSPC 
trial which used more strict criteria for patient selection concluded that PSA-based 
screening reduced the rate of death from PCa by 21% but indeed was associated with a 
high rate of overdiagnosis and overtreatment, with 781 men required to be invited for 
screening and 27 treated for PCa to prevent one PCa death [32, 33].  
Regardless of problems with PSA testing reliability, currently they are no better 
prognostic biomarkers for PCa and PSA levels together with the Gleason score and TNM 
staging remain essential factors in stratification of risk for PCa progression. Additionally, 
PSA is used as a marker for detecting residual disease after treatment and tumour 
recurrence during follow-up. An undetectable level of PSA after radical prostatectomy or 
radiation therapy indicates the absence of recurrence [36].  
1.1.6 Gleason grading system 
PCa is commonly graded by the method described by Gleason, which assigns a score 
between 1 and 5 on the basis of the glandular architecture (lower scores indicate a well-
differentiated glandular pattern) [37]. The Gleason score takes into account distinct 
patterns present in the same tumour, and is composed of the two most common patterns, 
ranging from 2 to 10 (Figure 3A). Gleason score is considered the most significant 
predictor of prognosis. It has been correlated to a number of clinical end points, including 
clinical stage, progression to metastatic disease and survival [38]. 
Over recent years Gleason score underwent several modifications. Gleason score 2 to 
4 is nowadays not used on needle biopsy and Gleason score 5 is also avoided due to 
poor correlation with prostatectomy grade with almost all cases showing higher grade at 
resection [39]. It has been proposed that the virtual absence of Gleason score 2 to 4 in 
clinical practice makes it more appropriate from the purpose of prognosis and treatment 
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to state that the Gleason score ranges from 6 to 10 rather than from 2 to 10. This would 
mean that patients with a Gleason score 6 have the lowest grade tumour [40]. The most 
clinically relevant change over recent years was limitation of pattern 3 and widening the 
scope of pattern 4 carcinoma, which resulted in disease upgrading. The updated 
Gleason system produced a more homogeneous Gleason score 6, which now has an 
excellent prognosis (virtually 100% curable) when the disease is organ confined [40, 41]. 
On the contrary, Gleason score 7 (combination of grade 3 and 4) defines prognostically 
heterogeneous group of tumours, which can take different clinical courses, some staying 
indolent, others progressing to invasive and metastatic disease [42, 43]. Therefore, 
Gleason grade 7 is usually associated with a critical decision-making step in patient 
management and treatment choice. Identification of patients with a high risk of disease 
progression is one of the current challenges in the treatment of PCa [44].  
For prognostic and therapeutic purposes Gleason grade is commonly grouped into three 
groups: 6, 7 and 8-10. Over the years, within the PCa with Gleason grade 7, numerous 
studies have demonstrated that patients with cancer of Gleason grade 4 + 3 have a 
worse prognosis than those with a score of 3 + 4, both in needle biopsies and radical 
prostatectomies [41]. Furthermore, patients with a Gleason grade 9-10 tumours had 
almost twice the risk of progression compared with Gleason grade 8. Therefore, 
classification of patients into low-, intermediate-, and high-risk categories based on a 
Gleason grade <7, 7, and >7 loses critical prognostic information and more accurate 
contemporary grading prognostic categories: 3 + 3, 3 + 4, 4 + 3, 8, and 9-10 were recently 
proposed [41, 45]. In 2016 the International Society of Urological Pathology (ISUP) has 
issued guidelines for the grading of PCa, recommending that Gleason scores ≤6, 3 + 4 
= 7, 4 + 3 = 7, 8 and 9-10, respectively, be reported as five groups named: ISUP grades 
1-5 (Figure 3B). This new grading system has been accepted by the World Health 
Organization for the 2016 edition of the genitourinary pathology blue book, as it can 
better predict patient outcome and facilitate patient communication [46-48]. 
Needle biopsy Gleason grade is routinely used to plan patient management and its 
accurate determination is crucial in deciding the best treatment [38]. However, there is a 
poor agreement between biopsy and prostatectomy Gleason score, with tendency of the 
score to be higher on prostatectomy, probably due to limited biopsy material and cancer 
heterogeneity [42, 49]. Failure of the biopsy specimen to accurately reflect the Gleason 
grade of the cancer has a key impact on patient treatment, leading to underestimation of 
the disease risk, and can compromise patient outcome [50]. 




FIGURE 3. GLEASON SCORE SYSTEM. (A), In the original Gleason grading system a score 
between 1 and 5 is assigned to the prostate tissue based on the pattern of glandular architecture 
and two most common scores are combined together to give a final score from 2-10. (B), Recently 
modified Gleason score by ISUP simplifies grading into 5 groups: grade group 1: Gleason score 
≤6; group 2: Gleason score 3 + 4 = 7; group 3: Gleason score 4 + 3 = 7; group 4: Gleason score 
4 + 4 = 8, 3 + 5 = 8, 5 + 3 = 8; group 5: Gleason scores 9–10 [37, 48]. 
 
1.1.7 Staging of prostate cancer 
Two types of staging can be distinguished for PCa. One is the clinical stage, which is an 
estimate of the spread of PCa at the time of diagnosis based on all information available 
before the first definitive treatment, including results of the physical exam (DRE), PSA 
tests, prostate biopsy, and any imaging tests performed.  
Pathologic stage is performed after surgical resection of the primary tumour and is based 
on gross and microscopic examination of the prostatectomy specimen and dissected 
regional lymph nodes (if included) [51]. PCa pathologic stage follows the TNM staging 
system, which is the international standard for designating the extent of cancer and its 
prognosis. It takes into account the extent of the primary tumour (T category), whether 
the cancer has spread to nearby lymph nodes (N category) and absence or presence of 
distant metastasis (M category) [52].  
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Pathologic stage is crucial for determination of patient treatment and prognosis and is 
linked to patient survival and disease progression [53, 54]. Nonetheless, evaluation of 
tumour stage is to certain degree subjective and pathologists do not always agree on 
criteria to assess seminal vesicle invasion, extraprostatic invasion or the radical 
prostatectomy specimen margins, factors that are vital for subsequent patient treatment 
and prognosis [55-58].  
1.1.8 PCa treatment 
Introduction of PSA screening resulted in more frequent detection of small volume, low 
grade and organ confined PCas, which are diagnosed earlier in their course and are 
unlikely to ever become symptomatic during lifetime (indolent or clinically insignificant 
cancers). However, some of those tumours may progress quickly resulting in lethal 
disease. Therefore, it is extremely important to effectively predict the course of a newly 
diagnosed PCa and to distinguish between tumours that need immediate, invasive 
treatment with curative intent and indolent tumours that are unlikely to become 
symptomatic during the patient’s lifetime [59, 60]. Nomograms to predict the outcome of 
disease treatments have been developed based on PSA, Gleason score and the TNM 
stage [59]. Currently (2016) clinical guidelines for PCa diagnosis and treatment (e.g. 
published by National Institute for Health and Clinical Excellence (NICE) 
https://www.nice.org.uk/guidance/qs91 and European Association of Urology (EAU) 
http://uroweb.org/guideline/prostate-cancer/) still categorise PCa into low, intermediate 
and high risk groups (Table 1) using regular Gleason score [61]. However ISUP-WHO 
2014 grade grouping is expected to be gradually introduced into the standard pathology 
reporting (http://uroweb.org/guideline/prostate-cancer/). 
 
TABLE 1 RISK STRATIFICATION FOR MEN WITH LOCALISED PROSTATE 
CANCER.
Risk stratification  PSA (ng/ ml) Gleason score Stage 
Low risk < 10  and ≤ 6 and T1-T2a 
Intermediate risk 10–20  or 7 or T2b-T2c 
High risk > 20  or 8-10 or T3-T4 
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1.1.8.1 Localised low-risk indolent prostate cancer 
Management of low-risk indolent PCa focuses on avoiding patient overtreatment and 
increasing quality of life by minimizing treatment side effects. ‘Watchful waiting’ was 
commonly used in the 1970s and 1980s (the pre-PSA era) and was an approach that 
deferred treatment until the disease became symptomatic. It involved elderly patients 
with a relatively short life expectancy, whose cancer was likely to progress very slowly, 
with no symptoms and would not cause their death. Subsequently, this approach has 
evolved into ‘active surveillance’, where time is used as a prognostic test and curative 
therapy initiated when predetermined signs of progression become evident (a rise in PSA 
level or adverse findings on biopsy). Criteria to define cancer progression differ but 
mostly include PSA doubling time with a cutoff ranging between ≤2 and ≤4 years, 
Gleason score progression to ≥7 at rebiopsy (at intervals ranging from 1 to 4 years) and 
PSA progression >10 ng/mL, with PSA testing no more often than every 6 months [62, 
63]. By these means, patients can avoid overtreatment without compromising their 
outcome [64] and are eligible for radical treatment if their disease progress [59, 60, 65]. 
Radical treatment includes radical prostatectomy and radiotherapy [61, 63].  
1.1.8.2 High-risk prostate cancer 
High-risk locally advanced PCa is treated with radical prostatectomy or combination of 
radiotherapy and androgen ablation. Androgen ablation involves androgen withdrawal 
by surgical castration (bilateral orchidectomy) or drug therapy with luteinising hormone-
releasing hormone (LH-RH) analogues. Alternatively, the anti-androgens are 
administered alone or anti-androgens and castration are applied together, which is 
known as maximum androgen blockade or MAB [61]. ADT can give good short-term 
disease control. Initially, over 80% of patients positively respond to androgen ablation by 
dramatic reduction of prostate epithelial cells. However, after 1-2 years disease 
eventually progresses to hormone refractory state [9, 66, 67]. Secondary treatment for 
patients with progressive disease after androgen deprivation also concentrates on 
reduction of androgens and includes administration of a secondary antiandrogen, 
inhibition of adrenal androgen production, and further LH inhibition with progesterone or 
estrogenic agents. Secondary hormonal therapy also eventually fails and disease 
progresses to metastatic state [68]. 
Metastatic disease is common at the diagnosis and in the UK one in five men (20%) have 
metastases at diagnosis [69]. For many years standard treatment for patients with 
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metastatic PCa was ADT; however, most patients would eventually develop resistance 
leading to progression to metastatic castration resistant prostate cancer (mCRPC). For 
patients with mCRPC, docetaxel was the first agent to demonstrate a survival benefit (2-
3 months in comparison to the standard chemotherapy) [70], and docetaxel plus 
prednisone became the new standard treatment for mCRPC. Vale et al [71] performed 
a meta-analysis of large randomised controlled trials combining docetaxel or 
bisphosphonates with standard of care in hormone-sensitive PCa patients. For 
metastatic (M1) disease they included results from three trials (CHAARTED [72], 
GETUG-15 [73], STAMPEDE [74]) representing 2992 (93%) of the 3206 patients 
enrolled in the relevant trials. They found an absolute 9% (95% CI 5–14) improvement 
in survival at 4 years in patients with docetaxel treatment, suggesting addition of 
docetaxel to standard of care should be considered standard treatment for men with M1 
hormone-sensitive PCa who are starting treatment for the first time. For patients with 
locally advanced (M0) disease, failure-free survival was consistently prolonged with 
docetaxel (hazard ratio 0.70 (95% CI 0.61–0.81)) but not the patient survival (0.87 (0.69–
1.09)), implying necessity for further studies of the effects of docetaxel on survival in the 
M0 disease. No evidence was found for improved survival with zoledronic acid in men 
with M1 or M0 disease.  
For patients with mCRPC who had progressed after docetaxel chemotherapy, second-
line therapies which improve overall survival include enzalutamide [75], abiraterone-
prednisone [76] and cabazitaxel-prednisone [77]. The second-line taxane chemotherapy 
with cabazitaxel, seems to be effective also in patients who acquired resistance to AR 
axis-targeting agents, abiraterone and enzalutamide [78]. For patients with refractory 
disease, mainly palliative systemic or local therapy remains with options including 
radiotherapy to dominant sites of bone pain and treatment with bone-targeting agents 
[61, 79, 80].  
1.2 Genetic alteration in prostate cancer 
1.2.1 Genomic instability and cancer 
Over a decade ago, six essential alterations in cell physiology that promote malignant 
transformation of normal human cells (hallmarks of cancer) have been proposed: self-
sufficiency in growth signals, insensitivity to growth-inhibitory (antigrowth) signals, 
evasion of programmed cell death (apoptosis), limitless replicative potential, sustained 
angiogenesis, and tissue invasion and metastasis [81]. Constant progress in cancer 
research lead to emerging additional hallmarks, including the development of genomic 
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instability in cancer cells, inflammation, reprogramming of cellular energy metabolism in 
order to support continuous cell growth and proliferation, and active evasion by cancer 
cells from attack and elimination by immune cells [82].  
Cancer is a complex disease, with multiple genes involved in its initiation, progression, 
invasion and metastasis. Most cancers show genomic instability, which can be described 
as an increased rate of alterations in the genome of tumour cells compared with normal 
cells. However, it is not clear at what stage of cancer development it arises and what is 
its molecular basis [83, 84]. Genomic instability exists at two distinct levels: nucleotide 
and chromosome.  
Microsatellite instability (MSI; also known as MIN) is observed at the nucleotide level and 
manifests as small increases or decreases (‘‘instability’’) in the number of repeats in 
microsatellites (also known as short tandem repeats). Microsatellites are simple repeat 
sequences of 1 to 6 base pairs scattered throughout the genome and their repetitive 
nature makes them particularly prone to DNA replication slippage and replication errors 
[85]. Most of these errors are repaired by mismatch repair genes (e.g. MLH1 and MSH2) 
and defects in these genes lead to microsatellite instability, resulting in high rate of 
mutations such as single nucleotide substitutions, duplications or deletions as well as 
deletions or insertions of few nucleotides [83, 86]. Single nucleotide changes can lead to 
modifications in subsequently translated amino acid sequence of the protein, resulting in 
amino acid change and/or different protein size (e.g. due to the creation of a premature 
stop codon). The deletion or insertion of one or two nucleotides within gene coding region 
causes a frameshift mutation resulting in the production of abnormal protein with an 
incorrect amino acid sequence that can be either longer or shorter than the normal 
protein. Defects in mismatch repair system dramatically increase mutation rates in 
affected cells, leading to accumulation of mutations in oncogenes and tumour-
suppressor genes in the progeny of these cells, fuelling the process of oncogenesis 
through positive selection [84, 87, 88]. 
The most common form of genomic instability is observed at the chromosome level. 
Chromosomal instability (CIN) is defined as a persistently high rate of loss and gain of 
whole or part of chromosomes [84, 89]. Gain or loss of whole chromosomes leads to 
aneuploidy, while large-scale structural rearrangements of chromosomes result in 
deletions, duplications, inversions and unbalanced and balanced translocations. 
Frequent missegregation of chromosomes constantly shuffles gene dosage and 
increases the likelihood of emerging karyotypes that promote phenotypes associated 
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with advanced stage disease including invasion and growth in new microenvironments 
[90].  
1.2.2 Prostate cancer susceptibility genes 
Observation that PCa clusters within families suggested shared familial genetic risk 
factors for this disease [91]. Early studies of prostate susceptibility loci used family-based 
linkage analysis in an attempt to identify high-penetrance genetic variants that confer 
increased risk of developing PCa. The results of linkage studies provided several 
candidate chromosomal regions for PCa susceptibility loci (with subsequent search for 
candidate genes), including HPC1 region (1q24-25, harbouring RNASEL), PCAP (1q42-
43), 8p22–23 (MSR1), 8q24, HPCX (Xq27-28), CAPB (1p36), HPC20 (20q13), HPC2 
(17p11 with ELAC2), 16q23, 17q21 (BRCA1) and 13q12–13 (BRCA2) [92-95]. However, 
none of these regions have been convincingly replicated [96]. The extreme difficulty in 
finding consistent linkage results for highly penetrant genes across different studies 
indicated that multiple common genetic variants with small to moderate effect 
(penetrance) might be involved in prostate carcinogenesis [97].  
Genome-wide association studies (GWAS) have recently emerged as a powerful tool to 
identify common genetic polymorphisms associated with cancer risk. GWASs are 
population-based case-control studies, which use high-resolution single-nucleotide 
polymorphisms (SNPs) array technology to search for association between common 
genetic variants (SNPs) and disease [98, 99]. GWASs have led to the identification of 
many loci that are potentially associated with PCa [95]. The most common region 
implicated in PCa susceptibility is located at 8q24 and is considered as gene desert. 
However, it contains regulatory elements involved in the tissue-specific transcriptional 
regulation of MYC expression, an oncogene which lies immediately downstream of that 
region. MYC is a well-known transcription factor essential to the regulation of cell 
proliferation and growth; is upregulated at both the mRNA and protein levels in 
aggressive PCa [100]. 
Linking genetic risk variants for PCa with potential biological functions is complicated by 
their large number. There are over 100 loci with thousands of surrogate SNPs in linkage 
disequilibrium [101, 102]. Most of variants are shared across populations, however some 
differences also exist [103-105]. Recent comprehensive analysis of data from 100 GWAS 
studies [97] revealed 250 PCa related SNPs mapped to 162 protein coding genes. 62 
SNPs mapped to 41 genes had strong association with PCa (p<10-8). Only ten of those 
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genes, including EEFSEC, HNF1B, JAZF1, KLK3, MSMB, NUDT11, PDLIM5, POU5F1, 
RFX6, and TERT contained multiple genetic variants with strong associations [97]. It is 
becoming clear now, that vast majority of PCa risk variants is located in regions outside 
of protein-coding exons, mainly among regulatory elements [101, 102, 106, 107]. 
Identification of the target gene of a regulatory element is challenging as regulatory 
elements can act over great distances [101]. Nonetheless, widespread disruption of 
ternary transcription factor–transcription factor–DNA complexes between AR, FOXA1 
and HOXB13 has been detected, which may potentially alter the genomic binding 
landscape of AR [106]. FOXA1 and HOXB13 were recently indicated in reprogramming 
genomic AR binding from a normal epithelial binding profile to a tumorigenic binding 
profile [108]. Other transcription factors with frequently disrupted binding sites by PCa 
risk variants found in that study were ERG and CTCF [106]. Another study analysing 103 
PCa risk variants also found transcription factors binding regions to be enriched for PCa 
risk variants, including AR, ERG, FOXA1, HOXB13 and CTCF binding regions [102]. 
Another genomic regions with potentially functional impact were CpG islands and regions 
for histone modifications. 
Linkage studies of PCa aggressiveness have reported several risk variants linked to 
aggressive PCa, including: 5q14.3 (rs35148638, intronic to the RAS p21 protein activator 
1, RASA1), 3q26.31 (rs78943174, intronic to the N-acetylated alpha-linked acidic 
dipeptidase-like2, NAALADL2) [109], 2q37.3 (rs2292884, in exon 9 of the melanophilin 
gene, MLPH), 12q13 (rs902774, in the type II keratin family cluster) [110], 17p12 
(rs4054823, region with no known gene) [111], 22q13 (rs9623117, at trinucleotide 
repeat-containing gene 6b TNRC6B) [112] but these data have to be yet convincingly 
replicated. 
The potential for false-positive results, lack of information on gene function, insensitivity 
to rare variants, requirement for large sample sizes, and possible biases due to case and 
control selection and genotyping errors, are important limitations of GWAS. Replication 
studies in independent cohorts are crucial to confirm associations of detected genetic 
variants with disease. Furthermore, the functional consequence of these replicated 
variants needs to be identified to accurately incorporate genetic predisposition into 
clinical decision making [113].  
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1.2.3 Somatic genetic changes in prostate cancer 
Mutations are rare in PCa [114]. The most commonly mutated gene is AR with mutations 
occurring mostly in castration resistant PCa. Common, broadly mutated oncogenes such 
as PIK3CA, KRAS and BRAF are not commonly mutated in PCa. Mutations in TSGs like 
TP53 and PTEN are also rare [115, 116] (Table 2). Exome sequencing identified novel 
recurrent gene mutations in PCa, including SPOP, NCOA2, FOXA1 and MED12, with 
the SPOP gene being the most commonly mutated (6-15%) in primary PCa [115-118]. 
In contrast, the frequency of copy number alterations (CNAs) and genomic 
rearrangements is high in PCa, suggesting that the development and progression of PCa 
is primarily the result of an accumulation of larger-scale genomic aberrations, such as 
deletions, gains, and gene fusions [115, 119, 120]. Whole-genome sequencing shows 
that large numbers of chromosomal rearrangements are particularly common in early 
onset cases, many involving known cancer-associated genes (commonly including ETS 
genes) [117]. 
In recent years, many studies of genomic changes in PCa were published, mostly 
employing comparative genomic hybridisation (CGH) methods, single nucleotide 
polymorphism (SNP) arrays, and most recently next generatin sequencing (NGS). Sun 
et al [119] performed a combined analysis of all published CGH studies of PCa up to 
2006 (41 CGH studies), including 659 localised, 225 advanced and 174 
metastatic/recurrent tumours as well as 51 PCa cell lines and xenografts. Most 
commonly reported deleted region in PCa was chromosome 8p with the peak at 8p21.3 
(34.1% tumours), followed by 13q21.31 (28%). Other commonly deleted regions were 
located at 6q14.1–21 (22.2%), 16q13–16q24.3 (17.85%), 18q12.1–23 (12.8%), 5q13.3–
21.3 (13%), 2q21.2–22.3 (12.4%), and 10q23.1–25.3 (11.7%). Chromosome 8q was the 
most commonly gained region with peak gains at 8q22.2 (25.1% cancer samples), 
8q24.13 (24.0%) and large gain at 8q21.3–24.3 (22.2%). The other commonly gained 
regions were: 7q11.21–32.3 (12.5%), Xq11.1–23 (10.8%), 17q24.1–25.3 (11.6%), and 
3q23–26.33 (10.2%). More recent meta-analysis of PCa somatic copy number 
alterations from 11 aCGH and SNP microarray publications that included 563 primary, 
161 advanced, 12 HGPIN and 110 matched benign samples generated very similar 
results with most common deletions at: 8p (8p23.3-p11.21, 61.8%), 13q123-q31.1 
(52.9%), 16q11.2-q24.3 (52.3%), 6q12-q22.33 (46.7%), 5q11.2-q23.3 (42.9%), 17p13.3-
p11.2 (37%), 10q23.2-q26.12 (36.3%), 18q12.1-q23 (32.8%), and 2q14.1-q24.2 (29.6%) 
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and common gains at 8q (8q11.21-q24.3, 31.9%), 16p13.3-p11.2 (26.3%), 7p22.3-q36.2 
(24.8%), 3q13.33-q27.3 (18.7%) and 20q11.22-q13.33 (12.5%) [121].  
Gene fusions are also reported in PCa. Tomlins et al [122] discovered recurrent gene 
fusions of the 5' untranslated region of the androgen-regulated gene, transmembrane 
protease serine 2 (TMPRSS2) to 3’ exons of ERG or ETV1 in PCa, subsequently leading 
to abnormally high expression of ERG or ETV1 protein. Since then, the same group and 
others confirmed fusion of TMPRSS2 with ERG and other members of ETV family 
(ETV1, ETV4, ETV5, and ELK4) in about 50% of cancers, 16% of high-grade PIN lesions 
and sporadically in normal tissue adjacent to the tumour [123-126], suggesting that this 
rearrangement could be an early event that predisposes to clinical progression as it 
continues to be expressed in metastatic and castration-resistant disease. Transgenic 
mouse models showed that TMPRSS2-ERG fusion in combination with heterozygous 
PTEN loss accelerated PIN development but not progression to adenocarcinoma, 
suggesting that TMPRSS2-ERG fusion plays a role in initiation of prostatic neoplasia 
[127]. Several studies identified an association of the TMPRSS2-ERG fusion with higher 
Gleason score, higher stage, and more aggressive tumour behaviour [128-130]. Though, 
contradictory data also exists [131]. Recent studies suggest that expression of ERG 
rather than presence of fusion itself should be considered as PCa prognostic marker, 
however ERG RNA and/or protein analysis in PCa samples also gives inconsistent 
results, with reports either positively correlating ERG expression with high grade and 
stage tumours and shorter progression-free survival or presence of metastasis [132, 133] 
or linking high ERG IHC to better recurrence-free survival [134], lower Gleason score, 
better overall survival and longer free progression times to castration resistant disease 
[135]. Further studies are needed to evaluate prognostic value of this fusion in PCa. 
To understand which of those genetic events occur early in PCa and which correlate with 
advanced high-risk disease, PCa progression models were developed, incorporating 
information from PCa animal models, aCGH studies, SNP arrays analysis and more 
recently, sequencing studies. Current PCa progression models generally indicate 
NKX3.1 loss, the TMPRSS2-ERG translocation, and SPOP and FOXA1 mutations as 
early events in PCa development. Subsequent loss or downregulation of TSGs such as 
PTEN, cyclin dependent kinase inhibitor p27 (CDKN1B), retinoblastoma (RB1) and TP53 
is considered to be responsible for early invasion PCa progression; with TP53 mutations 
and AR mutations/amplifications specifically enriched in metastatic samples [116, 136-
138]. AR pathway activation, often as a result of AR protein overexpression due to 
various genetic mechanisms (e.g. mutations, gene copy number gain or amplification), 
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is consistently involved in PCa progression to mCRPC and PCa treatment strategies are 
largely based on blockage of AR signalling [6, 115, 139-141]. Other genes like MYC and 
NCOA2 (Table 2) were also implicated in prostate carcinogenesis [115].  
The available whole-genome and gene expression profiling studies are increasingly used 
for molecular classification of PCa, aiming at identification of distinct genomic subclasses 
of PCa in order to help with risk stratification and possibly selection of management 
strategies. The PCas are commonly grouped, based on the identification of recurrent 
gene fusions consisting of androgen-regulated TMPRSS2 gene and members of the ETS 
family of oncogenic transcription factors, in ETS-fusion positive and ETS-fusion negative 
subclasses [114, 117, 137, 142]. ETS-fusion positive tumours are enriched in mutations 
and deletions in PTEN, TP53, and deletions at 3p13, 16q and gain of 7q [116, 118, 143, 
144]. In contrast, ETS-fusion negative tumours are positive for SPOP mutations, CHD1 
deletions, SPINK1 overexpression, as well as rare activating mutations in RAF, RAS, 
and FGFR genes [116-118, 122, 137, 145]. 
Classification of PCa based on gene expression analysis led to development of two 
commercially available gene panels aiming to help distinguish high-risk cancer from 
indolent disease at diagnosis. One of them (Prolaris®, Myriad Genetics, Salt Lake City, 
UT) measures Cell Cycle Progression score based on expression of 31 genes involved 
in cell cycle progression, and was proven highly prognostic, providing more information 
than either Gleason score or PSA [146, 147]. Another test (Oncotype Dx® Prostate 
Cancer Assay, Genomic Health, Redwood City, CA) utilises a 17 gene-expression-based 
signature, called the Genomic Prostate Score. Genes incorporated in the score represent 
multiple biological pathways, including stromal response, proliferation, cellular 
organization, basal epithelial, androgen signalling, and stress response [148]. Another 
genomic classifier test (Decipher, GenomeDx Biosciences, San Diego, CA, USA) was 
specifically developed to predicts early metastasis (within 5 years after surgery) in 
patients who underwent radical prostatectomy [149]. This test contains 22 RNA markers 
including a large number of non-coding RNA sequences and helps to better identify 
patients that require intensive multi-modal therapy.  
Difficulty in assessment of the exact nature and sequence of genetic changes involved 
in PCa progression and association of specific genomic events with metastatic cancer 
comes from limited number of metastatic material available for study [139]. Majority of 
the PCa genomic studies have been performed on prostatectomy specimens, including 
studies of metastatic cancers. Not many genomic projects looked at somatic copy 
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number alterations specifically at PCa metastatic sites. Comparison between localised 
prostate tumours and tumours from metastatic sites (e.g. lymph nodes, liver, lung, 
adrenal, spleen, skin, bone) showed many common genetic changes like losses on 8p, 
10q, 13q, and 16q and gains on 8q and Xq. However, tumours from metastatic sites had 
higher frequency of these changes and displayed additional rearrangements, suggesting 
that genomic changes accumulate with disease progression [150, 151]. Interestingly, an 
association of certain alterations within metastasis to specific distant sites has been 
proposed [151, 152]. Gains at 5q31.2–31.3, 5q35.2–35.3, 8p11.21, 11q13.2, and 
16p13.3 were found more frequently in PCa liver metastases, while gains at 6p21.32–
21.2 and 6p21.1 and loss at 22q12.1 were reported as common alterations for lymph 
node metastases [151]. Which genes within those regions are specifically involved in 
metastatic PCa and could be used as potential prognostic markers or treatment targets 
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TABLE 2 SOMATIC GENETIC CHANGES IN PROSTATE CANCER. 
Genetic change Chromosomal 
region 
Gene Reference 
Point mutations 17p13.1 TP53 [115, 116, 140, 153] 
 Xq12 AR [115, 140] 
 1p36.2 MTOR [153] 
 13q12.3–13.2 BRCA2 [115] 
 9p21 CDKN2 (p16)  [154] 
 10q23.31 PTEN [116] 
  3q26.32 PIK3CA [116, 140] 
 12p12-13.1 CDKN1B (p27) [116] 
 14q21.1 FOXA1 [116] 
 Xq13.1 MED12 [116] 
 17q21.33 SPOP [116, 117] 
 8q13.3 NCOA2 [115] 
    
Deletion 10q23.31 PTEN [115, 117, 121, 140, 
153, 155-157] 
 13q14.2 RB1 [115, 121, 140, 157-
159] 
 17p13.1 TP53 [115] 
 12p12-13.1 CDKN1B (p27) [160] 
 9p21 CDKN2 (p16)  [154] 
 8p21.2 NKX3.1 [115, 161] 
 13q12.3–13.2 BRCA2 [140] 
    
Copy number gain/ 
amplification 
8q24.21 MYC [115, 140, 157, 162-
164] 
 8q13.3 NCOA2 [115, 164] 
 8q24.2 PSCA [163] 
 Xq12 AR [115, 140, 153, 165] 
 7q35 EZH2 [115, 166] 
 7q34 BRAF [115] 
 11q13.3 CCND1 (cyclin D1) [138, 167] 
    
Gene fusion 21q22 TMPRSS2-ERG [122, 168] 
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1.3 Metastatic prostate cancer 
1.3.1 Mechanism of metastasis 
Metastasis is the process in which cancer cells spread throughout the body, establishing 
new colonies in organs different from the one where the primary tumour originated. The 
ability to metastasize is a property of malignant tumours, and metastasis is the principal 
cause of death among cancer patients [169].  
Metastasis is a complex, multistep process and involves angiogenesis, local invasion 
through the basement membrane (a hallmark characteristic of a metastatic cell), 
adhesion to vessel endothelium in the target organs, and extravasation into the tissue. 
Very few disseminated tumour cells will establish metastasis at distant organs and their 
success will depend on close collaboration with microenvironment (Figure 4) [170, 171]. 
 
 
FIGURE 4 THE STEPS INVOLVED IN TUMOUR CELLS METASTASIS TO THE BONE. 
Adapted from Mundy et al [171]. 
 
At the early stage, tumour tends to spread to local lymph nodes through the lymphatic 
system. However, aggressive tumour cells eventually enter the bloodstream and reach 
distant tissues. Interestingly, different tumours have unique patterns of organ 
colonisation. It is not clear when primary tumour cells acquire metastatic capacity and 
why they spread to some organs but not others. Several theories have been proposed 
to answer those questions. Some models advocate acquisition of metastatic potential as 
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a late event in primary tumour progression. Darwinian or evolution models state that 
metastasis is a rare event which results from the selection of rare clones that emerge 
from a genetically heterogeneous and unstable population due to repeated cycles of 
mutation and clonal selection. Those individual cell clones over time would acquire novel 
genetic changes conferring a selective advantage within the primary tumour 
microenvironment but at the same time would randomly acquire key pro-metastatic 
mutations determining their accumulation in specific organs [169, 172]. Other models 
support early acquisition of metastatic potential by primary tumour cells. Pre-
determination models state that a subset of the mutant alleles acquired by primary 
tumour cells early in tumourigenesis confers both: a selected replicative advantage and 
proclivity to metastasize later in tumourigenesis. Therefore, the tendency of a tumour to 
metastasize would be determined by the spectrum of mutations that progenitor cells 
acquire relatively early in tumourigenesis and then augmented by additional genetic 
changes at metastatic site [173]. Gene expression patterns of tumour cells at distant 
metastases seem to confirm both theories. A breast cancer study using in vivo selection 
described set of genes that marks and mediates breast cancer metastasis to the lungs 
[174]. Some of these genes provided growth advantages both in the primary tumour and 
in the lung microenvironment while others contribute to aggressive growth selectively in 
the lung. An expression signature was also suggested for breast cancer cells with 
osteolytic bone metastasis potential [175] where majority of highly overexpressed genes 
encoded cell membrane or secreted molecules relevant to the bone microenvironment. 
In that study, a parental MDA-MB-231 cell population already possessed previously 
reported poor-prognosis gene expression signature for primary breast cancer [173] and 
additionally expressed concrete set of bone metastasis genes, which gave it tissue-
specific metastatic phenotype.  
In 1889, Stephen Paget for the first time presented an explanation for the non-random 
patterns of cancer metastases. His ‘‘seed and soil’’ theory proposed that the metastatic 
sites contain factors that promote cancer cell growth similar to the tendency of seeds to 
grow in fertile soil [176]. Paget’s theory can therefore explain distant metastases that are 
organ-specific, such as metastases to the bone. Based on the Paget’s theory, circulating 
PCa cells would be able to establish bone metastases only if bone microenvironment 
was favourable for their growth [177, 178]. Contradictory theory was proposed by James 
Ewing and postulated that metastatic spread of cancer is determined purely by the 
vascular connections of the primary tumour; therefore cells released from a primary 
tumour will accumulate in the first highly vascularised organ that they encounter [176]. 
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However, this theory can explain some of the metastases but not all and Paget’s ‘‘seed 
and soil’’ theory is nowadays widely accepted. 
Several mechanisms may be involved in selective establishment of distant metastases, 
including chemokine-receptor-mediated chemotaxis, the establishment of a metastatic 
niche, and a tumour cell genetic program that facilitates adaptation to a particular 
microenvironment. Tumour cells are known to express a variety of chemokine receptors, 
including C-X-C chemokine receptor type 4 (CXCR4) that serves as a receptor for C-X-
C motif chemokine 12 (CXCL12, also known as stromal cell-derived factor-1, SDF-1) 
[179]. The CXCL12/CXCR4 pathway is involved in the retention and homing of 
endothelial (EPC) and hematopoietic progenitor cells (HPC) in the bone marrow 
microenvironment and lymphocyte trafficking. Functional CXCR4 is expressed on 
embryonic and tissue-committed stem cells, including proangiogenic cells and 
endothelial precursor cells. CXCL12 is constitutively expressed in many tissues and 
plays a role in the mobilisation and recruitment of CXCR4 expressing cells to the 
neoangiogenic niches [180]. CXCR4 is found on malignant epithelial cells and on cells 
from several hematopoietic malignancies which implies that the CXCL12/CXCR4 
pathway may play a pivotal role in directing the metastasis of CXCR4 positive tumour 
cells to organs that express CXCL12 (e.g., lymph nodes, lungs, liver, or bones). Several 
CXCR4 positive cancers metastasize to the bones and lymph nodes in a CXCL12-
dependent manner, including myeloma, acute and chronic leukaemia, breast, ovarian 
and prostate cancer [181]. PCa cell lines (PC3, DU145, LNCaP) express CXCR4 and 
they respond to CXCL12 treatment by migration across basement membrane 
monolayers and increased invasion [182]. Blocking CXCL12 binding with CXCR4 was 
shown to prevent the skeletal metastasis of PC3 cell line in nude mice [183] and blocking 
CXCR4 decreased the invasiveness of PC3 cells and reduced tumour spread with 
associated reduction in angiogenesis in in vivo orthotopic PCa model [184]. 
Homing to bone can also be caused by interaction between integrins on tumour cell 
surface and the supporting host stromal cells in bone (osteoclasts, new blood vessels, 
inflammatory cells, platelets and bone marrow stromal cells). The αvβ3 integrin interacts 
with bone-derived ostepontin (OPN), fibronectin and vitronectin, and expression of αvβ3 
by breast and prostate cancer cells is associated with higher rates of bone metastasis, 
tumour-associated osteolysis and colonisation in bone [185]. Expression of integrins like 
α5β1, α2β1 and α4β1 (receptors for fibronectin, collagen I and vascular cell adhesion 
molecule 1 (VCAM1), respectively) by tumour cells has been implicated in the 
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interactions of leukaemia, myeloma, prostate and breast cancer cells with bone marrow 
stroma, and can result in enhanced colonisation and survival in bone [186]. 
It has been suggested that tumour cells can use their cytokine and chemokine repertoire 
to prepare the microenvironment of distant organs to receive disseminating cells. Tumour 
and associated stromal cell–derived chemokines can recruit endothelial and 
hematopoietic progenitor cells to the relevant organs prior to tumour cell arrival, which, 
together with tumour cell–derived deposition of fibronectin, appear to precondition the 
local microenvironment to form premetastatic niche. The exact mechanisms of 
premetastatic niche formation are still unclear and remain to be confirmed [187, 188]. 
The secretion of exosomes by tumour cells is also involved in the formation of pre-
metastatic niches. Tumour-derived exosomes enhance vascular leakiness by inducing a 
pro-vasculogenic phenotype in bone marrow progenitor cells, “educating” the bone 
marrow to support tumour dissemination [189].  
The ability of cells to establish themselves in the new host tissue microenvironment, so 
they can survive and proliferate, is the most important rate-limiting step in metastatic 
process [190]. Microenvironment of metastatic site not only provides fertile soil for tumour 
growth, but also influences cancer cells, triggering permanent genetic and phenotypic 
changes, conferring cancer cells selective growth and survival advantages. This 
influence is reciprocal as PCa cells can exhibit osteomimicry (bone cell-like properties) 
through expression of transcription factors (Runx2, MSX2), which are regulators of 
osteoblasts differentiation, leading to improved homing, adhesion, proliferation and 
survival in the bone microenvironment [191]. This reciprocal interaction between 
microenvironment and cancer cells may explain failure of gene expression studies of 
primary tumours to predict organ specific tropism of cancer cells. Furthermore, it also 
highlights necessity of development site – specific treatment, as bone directed therapy 
would be selective and effective only against bone metastasis but not against other 
metastatic sites or primary tumour [192]. 
1.3.2 Bone metastases  
The most common metastatic site of PCa is bone: around 90% of patients dying from 
PCa have skeletal metastases. Less frequently PCa metastasize to lungs and kidney 
[193, 194]. Once tumours metastasize to bone, they are incurable and result in significant 
disease morbidity, causing pain, pathological fractures, nerve compression syndromes, 
and hypocalcaemia. Current treatments for metastatic disease are mainly palliative [193] 
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and therapies for mCRPC have shown only modest success, with prolonged survival 
measured in months [195]. Therefore, better understanding of bone metastases is 
needed in order to develop more efficient approaches and novel therapies to manage 
aggressive metastatic disease.  
1.3.2.1 Normal bone physiology 
Bone is made primarily of type I collagen (about 90% of the bone matrix proteins) that is 
mineralised with hydroxyapatite crystals. Collagen and most of the bone proteins are 
synthesised and secreted by bone forming cells, osteoblasts [196]. Osteoblast-mediated 
bone formation is balanced with osteoclast-mediated bone resorption in dynamic 
remodelling process in order to prevent accumulation of bone microdamage [170]. 
Osteoblasts are formed from mesenchymal stem cells in the bone marrow stroma, upon 
stimulation by bone morphogenic proteins (BMPs) and other bone matrix - derived 
factors such as transforming growth factor beta (TGF-β), insulin-like growth factor 1 and 
2 (IGF-1 and IGF-2), or fibroblast growth factor (FGF) [196]. Osteoblasts produce the 
collagenous precursors of bone matrix (osteoid) and regulate bone mineralisation. They 
express bone regulatory factors, including parathyroid hormone (PTH) receptors, 
prostaglandins, estrogen, vitamin D3, and various cytokines [197]. Osteoclasts are large 
multinucleated cells differentiating from haematopoietic stem cells and responsible for 
dissolving both, the mineral and organic bone matrix. Osteoclast formation, activation 
and resorption are regulated by three members of the tumour necrosis factor (TNF) 
family of receptors and ligands: RANK (Receptor Activator of Nuclear Factor-kappa B), 
RANKL (RANK ligand) and OPG (osteoprotegerin) [196, 198, 199]. RANK is a surface 
receptor expressed on mature osteoclasts and their progenitors; it induces 
osteoclastogenesis and controls calcium metabolism. RANKL belongs to type II 
transmembrane proteins and is found on the surface of osteoblasts, bone stomal cells 
and in a soluble form within the bone microenvironment. In the presence of low levels of 
macrophage colony-stimulating factor (M-CSF) RANKL binds to its receptor RANK which 
leads to the differentiation of osteoclast progenitors and limits apoptosis of mature 
osteoclasts. Other molecules, including PTH, parathyroid hormone related protein 
(PTHrP) 1, 25-dihydroxyvitamin D, TNF, interleukin 1 (IL-1) and IL-11 can also induce 
osteoclastogenesis. OPG is secreted by the osteoblasts and stromal cells and acts as a 
soluble decoy receptor for RANKL. OPG competes with RANK for RANKL; therefore, it 
prevents the RANKL–RANK interaction on the osteoclast cell membrane. Binding of 
OPG to RANKL inhibits osteoclastogenesis leading to cessation of bone resorption [170, 
198, 199].  
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1.3.2.2 Types of bone metastases 
Bone metastases are classified as osteolytic, osteoblastic (osteosclerotic) or mixed 
lesions (Figure 5). Osteolytic metastases are typical for breast cancer, where tumour 
cells stimulate the activity of bone-resorbing osteoclasts, leading to enhanced bone 
destruction. Histologically, tumour cells reside in the bone marrow and are surrounded 
by bone degrading osteoclasts. Ultimately, osteolytic lesions lead to complete 
destruction of the bone wall allowing tumour cells to infiltrate the surrounding tissues. 
These osteolytic areas are very prone to fracture even in the absence of traumas. 
Osteoblastic metastases are common in PCa and are caused by cancer-derived factors 
that stimulate the differentiation and activity of bone-forming osteoblasts, thus leading to 
increased bone formation. Histologically, tumour cells are located within bone marrow 
and are surrounded by a high number of osteoblasts that form poor quality woven bone 
anchored at the surface of pre-existing trabeculae of the patient and tend to fill the 
marrow cavity without extension in the soft tissues. This confinement to the marrow 
spaces makes osteoblastic metastases progress more slowly than osteolytic lesions 
[200]. Bone resorption and formation are almost always coupled, often leading to the 
development of mixed lesions [191]. 
 
FIGURE 5 CLASSIFICATION OF BONE METASTASES. Left: osteolytic bone metastases 
display high number of osteoclasts which resorb the mineralised matrix and destroy the bone. 
Right: osteosclerotic bone metastases contain numerous osteoblasts, which form new bone 
within bone marrow occluding the medullary cavity. Adapted from Clezardin et al [191]. 
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1.3.2.3 Model of osteolytic bone metastases  
Model of bone metastases has been developed for breast cancer by Guise et al [201]. 
Breast cancer cells produce PTHrP, which induces osteoclastogenesis, and its high 
expression is specific to the bone metastatic niche. 90% of breast cancer bone 
metastases were found to express PTHrP, compared to only 17% at non-bone sites and 
60% of the primary tumours [202]. Contradicting results for the relation between PTHrP 
expression in primary tumours and bone metastases lead to the conclusion that the bone 
microenvironment itself induces cancer cells to express PTHrP rather than cancer cells 
that metastasize to the bone have an intrinsically higher PTHrP expression [203, 204]. 
In bone marrow, PTHrP expressed by cancer cells binds to parathyroid hormone 
receptor 1 (PTHR1) on osteoblasts and causes osteoblastic expression of RANKL and 
M‑CSF, with a decrease in expression of OPG. RANKL then interacts with RANK 
expressed on hematopoietic osteoclast precursors, inducing their differentiation into 
mature osteoclasts. Osteoclasts degrade the bone, leading to release of bone-stored 
IGF-1 and TGF-β. IGF-1 stimulates breast cancer cell growth while TGF-β further 
stimulates production of PTHrP by cancer cells, resulting in a ‘vicious cycle’ of increased 
osteoclastic bone resorption (Figure 6). Breast cancer cells also produce multiple 
cytokines, including IL-6, IL-11, prostaglandin E2, M-CSF, and tumour necrosis factor 
alpha (TNF-α), which act to promote bone metastases by inducing osteoclastogenesis 
and suppressing osteoblasts [170, 197, 201, 205, 206]. 
 




FIGURE 6 THE VICIOUS CYCLE IN OSTEOLYTIC METASTASIS. Tumour cells stimulate bone 
destruction by production of PTHrP and induction of osteoclastogenesis. The osteoclasts in turn 
release growth factors from the bone matrix further supporting osteoclastogenesis and stimulating 
tumour cells to expand and produce more PTHrP. Adapted from Roodman et al [205].  
 
1.3.2.4 Model of osteoblastic bone metastases in prostate cancer 
The model of PCa bone metastasis is not well understood. PCa cells can influence bone 
homeostasis by secreting paracrine factors that regulate osteoblast proliferation or 
differentiation, including BMPs, TGF-β, IGF, PDGF, VEGF, endothelin-1 (ET-1), 
urokinase-type plasminogen activator (uPA) and PSA. These factors can support 
osteoblast proliferation directly (BMP, TGF, IGF, PDGF, VEGF and ET-1) or influence 
osteoblast proliferation by modifying growth factors present in the bone 
microenvironment (uPA and PSA) [207, 208]. ET-1 is expressed by osteocytes, 
osteoblasts, osteoclasts and vascular endothelial cells. It stimulates mitogenesis in 
osteoblasts and enhances the effect of other osteoblast-stimulatory factors to induce 
bone formation [209]. Prostate epithelium produces ET-1 and expresses its both A and 
B receptors (ETA and ETB). Prostate cancers express ET-1 and mostly ETA receptors 
[210]. Exogenous ET-1 via ETA receptors increases the proliferation of PCa cells through 
enhancement of mitogenic effects of IGF-1, IGF-2, PDGF, epidermal growth factor 
(EGF), and FGF-2 [209]. The paracrine effects of tumour-produced ET-1 on osteoblasts 
leads to their activation. The activated osteoblasts deposit new unmineralised matrix for 
bone formation, which provides a more fertile ‘soil’ for tumour cells, enriched with growth 
factors and BMPs. These factors help PCa cells survive and proliferate in the bone 
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microenvironment [170, 171, 211]. Breast cancers are also known to produce ET-1 and 
they express both, ETA and ETB receptors [212]. Culture media from osteoblastic MCF-
7 and T47D cell lines known to produce ET-1, can stimulate new bone formation and 
osteoblast proliferation, which is blocked by administration of ETA antagonist [209].  
Similar to other malignant cells, PCa cells can release cytokines that induce 
osteoclastogenesis, including PTHrP, IL-1, IL-6 and M-CSF. PTHrP is produced by 
normal prostate epithelial cells, and its immunoexpression increases with cancer 
progression. Upregulation of PTHrP in PCa cells can regulate malignant tumour growth 
in an autocrine manner and PTHrP expression can protect prostate and other cells from 
apoptosis [194]. As PTHrP expression in breast cancer bone metastases is a driving 
force of osteolytic lesions, it is unclear why PTHrP is overexpressed in osteoblastic PCa 
bone metastases. The possible explanation lies in proteolytic activity of PSA. Contrary 
to breast cancer, PSA producing PCa cells have ability to cleave PTHrP, an event that 
switches the downstream pathway from osteolytic to osteoblastic. Cleavage of PTHrP 
leads to its inactivation. On the other hand, the cleaved NH2-terminal region has a 
homology with endothelin-1, therefore can act through ETA receptor pathway as a 
mitogenic factor for osteoblasts [200, 201]. Tumour-secreted proteases such as PSA 
and uPA can also locally increase the amount of growth factors. uPA can cleave and 
activate latent form of TFG-β produced by osteoblasts. Both, uPA and PSA can also 
separate IGF-I from its binding protein IGF-BP3, therefore increasing the local amounts 
of free IGF in the bone microenvironment [194, 200]. 
PCa cells can also secrete bone morphogenic proteins (BMPs), the most potent 
stimulators of osteoblastogenesis. Primary and metastatic PCas have a different pattern 
of BMP expression and adopt different signalling pathways downstream of the BMP 
receptor. Most BMPs and their receptors are expressed in normal prostate tissue. With 
cancer progression, pattern of BMPs expression changes. BMPs production by PCa cells 
induces the osteoblastic activities leading to a predominantly osteoblastic lesion. In 
return, BMPs synthesised by osteoblasts or released from bone matrix enhance the 
growth and aggressiveness of PCa cells, allowing more BMPs to be produced from the 
tumour cells and sustaining the ‘vicious cycle’ [193, 213]. 
In addition to this ‘vicious cycle’, at a certain stage, both tumour-derived factors and 
osteoblasts expressing RANKL can activate osteoclasts, leading to some level of bone 
resorption, and subsequently generating bigger spaces for dominant osteoblastic 
lesions. The cytokines released from bone matrix during bone resorption can also 
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enhance this ‘vicious cycle’ through facilitating the proliferation of both PCa cells and 
osteoblasts [193, 194].  
Current chemotherapy regimens mainly debulk the tumour and palliate symptoms, but 
cannot eradicate late stage disease. They usually slow progression of lesions and reduce 
bone-related skeletal events (SRE; e.g. bone pain and pathological fractures). The 
standard bone-targeting treatment for PCa includes bone-seeking radiopharmaceuticals 
like strontium-89 (89Sr; calcium analog preferentially taken up at areas of increased 
bone turnover such as osteoblastic metastases) [195, 211, 214] and bisphosphonates 
(e.g. zoledronic acid), analogs of pyrophosphates that inhibit osteoclasts function [170, 
191, 195, 214]. Recently, new bone-targeted radiopharmaceutical, the alpha-emitting 
agent Ra223 was introduced into clinical practice, showing increased overall survival in 
patients with mCRPC [215]. 
Better understanding of the molecular mechanisms of PCa bone metastases is needed 
in order to identify new therapeutic targets and develop better treatment options. Many 
clinical trials already explore blockage of the RANK/RANKL/OPG axis as a potential 
therapeutic target for bone metastases. The anti-RANKL monoclonal antibody, 
Denosumab, proved to be a potent inhibitor of osteoclastogenesis and bone resorption 
and has been shown to reduce SRE [170, 191]. Atrasentan, an ETA receptor antagonist, 
has been shown to prevent osteoblastic bone metastases in mouse models and is tested 
in clinical trials for a wide range of solid tumours, including PCa [191, 195].  




The aim of this project is to study genomic alterations in PCa bone metastases in order 
to identify potential genomic mechanisms driving PCa progression. Identification of such 
genetic factors could aid treatment choice for patients with advanced lethal disease or 
help to develop better treatment strategies to improve patient management and possibly 
prolong survival. Genome-wide analysis with high density Affymetrix SNP 6.0 arrays will 
be performed on available fresh frozen PCa bone metastases. Genomic copy number 
changes will be identified with ‘in house’ GOLF software and scrutinised further with 
emphasis on recurrent chromosomal rearrangements.  
Some of the detected recurrent genomic changes in bone metastases will be selected 
for further analysis based on review of available literature on genomic alterations in PCa. 
Particular attention will be paid to recurrent genomic events which were previously 
sporadically found in primary tumours as they could be a driving force for cancer cells at 
primary site to acquire metastatic potential. Next, we will analyse copy number status of 
chosen genetic alterations (concentrating on regions with possible driver genes) by 
fluorescence in situ hybridisation (FISH) in larger cohorts of FFPE PCa bone metastases 
as well as in primary tumours and non-malignant BPH samples. Immunohistochemistry 
(IHC) staining will be also performed to see if observed gene alterations affect expression 
of coded by them proteins.  
Following FISH and IHC analysis, in vitro cell lines models will be generated with stable 
overexpression and downregulation of relevant genes in order to investigate how they 
drive PCa progression. Impact of gene deregulation on several cellular processes 
involved in malignant phenotype will be analysed, including proliferation, migration and 
invasion. If unknown, potential downstream targets or pathways of these genes will be 
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2 Material and Methods 
2.1 Clinical samples 
Tissue microarray (TMA) blocks containing prostate tissue cores from 152 FFPE primary 
PCa and 55 BPH cases were prepared from patient samples obtained from The Barts 
and The London Hospital NHS trust and Whipps Cross Hospital in London under ethical 
approval. Four fresh frozen primary PCa and four BPH samples were obtained from The 
Barts and The London Hospital NHS trust. Six fresh frozen and 43 FFPE (including 6 
cases for which fresh tissue was available) PCa bone metastases were obtained under 
ethical approval from The Robert Jones and Agnes Hunt Orthopaedic Hospital in 
Oswestry, Shropshire. All fresh frozen samples of PCa bone metastases came from 
patients with advanced PCa who were treated for pathological bone fractures. All 
available information about these samples is listed in Table 3. 
TABLE 3 AVAILABLE PATIENT AND TUMOUR INFORMATION FOR FRESH 










Sample 1 83 right tibia osteoblastic  















Sample 5 77 proximal left femur  widespread 
 tumour 
Sample 6 67 left proximal 
humerus 
osteoblastic extensive  
necrosis 
 
TMA sections of FFPE cases of conservatively managed clinically localised PCas 
diagnosed by transurethral resection of the prostate (TURP) were obtained from Prof 
Colin Cooper. These samples were part of Transatlantic Prostate Group (TAPG) PCa 
cohort containing in total 709 cases. Detailed description of the cohort is available 
CHAPTER 2               MATERIAL AND METHODS 
51 
 
elsewhere [216]. Over 10 years follow up data were available for those patients and were 
used to assess the prognostic value of 6q16 deletion in the early stage of PCa.  
2.2 Cell lines and cell culture 
Five PCa cell lines, 22RV1, PC3, DU145, LNCaP and VCaP, and two SV40-immortalised 
prostate epithelial cell lines, PNT1A and PNT2, were used in this project. Additionally, 
human embryonic kidney HEK293 cell line was also used. All cell lines were tested and 
authenticated in 2011, using the ABI AmpF/TSR Identifier kit. 
Frozen cell stocks were stored in liquid nitrogen in Dulbecco’s MEM (DMEM) (Sigma 
Aldrich, UK) or RPMI1640 (Sigma Aldrich, UK) media with 5-10% DMSO and 20% of 
Foetal Calf Serum (FCS) (Sigma Aldrich, UK). All cell lines were thawed at 37°C water 
bath and the cell suspension was diluted in 5 ml of pre-warmed culture media, pelleted 
by centrifugation at 1200 rpm for 5 minutes and resuspended in culture media. After 
thawing, cells were grown under standard conditions (5% CO2 and 37°C) in RPMI1640 
or DMEM with 10% FCS and 1% penicillin/streptomycin (100 units/ml). Cells were 
passaged after reaching 80-90% confluence. 
2.3 Hematoxylin-eosin (H&E) staining 
Fresh frozen sections were fixed in 100% methanol for 10 min and subsequently air-
dried. FFPE sections were first dewaxed in 2 changes of xylene, 5 min each and 
rehydrated in series of alcohols (100%, 90% and 70% ethanol, 5 min each). Slides were 
then rinsed in water and placed in haematoxylin solution for 10 min, differentiated in 1% 
acid ethanol for few seconds, washed under running tap water for 5 min and 
counterstained with eosin solution for 1 min. Next, slides were dehydrated with 90% and 
100% ethanol (3 min each), cleared in 2 changes of xylene (5 min each) and mounted 
with xylene based mounting medium (DPX, Sigma, UK). 
2.4 DNA extraction 
2.4.1 Fresh frozen samples and cell lines 
Primary PCa and BPH frozen tissue was first cut using cryostat (ThermoFisher, UK) and 
one slide was H&E-stained to guide subsequent macrodissection using sterile blade and 
stereo microscope. Five to ten sections were used per sample. For bone metastases, a 
small piece of frozen tissue was used for DNA extraction. The tissue was mashed and 
placed in 500 µl of TEN buffer (10 mM Tris 8.0, 10 mM EDTA, 150 mM NaCl). Cell lines 
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were first trypsinised, centrifuged (1200 rpm, 5 min), washed with PBS and then 
resuspended in 500 µl of TEN buffer. Next, for all samples SDS (1% vol) and proteinase 
K (0.5 mg/ml) were added and samples incubated at 50°C for 3-24 h (until completely 
digested). After complete digestion, samples were incubated with RNAse A (100 µl/ml) 
for 1 h at 37°C to digest the RNA. After incubation regular phenol/chloroform extraction 
was performed. Samples were mixed with equal volume of phenol, shaken in order to 
separate DNA from proteins and cell debris, and centrifuged for 15 min at 13000 rpm. 
The aqueous top layer containing DNA was transferred to another tube and equal volume 
of 50% phenol/chloroform solution was added to the samples. After 15 s of firm shaking, 
samples were centrifuged (13000 rpm, 15 min) and DNA top layer separated and 
cleaned again with equal volume of chloroform. Eventually, DNA was precipitated with 
sodium acetate (1/10 of sample volume) and 2.5 volume of ethanol for 30 min at -80°C. 
After centrifugation (13000 rpm, 15 min), DNA pellet was washed with 70% ethanol and 
resuspended in DEPC (diethylpyrocarbonate, 0.1%)-treated water. DNA concentration 
and quality were checked by Nanodrop Spectrophotometer (Thermofisher, UK). The 
purity of DNA (same for RNA) was considered as sufficient when the ratio of absorbance 
at 260/280 nm and 260/230 nm was between 1.8 and 2.2. Samples were stored at -20°C 
until further processing. 
2.4.2 Simultaneous DNA and RNA extraction  
DNA and RNA extraction from single cell line samples was done with TRIzol reagent 
(Invitrogen, Life Technologies, UK) according to manufacturer’s instructions. Cells (≤ 1 x 
106 cells) were tripsinised, centrifuged at 1200 rpm for 5 min and pellet resuspended in 
1ml of TRIzol. Subsequently, chloroform (1/20 volume) was added and, after a quick 
shake, samples were left at room temperature for 3 min for RNA to separate from the 
cellular DNA and proteins. After centrifugation at 4°C at 13,000 rpm for 15 min, the upper 
aqueous layer containing RNA was moved to a fresh vial and RNA was then precipitated 
by adding 500 μl of isopropanol (bottom organic layer was saved for simultaneous DNA 
extraction). After centrifugation at 4°C at 13,000 rpm for 10 min, supernatant was 
removed and the precipitated RNA was washed with fresh 80% ethanol, air-dried and 
resuspended in 25 μl of DEPC-treated water. RNA quality and quantity was assessed 
using Nanodrop. All RNA samples were stored at -80°C for further analysis. 
The bottom organic layer was used for DNA extraction. Any remaining aqueous phase 
containing RNA was removed. 0.3 ml of 100% ethanol was added to the samples, 
followed by gentle mix and incubation at room temperature for 2–3 min. Next, samples 
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were centrifuged at 2000 g for 5 min at 4°C to pellet the DNA. After centrifugation, the 
phenol-ethanol supernatant was removed and the DNA pellet washed with 1 ml of 
sodium citrate/ ethanol solution (0.1 M sodium citrate in 10% ethanol, pH 8.5) for 30 min 
at room temperature. Samples were then centrifuged at 2000 g for 5 min at 4°C and 
wash step followed centrifugation performed once more. Eventually, samples were 
rinsed with 1.5 ml of 75% ethanol for 20 min at room temperature and centrifuged at 
2000 g for 5 min at 4°C. Supernatant was discarded and DNA pellets air-dried and 
resuspended in 0.3–0.6 ml of 8mM NaOH. Once DNA pellets dissolved, pH was adjusted 
to 7.0 with HEPES (4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid, N-(2-
Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid)) buffer. DNA concentration and 
quality were checked by Nanodrop. DNA samples were stored at -20oC for future use.  
2.4.3 FFPE samples 
H&E stained slide was examined by a pathologist and area of cancer/normal tissue 
circled with the marker pen. Those slides were used for reference when cancer lesions 
from FFPE tissue sections were scraped from unstained slides using a sterile scalpel 
and collected into 1.5 ml tubes. FFPE sections were first dewaxed in three xylene 
washes, 7 minutes each and air dried before macrodissection. Ten sections were 
dissected for each case and directly resuspended in 500 µl of TEN buffer. Next, sodium 
dodecyl sulphate (SDS, 1% vol) and proteinase K (0.5 mg/ml) were added and samples 
incubated at 50°C for 2-3 days (until completely digested). After complete digestion, 
samples were incubated with RNAse A (100 µl/ml) for 1 h at 37°C to digest the RNA. 
Next, regular phenol/chloroform extraction was performed as described above. DNA 
concentration and quality were checked by Nanodrop. The integrity of DNA for clinical 
samples was assessed by agarose gel electrophoresis. 4 μl of DNA mixed with 1 μl of 
loading buffer was loaded into 1% gel (1 g agarose in 100 ml of 1X TBE (Tris-borate-
EDTA) buffer supplemented with 5% ethidium bromide). DNA was run on the gel at 120V 
for 30-60 min in 1X TBE buffer, and the resolving band in the gel was checked under 
ultraviolet (UV) light. Samples were stored at -20°oC until further processing. 
2.5 Sample preparation for SNP 6.0 array analysis 
Six fresh-frozen PCa bone metastases were used for genome-wide analysis. Genome-
Wide Human Single Nucleotide Polymorphis (SNP) 6.0 Arrays were purchased from 
Affymetrix (Santa Clara, CA, US). A single array contains 906,600 SNPs and 946,000 
probes for the detection of copy number variation. The median inter-marker distance 
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over all SNP and copy number markers combined is less than 700 bases. Samples were 
prepared strictly according to the manufacturer protocol (Affymetrix, Santa Clara, CA, 
US). The SNP array assay involves many consecutive steps such as: genomic DNA 
digestion, ligation, dilution, PCR, fragmentation, labelling, hybridisation, washing, 
staining, scanning and SNP data analysis. Genome-Wide Human SNP Nsp/Sty Assay 
Kit 5.0/6.0 was used for SNP array DNA preparation and hybridisation. 
2.5.1 Restriction enzyme digestion  
Genomic DNA was diluted to required 50 ng/μl with reduced TE buffer (10 mM Tris-HCl, 
0.1 mM EDTA, pH 8.0). Digestion master mix was prepared on ice in pre-PCR clean 
hood (TABLE 4). For each sample 5 μl of genomic DNA was mixed with 14.75 µl of the 
master mix in a PCR tube. The digestion reactions were performed in a PCR machine 
using the following program: 37ºC for 2 h, 65ºC for 20 min and 4ºC forever. 
TABLE 4 RESTRICTION DIGESTION MIX PREPARATION. 
Reagents Volume (μl) 
NE buffer 2 (10x) (for NspI)/NE buffer 3 (10x) (for StyI) 2 
BSA, 10x (1 mg/ml) 2 






Ligation master mix was prepared on ice (Table 5) and mixed with digested DNA. 
Adaptor ligation reaction was performed in PCR machine using following program: 16ºC 
for 3 h, 70ºC for 20 min and 4ºC forever. After adaptor ligation DNA samples were diluted 
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TABLE 5 LIGATION MIX PREPARATION. 
Reagents Volume (μl) 
Adaptor Nsp I or Sty I * 0.75 
T4 DNA Ligase (400 U/μl) 2 
T4 DNA Ligase buffer (10x) 2.5 
Total 5.25 
*: part of Genome-Wide Human SNP Nsp/Sty Assay Kit 5.0/6.0. 
2.5.3 PCR 
The PCR master mix was prepared on ice (Table 6). Three PCR reactions were prepared 
for each StyI digested sample and four for each NspI digested sample. For each reaction 
10 μl of diluted ligated DNA sample was mixed with 90 μl PCR master mix. For negative 
control 10 μl of water was used instead of DNA solution. The PCR cycling conditions 
were as follow: initial DNA denaturation at 94ºC for 3 min, followed by 30 cycles of: 94ºC 
for 30 s, 60ºC for 30 s and 68ºC for 15 s. Final extension step at 68ºC for 7 min was 
added at the end. Expected PCR product should be a DNA smear with size ranging 
between 200 and 1100 bp. 3 μl of PCR product mixed with 1 μl of 10x loading buffer was 
run on 2% agarose gel at 120 V for 30 min to confirm the size. 
TABLE 6 PCR MASTER MIX PREPARATION. 
Reagents Volume (μl) 
TITANIUMTM Taq PCR buffer (10x) 10 
G-C melt (5 M) 20 
PCR Primer 002 (100 μM) * 4.5 
dNTP (2.5 mM each) 14 
TITANIUMTM Taq DNA Polymerase (50x) 2 
H2O 39.5 
Total 90 
*: part of Genome-Wide Human SNP Nsp/Sty Assay Kit 5.0/6.0. 
 
2.5.4 PCR product purification 
Al seven PCR reaction products for each sample were pooled together in one vial and 
mixed thoroughly with 1 ml of magnetic beads. Samples were incubated at room 
temperature for 10 min to allow DNA binding to the magnetic beads. Next, samples were 
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centrifuged at 16000 g for 3 min and placed on the magnetic stand where supernatant 
was carefully removed without disturbing the bead pellet. DNA bound to the beads was 
then washed with 1.5 ml of 75% ethanol and samples centrifuged for 3 min at 16000 g. 
After centrifugations samples were placed again on the magnetic stand, supernatant 
removed and leftovers of ethanol allowed to evaporate by leaving the vials uncapped at 
room temperature for 15 min. After drying, 55 μl of elution buffer EB was added to each 
tube and samples placed on a benchtop MixMate® mixer (Eppendorf, UK) at 1150 rpm 
for 10 min in order to resuspend the DNA into solution. Eventually, the samples were 
centrifuged for 5 min at 16000 g, placed on the magnetic stand for 5 min to allow all 
beads to attach to the vials wall, and the supernatant containing samples’ DNA was 
retrieved into fresh vials. Final concentration of DNA into each sample should be 5.0 to 
6.0 μg/μl, which was confirmed by nanodrop (before nanodrop samples were diluted 100 
times in water: 2 μl of each sample plus 198 μl of water).  
2.5.5  Fragmentation 
45 μl of purified amplified DNA was further fragmented by adding 5 μl of 10X 
fragmentation buffer and 5 μl of diluted fragmentation reagent (Table 7). The 
fragmentation reaction was performed in PCR machine using following program: 37ºC 
for 35 min, 95ºC for 15 min and 4ºC forever. Expected average size of fragmented DNA 
should be below 180 bp which was confirmed by running 4 μl of fragmented PCR product 
on 2% agarose gel at 120 V for 30 min.  
TABLE 7 FRAGMENTATION REAGENT PREPARATION. 
Reagents Volume (μl) 
10x Fragmentation Buffer* 12 
Fragmentation Reagent (3 U/μl)* 1 
H2O 106 
Total 120 
*: part of Genome-Wide Human SNP Nsp/Sty Assay Kit 5.0/6.0. 
2.5.6 Labelling 
DNA fragments end-labelling with biotin, necessary for subsequent hybridisation to array 
chip was performed with terminal deoxynucleotidyl transferase (TdT) (Table 8). 19.5 μl 
of labelling mix was added to each sample of fragmented DNA and labelling was 
performed on PCR machine for 4 hours at 37ºC. After labelling TdT was inactivated by 
heating the samples at 95ºC for 15 min.  
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TABLE 8 LABELLING MIX PREPARATION. 
Reagents Volume (μl) 
5X TdT Buffer* 14 
TdT (30 U/μl)* 3.5 
Genechip® DNA Labelling Reagent (30 mM)* 2 
Total 19.5 
*: part of Genome-Wide Human SNP Nsp/Sty Assay Kit 5.0/6.0. 
 
2.5.7 Hybridisation 
Hybridisation mixture was prepared as shown in Table 9. The samples were then 
submitted to the array platform controller, Ms Tracy Chaplin, for final processing. For 
each sample hybridisation mix was denatured at 100ºC for 10 min and immediately 
placed on ice for another 10 min. Next, the samples were brought to 49ºC (1 min 
incubation) and 200 μl of each hybridisation mix was injected onto separate SNP array 
chip and incubated at 49ºC for 16 to 18 h in a rotating GeneChip® hybridisation oven 
640 (Affymetrix, Santa Clara, CA, US) at 60 rpm. 
TABLE 9 HYBRIDISATION MIXTURE PREPARATION. 
Reagents Volume (μl) 
MES (12X; 1.22 M)* 12 
DMSO (100%) 13 
Denhardt’s Solution (50X) 13 
EDTA (0.5 M) 3 
Herring sperm DNA (HSDNA) (10 mg/ml) 3 
Human Cot-1 DNA® (1 mg/ml) 3 
Tween-20 (3%) 1 
Tetramethylammonium chloride (TMACL) (5 M) 140 
OCR,100** 2 
Labelled DNA 70 
Total 260 
*: 1000 ml of 12xMES Buffer: 70.4 g of MES hydrate, 193.3 g of MES sodium salt, 800 ml of 
DEPEC treated water. pH 6.5 - 6.7. 
**: part of Genome-Wide Human SNP Nsp/Sty Assay Kit 5.0/6.0. 
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2.5.8 Washing and Staining 
After hybridisation, unhybridised mixtures were removed from the chips, and the chips 
were washed and stained with the mixture of streptavidin, a biotin-binding protein 
covalently attached to a fluorescent label - R-phycoerythrin, and biotinylated antibody 
according to the Fluidics Protocol (Table 10). All steps were performed on GeneChip® 
Fluidics Station 450.  
TABLE 10 WASHING AND STAINING PROCESS. 
Step Procedure 
Post Hyb Wash 6 cycles of 5 mixes/cycle with Wash Buffer Aa at 25ºC 
Post Hyb Wash 6 cycles of 5 mixes/cycle with Wash Buffer Bb at 45ºC 
Stain Stain the probe array for 10 minutes in Streptavidin 
Phycoerythrin (SAPE) at 25ºC 
Post Stain Wash 6 cycles of 5 mixes/cycle with Wash Buffer A at 25ºC 
2nd Stain Stain the probe array for 10 minutes in antibody solution c,d 
at 25ºC 
3rd Stain Stain the probe array for 10 minutes in SAPE solutione at 
25ºC 
Final Wash 10 cycles of 6 mixes/cycle with Wash Buffer A at 30ºC. The 
holding temperature is 25ºC 
Filling Array Fill the array with Array Holding Buffer 
a: Wash Buffer A: 300 ml of 20x saline-sodium-phosphate-EDTA (SSPE), 1 ml of 10% Tween 20, 
699 ml of water, filtered with 0.2 μM filter. 
b: Wash Buffer B: 30 ml of 20x SSPE, 1 ml of 10%Tween 20, 969 ml of water, filtered with 0.2 μM 
filter. 
c: Stain Buffer: 666.7 μl of water, 300 μl of 20x SSPE, 3.3 μl of 3% Tween 20, 20 μl of 50x 
Denhardt’s blocking solution (1% Ficoll (type 400), 1% polyvinylpyrrolidone, and 1% bovine serum 
albumin). 
d: Antibody stain solution: 5 ml of 0.5 mg/ml biotinylated antibody and 495 μl of Stain Buffer. 
e: SAPE solution: 5 μl of 1 mg/ml SAPE and 495 μl of Stain Buffer. 
f: Array Holding Buffer: 8.3 ml of 12x MES Stock Buffer, 18.5 ml of 5M NaCl, 0.1 ml of 10% Tween 
20 and 73.1 ml of water. 
 
2.5.9 Scanning 
After post-hybridisation washes, the array chip was scanned by Affymetirx Scanner 7G 
and signal intensity data were processed (including QC) using the Affymetrix Genechip 
Operating Software 1.4 (Affymetrix, Santa Clara, CA, US). 
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2.5.10 SNP array data analysis 
Signal intensity data from SNP arrays were analysed using in-house Genome-Oriented 
Laboratory File, GOLF (V4.1) software [24, 217]. The NCBI annotation of the human 
reference genome (NCBI build 36.2) was applied to define the genomic regions. 
Chromosomal copy number alterations were determined based on the log2 ratio of signal 
intensity from the PCa metastatic sample versus the average pooled signal intensity of 
seven unrelated control prostate samples. The control samples were available from 
previous analysis of primary PCa collected from prostatectomy specimens and contained 
DNA from normal prostate tissue adjacent to the tumour [218, 219]. Chromosomal gain 
and loss events were considered if the signal intensity ratio of the mean of 20 contiguous 
probes was significantly outside of 0±0.4 log2 ratio. Regions with copy number 
alterations were visually inspected and manually selected from the original SNP intensity 
plots generated by GOLF software. 
2.6 Fluorescent in situ hybridisation (FISH) 
2.6.1 FISH probe preparation 
2.6.1.1 Bacterial artificial chromosome (BAC) DNA preparation 
The BAC clones used for FISH probes preparation were obtained from the Institute of 
Cancer Research (Sutton, UK). Used clones and location of genes of interest are listed 
in Table 11. BAC clones were streaked for single colonies on standard Luria-Bertani (LB) 
agar (most widely used medium for the growth of bacteria) with 20 μg/ml of 
chloromphenicol (Sigma, UK) and grown at 37°C for 16 h. Single colony for each BAC 
was restreaked into 5 ml of broth liquid (LB) media supplemented with 12.5 µg/ml 
chloromphenicol and cultured at 37°C on the shaker at 225-300 rpm for 16 h. Alkaline 
lysis was performed for BAC plasmid extraction, using P1, P2, P3 solutions and modified 
protocol from Qiagen maxiprep kit. Briefly, 1ml of bacterial culture was pelleted at 13000 
rpm for 5 min and resuspended in P1 solution (Tris/ EDTA buffer with RNase A). DNA 
was lysed with sodium hydroxide and cell debris precipitated using sodium dodecyl 
sulfate (SDS, anionic detergent) (150 μl of P2 solution). The cell lysate was neutralised 
with potassium acetate (150 μl of P3 solution) and the solution gently mixed. BAC DNA 
now in solution was separated from cell debris by centrifugation at 13000 rpm for 20 min. 
BAC DNA was precipitated from supernatant with 1 volume of ice cold isopropanol and 
subsequent incubation at -20°C for 30 min. BAC DNA was then pelleted by centrifugation 
at 13000 rpm for 15 min, washed with 80% ethanol and centrifuged again at 13000 rpm 
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for 5 min. The BAC DNA-containing pellet was left to air-dry, resuspended in 10 mM Tris-
Cl, pH 7.5/1 mM EDTA (TE) buffer and stored at -20°C for further processing. 
2.6.1.2 BAC DNA amplification, cleaning and labelling 
Illustra GenomiPhi V2 DNA Amplification Kit (GE Healthcare, UK) containing Phi29 DNA 
polymerase and random primers was used for BAC DNA amplification according to 
manufacturer instructions. The bacteriophage Phi29 DNA polymerase exponentially 
amplify linear DNA templates via a strand displacement reaction and therefore thermal 
cycling is not required. DNA amplification starts after multiple random primers 
(hexamers) anneal to the template. When DNA synthesis proceeds to the next starting 
site, the Phi29 DNA polymerase displaces the newly produced DNA strand and 
continues its strand elongation. The displaced strands become then additional DNA 
templates for more primers to anneal.  
Before amplification, BAC DNA was heated at 55oC for 5 min to assure that it was well 
resuspended. 1µl of 300 ng/µl BAC DNA template was then mixed with 9 µl of sample 
buffer containing random hexamer primers, denatured at 95ºC for 3 min and cooled on 
ice for 5 min. Next, 9 µl of reaction buffer (with dNTPs) and 1 µl of polymerase were 
added to the sample, mixed and incubated at 30ºC for 1.5 h. After amplification, the 
Phi29 DNA polymerase was heat-inactivated at 65oC for 10 min. The amplification is 
expected to generate DNA smear with average product size of 10 kb, which was 
confirmed by agarose gel electrophoresis. 
Amplified BAC DNA was subsequently purified using standard phenol/chloroform 
method. 20 μl of each sample was diluted in 80 μl of TE buffer to final volume of 100 µl. 
Next, one volume of 1:1 phenol/chloroform was added per sample, solution mixed for 30 
s and briefly centrifuged at 13,000 rpm for 2 min. The aqueous upper layer containing 
the amplified BAC DNA was collected into another tube, mixed vigorously with 100 μl of 
chloroform for 30 s and centrifuged again at 13,000 rpm for 2 min. Top layer with BAC 
DNA was moved to the fresh tube and DNA precipitated with 2.5 volumes of isopropanol 
at -20°C for 30 min. DNA was then pelleted by centrifugation at 13,000 rpm at 4°C for 20 
min, washed with fresh 80% ethanol, centrifuged at 13,000 rpm at 4°C for 10 min and 
after supernatant removal left to air-dry at room temperature. Finally dried DNA was 
resuspended in 15 μl of TE buffer. The concentration of the amplified BAC DNA was 
determined by Nanodrop 1000 spectrophotometer (NanoDrop Technologies, 
Wilmington, US) (expected ~70-150 ng/ml). 
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BAC DNA labelling was done with BioPrime® DNA Labeling System (Invitrogen, Life 
Technologies, UK) according to the manufacturer protocol. 300 ng of amplified BAC DNA 
was diluted with DEPC-treated water to a final volume of 24 µl, and mixed with 20 µl of 
random primers (octamers). The mixture was denatured at 95°C for 5 min. For biotin-14-
dCTP probe labelling (red probe), 5 μl of 10 x dNTP kit biotinylated mixture was added 
to the DNA/primer mixture. For digoxigenin (DIG)-11-dUTP probe labelling (green 
probe), 1.75 μl of DIG-11-dUTP (Roche, UK) in combination with 5 μl of special 10x 
dNTP mixture containing 1mM dATP, dGTP, dCTP, and 0.65 mM dTTP was used. Next, 
1 μl of Klenow fragment polymerase from the kit was added and the labelling reaction 
was performed at 37°C for 3 h. The labelling was stopped with 5 μl of stop buffer. All 
labelled probes were cleaned on Microspin G50 columns (GE Healthcare, UK). Purified 
DNA was quantified by Nanodrop (expected ~90-150 ng/μL). 30 μl of COT-1 human DNA 
(Roche, UK) and 1 μl of herring sperm DNA (Sigma, UK) were added to prevent 
unspecific probe hybridisation. Total DNA was then precipitated with 4M NaCl (1/10 of 
sample volume) and 2.5 volumes of 100% ethanol. Probe DNA was pelleted by 
centrifugation at 13,000 rpm at 4°C for 20 min, washed with 80% ethanol, centrifuged 
again at 13,000 rpm at 4°C for 10 min, and after supernatant removal and air-drying, 
resuspended in 20 µl of DEPC-treated water and stored at -20°C freezer until further 
use. 
2.6.2 Cell and tissue pre-treatment 
Cells from culture were trypsinised, centrifuged (1200 rpm, 5 min), washed with PBS and 
resuspended in 15 ml of fixative (3:1 methanol: acetic acid). After 15 min fixation at room 
temperature, cells were pelleted at 1200 rpm for 5 min and resuspended in 15 ml of fresh 
fixative. This procedure was repeated twice and the last time cells were resuspended in 
small volume (200 - 500 μl) of fixative, dropped on slides using plastic pipette and 
allowed to air-dry. The slides were then stored at -20°C until further use. Immediately 
before FISH, slides were pre-treated for 10 min with 70% acetic acid to remove remains 
of cytoplasm, washed in PBS (2 x 5 min), dehydrated with 70%, 90% and 100% ethanol 
(3 minutes each) and air-dried. 
FFPE tissue from clinical samples was dewaxed with xylene (2 x 5 min), washed with 
ethanol (2 x 5 min) and rehydrated in water (2 x 3 min). Slides were then boiled in tissue 
pre-treatment solution for 15 min, followed by 5 min enzyme digestion to break cell 
membranes and expose nuclei for better FISH probe access (SPOT-Light Tissue Pre-
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treatment kit, Invitrogen, Life Technologies, UK). Eventually, slides were washed in water 
(2 x 3 min) and air-dried. 
2.6.3  Hybridisation and post-hybridisation washes 
1 μl of the DIG labelled probe (chromosome 1 centromere) and 1 µl of combined 4 biotin 
labelled probes (0.25 µl each; either for CCND1 or FBXL4 locus) were mixed with 10 μl 
of hybridisation buffer (60%formamide, 12% dextran sulphate, 2.4x SSC (sodium 
chloride, sodium citrate) buffer, 14 mM EDTA pH 8.0 and salmon sperm, 400 µg/ml). The 
mixture was then applied on pre-treated slides, which were subsequently coverslipped. 
Coverslips were sealed with rubber cement. Slides were denatured at 95°C for 10 min, 
placed in the humid chamber and probe hybridisation allowed overnight at 37°C. Next 
day (after ~16h) coverslips were removed and slides underwent standard post-
hybridisation washes at 42°C: twice in 50% formamide/2x SSC and twice in 2x SSC, 5 
min each. After 3 min wash with 4x SSC/0.5% Tween-20 (SSCT) buffer, slides were 
blocked with 200 μl of 5% milk/SSCT solution (SSCTM) for 15 min at 37°C. Next, 
blocking solution was removed and slides were incubated with 200 μl of SSCTM with 1 
μl of the streptavidin-Cy3 conjugate (Sigma, UK) at 37°C for 10 min. After incubation 
slides were washed 3 x 2 min with SSCT. Next, 200 μl of SSCTM with 1 μl of anti-DIG-
FITC antibody (Roche, UK) was added to each slide and slides incubated again at 37°C 
for 10 min. Eventually, slides were washed with SSCT (2 min), PBS (2 x 5 min), 
dehydrated in 70% ethanol (20 s) and air-dried. Slides were then coverslipped with 
Vectashield antifade containing DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride, 
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FISH slides were scanned and analysed using the Applied Imaging Ariol® System 
(Applied Imaging, San Jose, CA, USA). A minimum of 100 cells with clear hybridisation 
signals were counted per sample. FISH score for each locus in PCa samples was 
normalised to results from BPH cases serving as nonmalignant controls. Standard mean 
value of positive findings in ten control specimens (BPH) +3SD was used as a positive 
cut-off point [220, 221], which for both, CCND1 and FBXL4 loci was ≥30% of nuclei with 
copy number change. 
2.7 RNA expression analysis 
2.7.1 RNA extraction 
RNA was extracted with TRIzol reagent (Invitrogen, Life Technologies, UK) according to 
manufacturer’s instructions. Treated and untreated cells (≤ 1 x 106 cells) were washed 
with PBS before adding 1ml of TRIzol. For bone metastases less than 1 mg of tissue 
scrapes was mashed on ice and immediately mixed with 1 ml of TRIzol. Subsequently, 
chloroform (1/20 volume) was added and, after a quick shake, samples were left at room 
temperature for 3 min for RNA to separate from the cellular DNA and proteins. After 
centrifugation at 4°C at 13,000 rpm for 15 min, the upper aqueous layer containing RNA 
was moved to a fresh vial and RNA was then precipitated by adding 500 μl of 
isopropanol. After centrifugation at 4°C at 13,000 rpm for 10 min, supernatant was 
removed and the precipitated RNA was washed with fresh 80% ethanol, air-dried and 
Gene or region of 
interest 
BAC clone  Labelled FISH probe 
colour 
Chr6q16 deletion: RP11-639P13 Red 
 CTD-2073H5 Red 
 RP11-258I9 Red 
 CTD-2281M23 Red 
Chr11q13 gain: CTD-2009H2 Red 
 RP11-681H17 Red 
 RP11-278A17 Red 
 RP11-599F23 Red 
Chr1 centromere: 
 
Green control probe for 
6q16 and 11q13 regions 
Chr6p12.3 control: RP11-727H16 Green control probe for 
TAPG cohort 
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resuspended in 25 μl of DEPC-treated water. RNA quality and quantity was assessed 
using Nanodrop. All RNA samples were stored at -80°C for further analysis. 
2.7.2 Complementary DNA (cDNA) synthesis 
cDNA synthesis was performed using Moloney Murine Leukemia Virus Reverse 
Transcriptase, RNase H Minus, Point Mutant (M-MLV RT (H–)) supplied with reaction 
buffer (Promega, UK). Total of 1 µg of RNA (per sample) diluted in DEPC-treated water 
to a final volume of 11 µl was mixed with 1 µl of random hexamers (Applied Biosystem, 
Life Technologies, UK) and denatured at 72°C for 5 min. After 5 min incubation on ice, 6 
µl of 5x M-MLV RT buffer and 10 µl of 2.5 mM dNTP (Roche, UK) were added and cDNA 
synthesis was performed at 42°C for 1 h, followed by enzyme inactivation by heating at 
95°C for 5 min. Eventually, RNA was digested by adding 1 μl of RNase H (Invitrogen, 
Life Technologies, UK) and heating the mixture at 42°C for 20 min. Samples were stored 
at -20°C for future use.  
2.7.3 Quantitative Polymerase Chain Reaction (qPCR) 
qPCR reactions were prepared with Taqman Universal PCR Master Mix (Applied 
Biosystem, Life Technologies, UK), using TaqMan Gene Expression Assays (Applied 
Biosystem, Life Technologies, UK) or Copy Number Assays (CNAssays) listed in Table 
12. TaqMan GAPDH Expression Assays (Applied Biosystem, Life Technologies, UK) 
was used as an endogenous control for expression assays and RPPH1 (14q11.2, coding 
RNase P) Copy Number Reference Assay for CNAssays.  
For cyclin D1b splice variant detection, POWER SYBR Green assay was chosen 
(Applied Biosystems, Life Technologies, UK) as there is no commercially available 
TaqMan expression assay. Primers used were described elsewhere [222]. Forward 
primer (GTGCCACAGATGTGAAGTTC) spans the junction of exon 3 and 4, and reverse 
primer (GGACATCACCCTCACTTAC) lays within beginning of intron 4. This primer 
combination avoids possibility of amplification of genomic DNA or full length cyclin D1a 
variant. Amplicon length is 175 bp. β-actin primers were used as endogenous control 
(forward: TCTTCCAGCCTTCCTTCCT, reverse: GCAGTGATCTCCTTCTGCAT, 
amplicon size: 175 bp).  
To assure reaction specificity, melting curves were performed along the SYBR Green 
based qPCR to detect potential primer – dimers or unspecific amplification products, and 
2% agarose gel was run for each plate after completion of qPCR. All samples were 
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prepared according to manufacturer recommendations. PCR mixture content is listed in 
Table 13.  
TABLE 12 LIST OF USED TAQMAN ASSAYS. 
Gene  TaqMan assay type Assay ID/part number Exon boundary 
GAPDH Gene Expression Assay Hs02758991_g1/4331182 6-7 
CCND1 Gene Expression Assay Rn00432360_m1/4331182 4-5 
FBXL4 Gene Expression Assay Hs00273315_m1/4351370 5-6 
CCND1 Copy Number Assay Hs01425024_cn 1 






TABLE 13 QRT-PCR MASTER MIX. 
Reagents Volume (µl) 
TaqMan Universal PCR Master Mix/ POWER SYBR 
Green Master Mix 
10 
DEPC-treated water 8 
TaqMan Gene Expression Assays/ CNAssay/ cDNA 
specific primers 
1 
cDNA (or 15-25 ng of DNA for CNAssay) 1 
Total volume 20 
 
Samples in MicroAmp® fast optical 96-well reaction plates (Applied Biosystems) were 
loaded on an ABI 7500 Real-Time PCR System (Applied Biosystems, UK) with default 
settings. Cycling conditions are listed in Table 14. Samples were run in triplicates. RNA 
levels were calculated using relative quantification method. DNA copy number was 
calculated according to manufacturer instructions: samples were run with absolute 
quantification program and data were loaded into CopyCaller software (version 2.0) for 
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TABLE 14 STANDARD QPCR PROGRAM. 
Step Temperature (°C) Time 
Denaturation 95 10 min 
40 cycles of subsequent:   
Denaturation 95 15 sec 
annealing and extension 60 1 min 
 
2.8 Protein analysis 
2.8.1 Western blot (WB) 
2.8.1.1 Protein extraction 
Protein extraction was done on ice with freshly prepared lysis buffer (Table 15). 100-200 
µl of lysis buffer was added to each well of 6-well plate and cells were mechanically 
homogenised with a cell scraper. Cell lysates were incubated on ice for 30 min with 
vortexing every 5-10 min. Eventually, cell lysates were spin at 1000 g for 2 min to remove 
cell debris. The supernatant was collected and stored at -80°C until further use. 
TABLE 15 LYSIS BUFFER PREPARATION. 
Reagent Volume (µl) 
50mM TRIS/150 mM NaCl pH 8.0 752 
10% Triton X-100 100 
protease inhibitor cocktail 7x 143 
phosphatase inhibitor 5 
Total volume 1000 
 
2.8.1.2 Bradford assay 
The Bradford assay relies on the binding of the dye Coomassie Blue G-250 to protein. 
Protein binding stabilises the anionic form of the dye, causing a visible colour change 
(reaction turns blue). The quantity of protein can be estimated by determining the amount 
of dye in the blue ionic form by measuring the absorbance of the solution at 565 nm. 
Measurements were done in 96-well plates and in duplicates for each sample. 10 µl of 
each protein solution was added to 190 µl of diluted to 1x Protein Assay Dye Reagent 
Concentrate (BioRad, UK). Protein concentration was quantified relative to the standard 
curve constructed from bovine serum albumin (BSA) standard solutions (125, 250, 500, 
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750, 1,000, 1,500 and 2,000 μg/ml, Fisher Scientific, UK). Briefly, 10 µl of BSA standard 
solutions or relevant protein lysates were added to 190 µl of diluted to 1x Protein Assay 
Dye Reagent Concentrate. Samples and standards were loaded on plate reader (Opsys 
MR Microplate Reader, DYNEX, VA, US) for standard curve preparation and sample 
quantification. Absorbance of sample was then compared to standard curve prepared 
with BSA protein standards and concentrations calculated with Revelation Quicklink 
software version 4.25. 
2.8.1.3 Sodium Dodecyl Sulphate-PolyacrylAmide Gel Electrophoresis (SDS-
PAGE) and PVDF membrane transfer 
Protein samples (15-50 μg) were diluted in 1x NuPAGE® LDS Sample Buffer (BioRad, 
UK) containing Coomassie G250 and Phenol Red. Tertiary protein structure was 
disrupted by adding 1x reducing buffer (BioRad, UK). Samples were denatured at 97°C 
for 10 min.  
Classic SDS-PAGE Laemmli system was used. The gel was divided into an upper 
‘stacking’ gel of low percentage (large pore size) and low pH (6.8) used to pack proteins 
together after loading, and a resolving gel with a pH of 8.8 and much smaller pores. Gel 
recipes are listed in Table 16 and  
Table 17. Addition of SDS allowed separation of the proteins by size only. Polymerisation 
of gels was increased by the catalysts: amonium persulphate and 
tetramethylethylenediamine (TEMED). After casting, gels were assembled into running 
module (BioRad, UK), which was filled with 1x Tris-Glycine-SDS PAGE Running Buffer 
(0.25 M Tris base, 1.92 M glylcine, 1% SDS, National Diagnostics, UK). Denatured 
protein samples (95°C for 5 min) and Spectra™ Multicolor Broad Range Protein Ladder 
(Fisher Scientific, UK) were then loaded on the gel. Gel electrophoresis was done at 100-
120 V for 1.5 h. 
After electrophoresis proteins were transferred on Polyvinylidene difluoride (PVDF) 
membrane (Immobilon-P Membrane, 0.45 µm, Millipore, UK). PVDF membrane was pre-
treated by sequential 1 min washes in 100% methanol, water and the transfer buffer 
(10% Tris-Glycine Buffer (0.25 M Tris base and 1.92 M glycine, National Diagnostics, 
UK), 20% methanol, 70% distilled water). Protein transfer to the PVDF membrane was 
done by wet transfer method. Transfer cassette with the gel and the PVDF membrane 
covered by blotting paper and sponges was submerged in the tank with transfer buffer 
and ice container (for cooling), and an electrical field was applied. Protein transfer was 
done at 200 mA for 120 min. After transfer membrane was washed briefly in water.  
CHAPTER 2               MATERIAL AND METHODS 
68 
 
TABLE 16 10% RESOLVING GEL PREPARATION. 
Reagent Volume 
ProtoFLOWGel 37:5:1 (Flowgen Bioscience, UK) 6.6 ml 
4x ProtoFLOWGel Resolving Buffer (Flowgen 
Bioscience, UK) 
5 ml 
H2O 8.2 ml 
TEMED (Sigma, UK) 20 µl 
Amonium persulphate 10% (Sigma, UK) 200 µl 
 
TABLE 17 STACKING GEL PREPARATION. 
Reagent Volume 
ProtoFLOWGel 37:5:1 (Flowgen Bioscience, UK) 1.3 ml 
ProtoFLOWGel Stacking Buffer (Flowgen 
Bioscience, UK) 
2 ml 
H2O 6.1 ml 
TEMED (Sigma, UK) 10 µl 
Amonium persulphate 10% (Sigma, UK) 50 µl 
 
2.8.1.4 Antibody incubation and protein detection 
To prevent non-specific background binding of the primary and/or secondary antibodies, 
membrane was blocked with 5% BSA (powder milk for FBXL4) solution in Tris Buffer 
Saline/0.1% Tween-20 (TBST) for 30 min. After blocking, membrane was incubated with 
primary antibody diluted in 5% BSA (powder milk for FBXL4) /TBS buffer overnight at 
4°C under agitation. All antibodies used are listed in Table 18. Next day, membrane was 
washed 3 x 7 min in TBST and incubated in secondary peroxidase conjugated antibody 
diluted in 5% milk/TBST buffer for 1 h at room temperature on rocking platform. After 
incubation membrane was washed 3 x 7 min again with TBST buffer. 
Protein detection was done with Immobilon Western Chemiluminescent HRP Substrate 
(Millipore, UK) or with SuperSignal™ West Femto Maximum Sensitivity Substrate 
(Thermo Fisher, UK), which is an ultra-sensitive enhanced chemiluminescent substrate 
for low-level protein detection, containing luminol and horseradish peroxidise (HRP) 
solutions. After TBST wash, 1 ml of chemiluminescent HRP substrate was added on the 
membrane, which was then incubated for 1 min at room temperature. Stained protein 
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bands were subsequently captured on X-ray film (Fuji Photo Film, Fisher Scientific, UK). 
Exposure time was different for each antibody and varied from 1 s to 30 min. β-actin 
protein bands were used as protein load control. Membrane was eventually washed 
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TABLE 18 PRIMARY AND SECONDARY ANTIBODIES USED FOR WESTERN BLOT. 
Antibody Cat. No./ Manufacturer Dilution 
FBXL4, mouse polyclonal Ab ab172441, 
Abcam, UK 
1:1000 
FBXL4, rabbit polyclonal Ab ab153812, 
Abcam, UK 
1:1000 
FBXL4, rabbit polyclonal Ab ab181704, 
Abcam, UK 
1:1000 
FBXL4, mouse monoclonal Ab sc-376102, 
Santa Cruz, US 
1:1000 
FBXL4, mouse monoclonal Ab sc-81270, 
Santa Cruz, US 
1:500 
Flag, rabbit polyclonal Ab F7425,  
Sigma-Aldrich, UK 
1:500 
Flag, mouse monoclonal Ab, Clone M2 F1804,  
Sigma-Aldrich, UK 
1:200 
N-cadherin, mouse monoclonal Ab ab98952, 
Abcam, UK 
1:1000 
E-cadherin, mouse monoclonal Ab M106, 
Takara, France 
1:1000 
Vimentin, rabbit monoclonal Ab AC-0024, 
Epitomics, UK 
1:1000 
FAK, mouse monoclonal Ab 05-537, 
Millipore, UK 
1:1000 
Phospho-FAK (Y397), rabbit monoclonal Ab ab81298, 
Abcam, UK 
1:250 
Anti-β-Actin, mouse monoclonal Ab, clone 
AC-15 
A5441  
Sigma Aldrich, UK 
1:2000 
Goat Anti-Mouse IgG (H+L), Peroxidase 
Conjugated 
32430 
Fisher Scientific, UK 
1:2000 
Goat Anti-Rabbit IgG (H+L), Peroxidase 
Conjugated 
32460 
Fisher Scientific, UK 
1:2000 
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2.8.2 Immunochistochemistry (IHC) 
2.8.2.1 Cell lines 
Stable HEK293 cells overexpressing FBXL4 with related controls (wild type (wt) HEK293 
and HEK293 transfected with empty vector (EV)) and 22RV1 single clones with FBXL4 
knockdown by shRNA (shFBXL4) with adequate controls (wt 22RV1 and 22RV1 
transfected with non-targeting shRNA (NT)) were stained for FBXL4 and ERLEC1. All 
antibodies used for IHC including dilutions are listed in Table 19. 
TABLE 19 PRIMARY ANTIBODIES USED FOR IHC/IF. 
Antibody Cat. No./ Manufacturer Dilution 
FBXL4, mouse polyclonal Ab ab172441, 
Abcam, UK 
1:100 
FBXL4, rabbit polyclonal Ab ab153812, 
Abcam, UK 
1:500 
FBXL4, rabbit polyclonal Ab ab181704, 
Abcam, UK 
1:1000 
FBXL4, mouse monoclonal Ab sc-376102, 
Santa Cruz, US 
1:1000 
FBXL4, mouse monoclonal Ab sc-81270, 
Santa Cruz, US 
1:50 
Flag, mouse monoclonal Ab, Clone M2 F1804,  
Sigma-Aldrich, UK 
1:100 
Cyclin D1 (SP4), rabbit monoclonal Ab VPRM03,  
Vector Laboratories, UK 
1:50 




Four different FBXL4 antibodies were tested for immunohistochemistry using stable 
HEK293 cells overexpressing FBXL4 as a positive control. ERLEC1 antibody was 
previously confirmed to be specific using WB. Cells were seeded in full DMEM medium 
onto glass slides and allowed to attach and grow for 2 days. During that time, HEK293 
cells were treated with tetracycline to induce FBXL4 expression. Next, medium was 
removed, cells rinsed with PBS and fixed with 10% formalin in PBS for 20 min. After 
fixation slides were rinsed in PBS 2x5 min and permeabilised with 0.2% Tween 20 in 
PBS for 10 min. Next, slides were washed in PBS 2x5 min and incubated with primary 
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antibody for 1 h at the dilutions specified in Table 19. Primary antibodies were diluted in 
PBS with 1% BSA. After incubation primary antibody solution was washed off with PBST 
buffer (2x3 min) and secondary biotinylated universal antibody (Vectastain Universal 
Elite ABC Kit, Vector Lab, UK) diluted in PBS was applied for 30 min. After rinse with 
PBST (2x3 min), slides were incubated with avidin-peroxidise complex (Vectastain 
Universal Elite ABC Kit, Vector Lab, UK) for 20 min. Slides were rinsed again with PBST 
(2x3 min). Colour development was done by applying 3,3′-Diaminobenzidine (DAB) 
solution (BioGenex, UK) for 10 min. Slides were then conterstained with haematoxylin 
for 3 min, differentiated in 70% acid ethanol for few seconds and washed under running 
tap water for 5 min. Eventually, slides were dehydrated through series of 70%, 90% and 
2x100% ethanols (3 min each), cleared with two changes of xylene (5 min each) and 
mounted with xylene based mounting medium (DPX, Sigma, UK). 
2.8.2.2 FFPE tissue sections 
FFPE clinical samples were cut at 4 µm with microtome (Leica, UK). Tissue sections 
were then dewaxed in 2 changes of xylene (5 min each) and rehydrated through series 
of alcohols (100%, 90% and 70% ethanol, 5 min each). Endogenous peroxidise was 
blocked by incubation in 3% H2O2 solution in methanol for 10 min. For FBXL4 and 
ERLEC1 antibodies antigen retrieval was performed by pressure-cooking the slides in 
citric acid solution, pH 6.0 (Vectastain, UK) for 10 min and immediately cooled under 
running tap water. For cyclin D1 antibody only, antigen retrieval was performed by 
microwaving the slides in TRIS-based, high pH solution (Vectastain, UK) for 15 min, 
followed by 30 min cooling on bench. After antigen retrieval slides were rinsed in water 
and placed in TBST, pH 7.6 for 2 min. Next, slides were incubated at room temperature 
for 1 h with primary antibody diluted in PBS with 1% BSA. Normal tonsil tissue was used 
as a positive control for cyclin D1 (basal layer of squamous epithelium is cyclin D1 
positive) and BPH section served as a positive control for FBXL4. Primary antibody 
solution was washed off with TBST buffer (2x3 min) and secondary biotinylated universal 
antibody (Vectastain Universal Elite ABC Kit, Vector Lab, UK) diluted in PBS was applied 
for 30 min. After rinse with TBST (2x3 min), slides were incubated with avidin-peroxidise 
complex (Vectastain Universal Elite ABC Kit, Vector Lab, UK) for 20 min. Slides were 
rinsed again with PBST (2x3 min). Colour development was done by applying 3,3′-
Diaminobenzidine (DAB) solution (BioGenex, UK) for 10 min. Slides were then 
conterstained with haematoxylin for 3 min, differentiated in 70% acid ethanol for few 
seconds and washed under running tap water for 5 min. Eventually, slides were 
dehydrated through series of 70%, 90% and 2x100% ethanols (3 min each), cleared with 
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two changes of xylene (5 min each) and mounted with xylene based mounting medium 
(DPX, Sigma, UK). After drying, slides were examined under light microscope and scored 
for protein expression by pathologist, Dan Berney. Cyclin D1 nuclear expression was 
scored for staining intensity (score 1-weak, 2-medium, 3-strong) and percentage of 
stained nuclei (0-100%). FBXL4 cytoplasmic expression was scored for intensity only. 
2.8.3 Immunofluorescence (IF) 
For IF cells were grown on coverslips in 2 ml of medium/well in 6 well plate. Stable 22RV1 
cells transfected with shRNA were grown on coverslips for 2 days; stable T-Rex-293 
cells were treated for 48h with tetracycline and HEK293 cells transfected with ERLEC1 
siRNA were allow to grow till 48 h post-transfection. If mitochondria staining was 
required, cells were incubated with 100 nM of MitoTracker Red CMXRos (M7515, Life 
Technologies, UK) for 30 min before proceeding to PBS rinse and cell fixation. Cells 
were washed with 2 ml PBS and fixed in 10% formalin for 20 min. After washing 
coverslips with PBST 2x5 min, cells were permeabilised with 0.2% Tween in PBS for 10 
min, washed again in two changes of PBS, 5 min each and unspecific antibody binding 
blocked with 1% BSA in PBS. Blocking solution was then removed and coverslips were 
incubated at room temp for 1 h with 100 µl of primary antibody diluted in blocking solution: 
mouse anti-Flag (1:100), mouse anti-FBXL4 (1:50), mouse anti-FAK (1:100), or rabbit 
anti-ERLEC1 (1:20). For antibodies details please see Table 18 and Table 19. Negative 
control slide was incubated with primary antibodies diluent only. Primary antibodies were 
washed with PBS, 2x5 min and Donkey anti-Rabbit IgG Secondary Antibody, Alexa 
Fluor® 488 conjugate (Life Technologies, UK) or Goat anti-Mouse IgG Secondary 
Antibody, Alexa Fluor® 488 conjugate (Life Technologies, UK) were applied at dilution 
1:100 in PBS for 30 min. For single IF staining, cells were then washed in PBS for 2x5 
min, air-dried and covered with antifade containing DAPI (Invitrogen, UK). For double IF 
staining, cells were next incubated for 40 min with Alexa Fluor 595 Phalloidin (Life 
Technologies, UK) diluted 1:40 (methanol stock 200U/ml) for F-actin staining. Next cells 
were washed in PBS for 2x5 min, air-dried and covered with antifade containing DAPI 
(Invitrogen, UK). 
Fluorescence signal (green for ERLEC1/ FBXL4, red for mitochondria/ F-actin and blue 
for nuclei) was checked using Axioplan microscope or confocal microscope LSM710. 
Signal intensity was compared to control cells. Slides were stored at 4oC and protected 
from light. 
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2.9 FBXL4 gene knockdown  
2.9.1 Gene knockdown with small interfering RNA (siRNA)  
Cells were seeded 24 h before transfection in 6 well plates at 40-50% confluence (Table 
20). No antibiotic was added to the growth medium. All siRNAs used were resuspended 
to 20 µM stock solution according to manufacturer instructions and are listed in Table 
21. 
TABLE 20 CELL SEEDING DENSITIES FOR SIRNA KNOCKDOWN. 
Cell line Medium 6 well plate  
HEK293 DMEM 7x104 /well 
22RV1 DMEM 12x104 /well 
DU145 DMEM 10x104 /well 
PC3 DMEM 7x104 /well 
 
TABLE 21 LIST OF SIRNAS USED FOR KNOCKDOWN EXPERIMENTS. 
siRNA Manufacturer/cat.no. Targeted gene 
ON-TARGETplus SMARTpool  Dharmacon/ L-003210-00 CCND1 
ON-TARGETplus SMARTpool Dharmacon/L-013564-00 FBXL4 
ON-TARGETplus SMARTpool Dharmacon/ L-010658-00 ERLEC1 
ON-TARGETplus Non-targeting  
Control Pool  
Dharmacon/ D-001810-10 none 
 
Cells were transfected with 100 nM of siRNA/well. For each well of the 6 well-plate, 5 µl 
of the siRNA (20 µM stock) was mixed with 180 µl of plain culture medium in 1 vial. In 
another separate vial 5 µl of oligofectamine (Invitrogen, Life Technologies, UK) was 
mixed with 20 µl of plain culture medium. Both tubes were incubated at room temperature 
for 5 min. The content of both tubes was then mixed together and incubated for another 
20 min at room temperature. Next, 790 µl of plain medium was added to the mixture. 
Meantime, cells in the 6-well plate were washed with PBS and 1 ml of siRNA mixture 
was added to each well. Plates were then placed in the incubator for 4 h to allow siRNA 
enter the cells. After 4 h, 500 µl of culture medium with 30% of FCS was added to each 
well and plates were incubated under standard conditions for 24, 48 or 72 h. For each 
experiment time point, equal numbers of wells were prepared with siRNA targeting gene 
of interest, non-targeting siRNA and control cells not treated with siRNA.  
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For 96 well plate reagents volumes were adjusted accordingly. Cells were transfected 
with 10 nM of siRNA/well. For each well of the 96 well-plate, 0.5 µl of the suitable siRNA 
(20 µM) was mixed with 16 µl of plain culture medium in 1 vial. In another separate vial 
0.5 µl of oligofectamine (Invitrogen, Life Technologies, UK) was mixed with 3 µl of plain 
culture medium. Both tubes were incubated at room temperature for 5 min. The content 
of both tubes was then mixed together and incubated for another 20 min at room 
temperature. Meantime, old medium was removed from the plates and 80 µl of fresh 
plain DMEM was added to each well. After incubation, 20 µl of siRNA mixture was added 
to each well and placed in the incubator for 4 h to allow siRNA enter the cells. After 4 h, 
50 µl of culture medium with 30% of FCS was added to each well and plates were 
incubated under standard conditions for 24, 48 or 72 h. For each experiment time point, 
equal numbers of wells were prepared with siRNA targeting gene of interest, non-
targeting siRNA and control cells not treated with siRNA.  
2.9.2 Gene knockdown with short hairpin RNA (shRNA) constructs 
Transduction-ready high-titer GIPZ lentiviral particles with TurboGFP (allowing the visual 
marking) were purchased from Thermo Fisher Scientific, UK (Figure 7). Three different 
GIPZ shRNA against FBXL4 were obtained at titres (number of viral particles or 
transducing units present per ml of solution): shFBXL4_1, 2.75 x 108 TU/ml; shFBXL4_2, 
4.12 x 108 TU/ml and shFBXL4_3, 8.24 x 108 TU/ml. The GIPZ Non-silencing lentiviral 
shRNA vector (8.24 x 108 TU/ml) and GAPDH GIPZ lentiviral shRNA vector (1.67 x 109 
TU/ml) were purchased to serve respectively as negative and positive controls. The 
pGIPZ lentiviral vector can be transfected using the replication incompetent lentivirus; it 
contains TurboGFP which together with shRNA is part of a bicistronic transcript allowing 
visual marking of shRNA expressing cells as well as contain puromycin resistance gene 
allowing stable cell line selection (Figure 7). 
Generation of stable 22RV1 cells expressing the pGIPZ lentiviral vector was based on 
resistance to puromycin. Determination of the minimum amount of antibiotic required to 
kill non-transfected cells was based on antibiotic dose response (kill curve). 22RV1 cells 
were seeded in 1ml of full DMEM in 24 well plates at 7.5x104 cells/well (60% confluence). 
After 24 h, full DMEM medium was replaced with fresh medium containing different 
concentrations of puromycin. 10 mg/ml stock solution of puromycin (Sigma, UK) in water 
was used to prepare a range of 11 puromycin concentrations (0 (untreated control)-15 
µg/ml) to treat 22RV1 cells. After 4 days of antibiotic treatment cell viability was assessed 
with The CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay (Promega, UK) 
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according to manufacturer instructions. 1 µg/ml of puromycin was identified as the 
minimal concentration of antibiotic to kill all non-transfected 22RV1 cells. 
 
 
FIGURE 7. GIPZ LENTIVIRAL PARTICLES. hCMV, Human cytomegalovirus 
promoter drives strong transgene expression; tGFP, TurboGFP reporter for visual 
tracking of transduction and expression; PuroR, Puromycin resistance permits antibiotic-
selective pressure and propagation of stable integrants; IRES, Internal ribosomal entry 
site allows expression of TurboGFP and puromycin resistance genes in a single 
transcript; shRNA, microRNA-adapted shRNA (based on miR-30) for gene knockdown; 
5' LTR, 5' long terminal repeat; 3' SIN LTR, 3' self-inactivating long terminal repeat for 
increased lentivirus safety; Psi, packaging sequence allows viral genome packaging 
using lentiviral packaging systems; RRE, Rev response element enhances titer by 
increasing packaging efficiency of full-length viral genomes; WPRE, Woodchuck 
hepatitis posttranscriptional regulatory element enhances transgene expression in the 
target cells.  
 
For viral transduction 22RV1 cells were plated at a density of 5x104 cells/well (~40% 
confluence) in 1.5 ml of full DMEM in 24-well plates. Using these specific conditions 
titration of stock GAPDH GIPZ lentiviral shRNA vector (1.67 x 109 TU/ml) was performed 
to determine the optimum number of transducing units (TU)/ viral particles per every cell 
in the well (so called multiplicity of infection, MOI). To do that serial dilutions of the shRNA 
viral stock were made in a 96-well plate using serum free DMEM with 8 µg/ml of 
polybrene. Polybrene (hexadimethrine bromide, a cationic polymer) increases the 
efficiency of infection by neutralizing the charge repulsion between virions and cell 
surface. 10 µl of stock viral titer was added to 50 µl of DMEM with polybrene and mixed. 
30 µl of this solution was transferred to first well of 96 well plate and mixed again with 30 
µl of DMEM, making 1:2 dilution of previous concentration. Altogether, 14 serial dilutions 
1:2 were prepared as listed in (Table 22); starting from 167 virus particles to 0.016/cell/30 
µl volume in the final dilution. 
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TABLE 22. OPTIMISATION OF THE NUMBER OF TRANSDUCING UNITS (TU)/ 
VIRAL PARTICLES PER EVERY CELL IN THE WELL (MOI). 
Well Viral particles (µl) Medium (µl) MOI (viral particles/cell) in 30 µl 
1 30 from stock titer 30 167 
2 30 from well 1 30 83 
3 30 from well 2 30 41 
4 30 from well 3 30 20 
5 30 from well 4 30 10 
6 30 from well 5 30 5 
7 30 from well 6 30 2.5 
8 30 from well 7 30 1.25 
9 30 from well 8 30 0.62 
10 30 from well 9 30 0.31 
11 30 from well 10 30 0.15 
12 30 from well 11 30 0.075 
13 30 from well 12 30 0.032 
14 30 from well 13 30 0.0016 
 
Once the virus dilutions were made, 22RV1 cells were washed with PBS and 220 µl of 
serum free DMEM with 8 µg/ml of polybrene was added to each well. Next, 30 µl of 
diluted virus was added (14 different dilutions, 1 dilution per well) and cell transduction 
performed for 6 h at 37oC. After 6 h, 1 ml of full DMEM was added to each well and cells 
were incubated for another 72 h. Transduction efficiency was analysed by counting GFP 
positive colonies using immunofluorescent microscopy. After the optimal MOI was 
determined, 22RV1 cell transduction with 3 different stocks of pGIPZ lentiviral vector 
containing shRNA targeting FBXL4 was performed using exactly same conditions. The 
GIPZ Non-silencing lentiviral shRNA vector and GAPDH GIPZ lentiviral shRNA vector 
were used respectively as negative and positive controls. 72 h post transduction, old 
medium was replaced with 1.5 ml of full DMEM with 1 µg/ml of puromycin for positive 
selection of successfully transduced 22RV1 cells. Puromycin selection was continued 
for 2 weeks with culture medium changed every 3 days. After 2 weeks all cells were 
positive for GFP confirming presence of GIPZ lentiviral shRNA vector and FBXL4 
knockdown was assessed at RNA level by qPCR. Cell population with best FBXL4 
knockdown was chosen for subsequent single clone selection. Single clone selection 
was achieved by serial dilution of mixed cell population to 0-1 cell/well concentration in 
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96 well plates. All clones were maintained in selective medium. Wells were visually 
examined to assure presence of only a single colony/well before growth expansion.  
2.10 FBXL4 cloning 
2.10.1 C-terminus Flag tag FBXL4 construct preparation 
Whole coding region of FBXL4 was amplified from VCaP cDNA using PCRBIO HiFi 
polymerase (2 U/µl, PCR Biosystems, UK) (an error rate of approximately 1 error per 4.5 
x 107 nucleotides incorporated) and PCRBIO 5x Reaction buffer containing 15mM 
MgCl2, 5mM dNTPs, enhancers and stabilizers. FBXL4 primers containing restriction 
sites for subsequent cloning and Flag tag sequence were ordered from Sigma (Sigma 
Aldrich, UK). Forward primer contained restriction site for AfI II enzyme upstream of ATG 
start codon (5’-AGTCTTAAGATCTAGATGGAGACTGGGGGC) and reverse primer had 
flag tag sequence included before stop codon and restriction site for Xho I enzyme past 
stop codon (5’-
ACTCTCGAGTCACTTATCGTCGTCATCCTTGTAATCCTGAGTAAAGCTCTTTTTTAT
GAACA). The amplicon size was 1914 bp. PCR reaction mixtures and cycling conditions 
were prepared according to PCRBIO HiFi polymerase manufacturer instructions and 
listed in Table 23 and Table 24. PCR was performed using PTC-225 Thermal Cycler, MJ 
Research (Waltham, MA, US). Product size and PCR reaction specificity was confirmed 
by 1% agarose gel electrophoresis. 1 kb+ ladder (Invitrogen, Life Technologies, UK) was 
used as a size marker. The bulk of the sample was run on 1% low-melt agarose gel for 
subsequent purification with Minelute Gel extraction Kit (Qiagen, UK). Sequence of 
amplified FBXL4 was confirmed by Sanger sequencing. Primers for sequencing are 
listed in Table 25. PCR master mix and cycling conditions are listed in Table 26 and 
Table 27.  
TABLE 23. PCR MASTER MIX. 
Reagent Volume (µl) 
5x PCRBIO Reaction buffer 10 
PCRBIO HiFi polymerase (2 U/ul) 0.5 
Forward primer (10 μM) 3 
Reverse primer (10 μM) 3 
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TABLE 24. PCR CYCLING CONDITIONS. 
Temp (0C) Time Step Cycling 
95C 5’ initial denaturation  
95C 30’’ denaturation  
63C 45’’ annealing  Step 2-4: 35 cycles 
72C 45’’ extension  
72C 10’ final extension  











Fbxl4_1F: ATCTAGATGTCACCGGTCTTTC 1869 56 
Fbxl4_1R: CTGAGTAAAGCTCTTTTTTATGAACA   
Fbxl4_1Fa: 
AGTCTTAAGATCTAGATGTCACCGGTCTTTC 1914 62 
Fbxl4_1Ra: 
ACTCTCGAGTCACTTATCGTCGTCATCCTTG 
TAATCCTGAGTAAAGCTCTTTTTTATGAACA   
Fbxl4_1F: ATCTAGATGTCACCGGTCTTTC 389 56 
Fbxl4_2R: TGACCAAAGAATCTCCCATC    
Fbxl4_3F: CAGAGCCAGGACTATGTGGA 577 58 
Fbxl4_3R: AATGCTGGCTCAGTAGTTTGC   
Fbxl4_5F: TGGACAGTCTTAACAAAAAGTTTAGC 603 58 
Fbxl4_5R: TGCCTAAACTGAGGTGCTGA   
Fbxl4_6F: CAGGCCTTAAATCTCTCCTCCT 654 56 
Fbxl4_1R: CTGAGTAAAGCTCTTTTTTATGAACA   
FBXL4_Flag_F: AGCTCCCAAACTTGCAAAAA 458 58 
pcDNA4TO_Flag_R: GCGATGCAATTTCCTCATTT   
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TABLE 26. PCR MASTER MIX. 
Reagent Volume (µl) 
10 x PCR buffer 2.5 
dNTP (10mM) 0.5 
Forward primer  0.5 
Reverse primer  0.5 
Taq polymerase 0.2 
Water + cDNA 20.8 
Total volume 25 
 
TABLE 27. PCR CYCLING CONDITONS. 
Step Temperature (0C) Time Cycling 
1 95 5’  
2 95 45’’  
3 Primer set specific (56 to 62) 45’’ Step 2 – 4: 34 cycles 
4 72 45’’  
5 72 10’  
6 4 hold  
 
2.10.2 DNA purification using Minelute Gel extraction Kit 
FBXL4 band was identified under UV light in presence of gel red and excised with a 
scalpel. DNA was extracted from the gel with Minelute Gel extraction Kit (Qiagen, UK) 
according to manufacturer instructions. Three volumes of Buffer QG (solubilizes the 
agarose gel slice and provides the appropriate conditions for subsequent binding of DNA 
to the silica membrane of the MinElute column) was added to 1 volume of gel (300 μl of 
Buffer QG to 100 mg of gel) followed by incubation at 50°C for 10 min with periodical 
vortexing (until the gel slice has completely dissolved). Next, 100 μl of isopropanol (1 gel 
volume) was added to the sample and mixed by inverting the tube several times. DNA 
sample was then placed on a MinElute column and centrifuge for 1 min at 13000 rpm. 
The flow-through was discarded and bound DNA washed with 500 μl of Buffer QG by 
centrifugation for 1 min at 13000 rpm. The flow-through was discarded again and DNA 
washed with 750 μl of ethanol-containing Buffer PE by centrifugation for 1 min at 13000 
rpm. The flow-through was discarded and the MinElute column was centrifuged again 
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for an additional 1 min at 13000 rpm to remove any traces of ethanol. DNA was eluted 
by adding 10 μl of Buffer EB (10 mM Tris·Cl, pH 8.5) on top of the column followed by 
centrifugation for 1 min at 13000 rpm. DNA concentration was measured with a nanodrop 
and stored at –20°C.  
2.10.3 Cloning of FBXL4 construct into TOPO® TA vector  
Gel-purified C-Flag FBXL4 DNA was subcloned into pCR™4-TOPO® TA Vector using 
TOPO® TA Cloning® Kit (Invitrogen, Life Technologies, UK). The pCR™4-TOPO® TA 
vector (Figure 8) is supplied linearized with 3´ thymidine (T) overhangs and covalently 
bound to topoisomerase I for efficient ligation of Taq polymerase amplified PCR products 
with 3´A overhangs. Taq polymerase has a nontemplate-dependent terminal transferase 
activity that adds a single deoxyadenosine (A) to the 3´ ends of PCR products. PCRBIO 
HiFi polymerase used to generate C-flag FBXL4 sequence has the ability to proofread, 
using 3’ → 5’ exonuclease activity. Proofreading polymerases remove the 3´ A-
overhangs necessary for TA Cloning, therefore 3´ adenines were added to the blunt-
ended C-Flag FBXL4 DNA through incubation with Taq polymerase in presence of PCR 
buffer and dATP (Table 28).  
 
FIGURE 8. PCR™4-TOPO® TA VECTOR MAP. 
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TABLE 28. ADDING POLYA TAIL TO C-FLAG FBXL4 PCR PRODUCT. 
Reagent Volume (µl) Incubation 
C-Flag FBXL4 DNA (8 ng/µl) 8.7  
Taq polymerase 0.1 at 70oC for 30 min 
10mM dATP 0.2  
10X PCR buffer  1  
 
PCR product was directly used for TOPO cloning. Ligation was performed at room temp 
for 30 min according to manufacturer instructions. Reaction mixture is listed in Table 29. 
Ligation product was directly used for transformation of One Shot® TOP10 Chemically 
Competent E. coli cells. 
TABLE 29. LIGATION MIXTURE USING TOPO® TA CLONING® KIT. 
Reagent Volume (µl) 
Fresh ampli Taq PCR product (30 ng/µl) 4 
Salt Solution 1 
pCR4 TOPO TA vector (10 ng/µl) 1 
Final volume 6 
 
2.10.4 Transformation of Chemically Competent Cells 
One Shot® TOP10 Chemically Competent E. coli cells supplied with S.O.C Medium (2% 
tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 
and 20 mM glucose) were purchased from Invitrogen, UK. Agar plates with 100 µg/ml 
ampicillin (selective antibiotic for cells transformed with pCR™4-TOPO® TA Vector) 
were freshly prepared before transformation. One Shot® Chemically Competent Cells 
and ligation product were thawed on ice. 2 µl of ligation product was directly pipetted into 
25 µl of competent cells, gently mix by tapping and incubated on ice for 30 min. Next, 
competent cells were heat-shocked at 42°C for exactly 30 seconds on the hot block and 
125 µl of pre-warmed S.O.C medium was added, following 1 h incubation on shaker at 
37°C and at 225 rpm. After incubation, 100 µl of cell mixture was spread on selective 
agar plate and incubated overnight at 37°C (16 h). Next day, several single colonies were 
transferred into separate tubes with 10 ml selective LB BROTH medium and incubated 
on a shaker at 37°C and at 225 rpm for 16 h. C-Flag FBXL4 pCR™4-TOPO® TA vector 
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was purified with Wizard® Plus Minipreps DNA Purification System (Promega, UK). 
Insert size was confirmed by restriction digestion.  
2.10.5 Plasmid purification with The Wizard® Plus Minipreps DNA Purification 
System 
The Wizard® Plus Minipreps DNA Purification System was used for small scale plasmid 
purification for confirmation of correct cloning results. This system can be used to isolate 
any plasmid from E.coli hosts below 20 kb in size. Purification procedure was done 
following protocol supplied with the kit. About 2 ml of C-Flag FBXL4 pCR™4-TOPO® TA 
vector containing bacterial growth was pelleted by centrifugation for 10 min at 10000 g. 
Cell pellet was resuspend in 250 µl of Cell Resuspension Solution (Tris-EDTA buffer with 
RNase A) and lysed for 5 min at room temp with 250 µl of Cell Lysis Solution (SDS + 
NaOH). Lysis was stopped by adding 350 µl of Neutralization Solution (containing 
potassium acetate). Cell debris were removed by pelleting at 14000 g in a 
microcentrifuge for 10 minutes. The cleared plasmid containing lysate was transferred to 
spin column and centrifuged at maximum speed for 1 min at room temperature. Column 
was then washed twice with Column Wash Solution following plasmid elution with 100 µl 
of Nuclease-Free Water. Plasmid quality and quantity was assessed using a nanodrop. 
C-Flag FBXL4 insert size was confirmed by restriction digestion. 
2.10.6 Restriction digestion of C-Flag FBXL4 pCR™4-TOPO® TA vector and 
subcloning into pcDNA4/TO expression vector 
All restriction enzymes and additional reagents were purchased from New England 
Biolabs, UK. Reaction mixture is listed in Table 30. Digestion was performed at 37oC for 
2 h. Enzymes were inactivated by heat (65oC) for 20 min. C-Flag FBXL4 DNA fragment 
size was confirmed by 1% agarose gel electrophoresis. DNA samples from clones with 
correct C-Flag FBXL4 DNA fragment size were subjected to Sanger sequencing using 
primers described in Table 25. Clone for which intact sequence of C-Flag FBXL4 DNA 
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TABLE 30. RESTRICTION DIGESTION REACTION MIX. 
Reagent Volume (µl) 
Afl ll 1 
Xhol 1 
10 x BSA 3 
10 x buffer 4 3 
C-Flag FBXL4 pCR™4-TOPO® TA vector (100 ng/µl) 4 
WATER 18 
Total volume 30 
 
2.10.7 Subcloning C-Flag FBXL4 fragment into pcDNA4/TO expression vector 
pcDNA4/TO expression vector was purchased from Invitrogen, UK as a part of a 
Tetracycline-Regulated Expression System for Mammalian Cells (T-REx™ System) 
containing pcDNA4/TO expression vector (Figure 9) and pcDNA6/TR regulatory vector 
(Figure 10). pcDNA4/TO inducible expression plasmid is designed for expression of gene 
of interest under the control of the strong human cytomegalovirus immediate-early (CMV) 
promoter and two tetracycline operator 2 (TetO2) sites. pcDNA6/TR regulatory plasmid 
encodes the Tet repressor (TetR) under the control of the human CMV promoter. In the 
absence of tetracycline, the Tet repressor forms a homodimer which binds to each TetO2 
sequence in the promoter of the inducible expression vector and represses transcription 
of gene of interest. Addition of tetracycline leads to its binding to Tet repressor 
homodimer, preventing it from binding to the Tet operator. The Tet repressor: tetracycline 
complex then dissociates from the Tet operator and allows induction of transcription from 
the gene of interest. Transfection of pcDNA4/TO vector without regulatory vector will lead 
to constitutive gene expression.  
1 µg of C-Flag FBXL4 pCR™4-TOPO® TA vector and pcDNA4/TO expression vector 
were digested with Afl II and Xho I restriction enzymes as described in Table 30 and the 
whole reactions run on a low-melt agarose gel. C-Flag FBXL4 fragment and linear 
pcDNA4/TO vector were then extracted from the gel and purified as described in chapter 
2.10.2. 
 




FIGURE 9. PCDNA4/TO VECTOR MAP.  Part of Invitrogen T-REx™ System (A Tetracycline-
Regulated Expression System for Mammalian Cells). 
 
 
FIGURE 10. PCDNA6/TR VECTOR MAP.  Part of Invitrogen T-REx™ System (A Tetracycline-
Regulated Expression System for Mammalian Cells).  
 
Next, the fragments were ligated using Rapid DNA Ligation Kit (Invitrogen, UK), 
according to manufacturer instructions. Ligation mix was prepared as described in Table 
31.  
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TABLE 31. DNA LIGATION MIX. 
Reagent Volume (µl) 
pcDNA4/TO linear vector (36 ng/µl) 1  
C-Flag FBXL4 DNA fragment (10 ng/µl) 9 
T4 DNA Ligation Buffer (vial 1) 10 
T4 DNA Ligase (vial 3) 1 
 
Ligation reaction was allowed to proceed for 1 h at room temp. 1 µl of ligation mix was 
then used to transform TOP10 cells as described in chapter 2.11.5, using zeocin 
(50µg/ml) as a selective antibiotic. 12 bacterial single colonies were picked next day and 
expanded into 10 ml liquid BROTH. After 16 h incubation on shaker at 37oC, C-Flag 
FBXL4 pcDNA4/TO vector DNA was extracted from bacteria as described in chapter 
2.11.6. Restriction digestion reaction with Afl ll and Xho l was performed for 2 h (Table 
32) and digestion products were run on 1% agarose gel to confirm insert size. DNA 
samples from single clones with correct C-Flag FBXL4 fragment size were send for 
sequencing using sequencing primers described in chapter 2.10.1.  
TABLE 32. C-FLAG FBXL4 PCDNA4/TO VECTOR RESTRICTION DIGESTION. 
Reagent  Volume (µl) 
Afl ll 1 
Xhol 1 
10 x BSA 3 
10 x buffer 4 3 
C-Flag FBXL4 pcDNA4/TO vector DNA (100 ng/µ) 4ul (400 ng) 
WATER 18 
Total volume 30 
 
2.10.8 Large scale pcDNA4/TO expression vector with C-terminus Flag tag FBXL4 
construct amplification 
After restriction digestion and sequencing validation of correct C-Flag FBXL4 insert, 1 ml 
of the same bacterial culture in selective LB BROTH medium (chapter 2.10.4) was added 
to 100ml of selective LB BROTH medium and incubated on shaker at 37°C and at 225 
rpm for 16 h for maxi scale plasmid purification. Next day cells were pelleted by 
centrifugation for 15 min at 6000 g at 4°C. Plasmid extraction and purification was done 
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using the EndoFree Plasmid Maxi Kit and supplied protocol (Qiagen, UK). Briefly, 
bacterial pellet was resuspended in 10 ml of Buffer P1 (50 mM Tris-Cl, pH 8.0, 10 mM 
EDTA, 100 µg/mL RNase A) and lysed with 10 ml of Buffer P2 (200 mM NaOH, 1% SDS) 
for 5 min at room temperature. Cell debris were precipitated with 10 ml of chilled Buffer 
P3 (3.0M potassium acetate, pH 5.5) and whole lysate was immediately poured into the 
QIAfilter Cartridge. After 10 min incubation at room temp cell lysate was filtered into a 50 
ml tube. Next, 2.5 ml of Buffer ER was added to the filtered lysate, mixed and incubate 
on ice for 30 min. After incubation filtered lysate was loaded onto a QIAGEN-tip 500 and 
allowed to go through the resin by gravity flow. Resin – bound plasmid was washed twice 
with 30 ml Buffer QC and eluted with 15 ml Buffer QN. Plasmid DNA was then 
precipitated by adding 10.5 ml isopropanol and pelleted by centrifugation at 15000 g for 
30 min at 4°C. Plasmid pellet was washed with 5 ml of endotoxin-free 70% ethanol, air 
– dried and resuspended in endotoxin-free Buffer TE to the concentration of 2 µg/µl. 300 
ng of purified plasmid was again digested with Afl ll and Xho l restriction enzymes for 
insert size confirmation. 
2.11 Transient FBXL4 overexpression 
Cells were seeded 24 h before transfection in 6 or 96 well plates at densities listed in 
Table 33 in order to achieve 70-90% confluence. No antibiotic was added to the growth 
medium. 
TABLE 33. CELL SEEDING DENSITIES FOR GENE OVEREXPRESSION. 
Cell line Medium 6 well plate  96 well plate 
22RV1 RPMI 40x104 /well 1x104 /well 
PC3 RPMI 30x104 /well 0.5x104 /well 
DU145 DMEM 40x104 /well 1x104 /well 
HEK293 DMEM 40x104 /well 1x104 /well 
 
Cells were transfected with 2 µg/well of C-Flag FBXL4 plasmid DNA. For each well of 6 
well plate, 1 µl of 2 µ/µl plasmid DNA was mixed with 249 µl of plain culture medium in 1 
vial. In another separate vial, 5 µl of lipofectamine (Invitrogen, Life Technologies, UK) 
was mixed with 245 µl of plain culture medium. Both tubes were incubated at room temp 
for 5 min. After 5 min content of both tubes was mixed together and incubated for another 
20 min. Meantime, cells were washed with PBS and 1.5 ml of plain medium was added 
to each well. After 20 min incubation, 500 µl of transfection mixture was added to each 
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well of 6 well plate. Plates were placed in the incubator for 6 h to allow plasmid DNA to 
enter the cells. After 6 h, transfection medium was aspirated and replaced with culture 
medium with 10% FBS. For 96 well plates volumes were reduced to fit 200 µl/well 
volume, with 0.5 µg of plasmid DNA/well. For each experiment/time point, equal number 
of wells was prepared with plasmid DNA targeting gene of interest, empty plasmid and 
control, untreated cells. As a transfection rate control pmaxGFP Vector (Lonza, US) was 
used. 
2.12 Production of stably transfected cells with C-Flag FBXL4 plasmid DNA 
2.12.1  Production of cells constitutively overexpressing FBXL4 
PC3 and DU145 cells were transfected with C-Flag FBXL4 plasmid DNA as described in 
chapter 2.11. After 48 h cells were treated with selective antibiotic, zeocin at 300 µg/ml 
of full DMEM medium for 4 weeks. Zeocin is a copper-chelated glycopeptide antibiotic, 
which causes cell death by intercalating into DNA and cleaving it. pcDNA4/TO vector 
contains the Sh ble gene, which product inactivates zeocin by binding to the antibiotic. 
Therefore, cells retaining pcDNA4/TO vector are resistant to zeocin treatment. During 
that time medium was replaced every 3 days (to sustain steady levels of fresh antibiotic) 
and death of non-transfected cells and outgrow of transfected cells was observed. After 
two weeks of selection, FBXL4 expression levels were checked by qPCR in 3 
consecutive weeks to assess gene overexpression. Additionally, PCR of flag tag region 
was performed to confirm presence of C-Flag FBXL4 plasmid DNA in those cells. 
Regular PCR master mix and cycling conditions were applied as described in Table 26 
and Table 27, using forward primer within last exon of FBXL4 and revere primer located 
within pcDNA4/TO vector (Table 34). 







FBXL4_Flag_F: AGCTCCCAAACTTGCAAAAA 458 58 
pcDNA4TO_Flag_R: GCGATGCAATTTCCTCATTT   
 
2.12.2 Tetracycline - inducible system for FBXL4 overexpression 
22RV1 cells (single clone) containing pcDNA6/TR regulatory vector were generated 
previously in our laboratory by Dr Marc Yeste-Velasco and maintained in full DMEM 
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medium with 5 µg/ml of blasticidin (selective antibiotic). Blasticidin is a peptidyl 
nucleoside antibiotic that inhibits protein synthesis by interfering with the peptide-bond 
formation in the ribosomal machinery. Resistance to blasticidin is conferred by the 
blasticidin resistance gene (bsr) present in the pcDNA6/TR regulatory vector, which 
codes for blasticidin-S deaminase. 
Commercial T-REx™-293 cells were purchased as a part of T-REx™ System and 
maintained in full DMEM medium with 5 µg/ml of blasticidin. Both cell lines were 
transfected with C-Flag FBXL4 expression vector and maintained in full DMEM medium 
with 5 µg/ml of blasticidin and 400 µg/ml of zeocin as described in chapter 2.12.1. After 
2 weeks of selection, cells were seeded in 6 well plates at 60% confluence and 1 µg/ml 
of tetracycline was added to some wells to induce expression of FBXL4 from expression 
vector. After 24 h of tetracycline treatment, RNA was extracted and FBXL4 
overexpression checked by qPCR. FBXL4 expression levels were checked by qPCR in 
3 consecutive weeks. Additionally, PCR of flag tag region was performed to confirm 
presence of C-Flag FBXL4 plasmid DNA in those cells. Regular PCR master mix and 
cycling conditions were applied as described in chapter 2.12.1. 
For C-Flag FBXL4 T-REx™-293 cells single clones were generated through serial 
dilutions, including control clones with empty pcDNA4/TO vector. After additional 2 
weeks of selection, FBXL4 expression levels were checked by qPCR in all clones and 
clone with highest FBXL4 expression was chosen for further experiments. To assess if 
continuous treatment with tetracycline leads to constant and stable FBXL4 
overexpression, C-Flag FBXL4 T-REx™-293 cells were kept at 60% confluence and 
subjected to continuous tetracycline treatment for 60 days with periodical assessment of 
FBXL4 expression by qPCR and presence of C-Flag FBXL4 pcDNA4/TO expression 
vector by PCR of the flag tag region. 
2.13 Cell viability assay 
Cells were seeded into 96-well plates at 40-50% confluence (0.3-0.5 x 104 cells/well) and 
siRNA knockdown was performed as described in section 2.9.1. Viability was assessed 
48 and 72 h post siRNA transfection with The CellTiter 96 Aqueous Non-Radioactive Cell 
Proliferation Assay (Promega, UK) according to manufacturer instructions. This 
colorimetric assay is composed of solutions of a tetrazolium compound [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, 
inner salt (MTS) and an electron coupling reagent (phenazine methosulfate; PMS). MTS 
CHAPTER 2               MATERIAL AND METHODS 
90 
 
is bioreduced by cells into a formazan product that is soluble in tissue culture medium. 
The absorbance of the formazan at 495 nm is then measured directly from the plate. The 
quantity of formazan product is directly proportional to the number of living cells in 
culture. Briefly, at each time point 200 µl of old culture media was replaced with 100 µl 
of fresh medium. MTS and PMS reagents were mixed together at ratio1:20 and 20 µl of 
this solution directly added to each well of cultured cells. Cells were the incubated at 
37ºC for 2-6 h. Absorbance was measured using plate reader (Opsys MR Microplate 
Reader, DYNEX, VA, US). Wells containing only culture medium were used as a 
background control. Three biological repeats of experiment were performed. Statistical 
difference in cell viability between FBXL4 knockdown cells and control cells transfected 
with non-targeting siRNA was assessed using paired t-test. 
2.14 Cell migration assay 
Cell migration was assessed by transwell migration assay. DU145, PC3 and 22RV1 cells 
were seeded in 6-well plates and transfected with anti FBXL4 siRNA as described in 
chapter 2.9.1. Stable HEK293 were treated with tetracycline for 48-72 h before transwell 
assay. For transwell assay cells were trypsinised 48 h post transfection/tetracycline 
treatment and seeded into transwell inserts with 8 µm pore size (BD Biosciences, US) at 
3x104 cells/well for PC3 and DU145, 5x104 for 22RV1 and 7x104 for HEK293. Before cell 
seeding, 650 µl of DMEM medium with 10% FCS (acting as chemoatractant) was 
pipetted into wells and inserts placed on top of the wells. Meantime, cells were 
trypsinised from 6-well plate, centrifuged at 1200 rpm for 5 min and resuspended in 300 
– 500 µl of medium with 1% serum. Next cells were counted and seeded into inserts at 
density mentioned above in 200 µl of medium with 1% serum to form confluent layer. 
Cells were allowed to migrate across the membrane for 24 h. After 24 h (72 h post 
transfection), inserts were washed with PBS and fixed in 10% formalin in PBS, rinsed in 
PBS 2 x 5 min and not migrated cells from the top of the insert membrane gently removed 
with cotton buds. Next, migrated cells attached to the bottom of the membrane were 
stained with hematoxylin for 20 min. After staining inserts were washed in tap water for 
5 min and dehydrated in 70%, 90% and 100% ethanol for 5 min. Next, membranes with 
migrated cells were cut from the inserts with scalpel blade, rinsed in xylene and mounted 
on the glass slides in DPX mounting medium. After drying, slides were scanned using 
the Applied Imaging Ariol® System (Applied Imaging, San Jose, CA, USA). Equal size 
area on each membrane was marked for cell counting.  
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2.15 Cell invasion  
2.15.1 Matrigel invasion 
BD BioCoat™ BD Matrigel TM Invasion Chamber, 8.0 µm PET Membrane 24-well Cell 
Culture Inserts were purchased from (Corning, BD Biosciences, US). Invasion chambers 
were stored at -20oC and brought to room temp before placing them in incubator at 37oC 
for 30 min. Invasion assay was performed in the same manner like the transwell 
migration assay (see chapter 2.14). 
2.15.2 Collagen invasion 
2.15.2.1 Single cell collagen invasion assay through native collagen type-I matrice 
Single-cell collagen invasion model was performed according to de Weaver at al (Figure 
11) [223]. 3 mg/ml collagen I solution extracted from rat tail (the most common fibrillar 
collagen found in skin, bone, tendons, and other connective tissues) was purchased from 
Applied Biosystems, UK. All ingredients for 1 mg/ml collagen mixture preparation were 
kept on ice at all time. 1.2 ml of 1 mg/ml collagen solution prepared as described in Table 
35 was added per well of 6 well plate and immediately plates were placed in tissue culture 
incubator at 37oC where the collagen was allowed to solidify for 1 h. Meanwhile, PCa 
cells at 48 h post FBXL4 knockdown along with controls were tripsinised, spun down at 
1200 rpm for 5 min, resuspended in full DMEM and counted. 100,000 cells were 
resuspended in 1.5 ml of full DMEM and added per well in triplicates. Plates then were 
placed in the incubator and cells allowed to invade collagen for 24 h. After 24 h cells with 
cellular extensions (pseudopodia) invading the collagen matrix were counted in 10-15 
microscope fields (at 200x magnification).  
 




FIGURE 11. PROTOCOL FOR SINGLE CELL INVASION THROUGH COLLAGEN.  Adapted 
from de Weaver at al [223]. 
 
 
TABLE 35. 1 MG/ML COLLAGEN PREPARATION. 
Solutions Volume (ml) 




DMEM full medium 3.4 
NaOH 1M 0.2 
Final volume 18 
 
2.15.2.2 Single cell invasion assay through collagen type-I/Matrigel matrix 
Single cell invasion assay through collagen type-I/Matrigel (1.6 mg/ml/~50%) matrix was 
adopted from Godinho et al [224]. BD Matrigel Matrix Growth Factor Reduced was 
purchased from Applied Biosystems, UK. 1.6 mg/ml collagen/~50% matrigel was 
prepared on ice according to Table 36. 
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TABLE 36. COLLAGEN-MATRIGEL MATRIX COMPOSITION. 
Ingredient Volume (µl) 
collagen(3 mg/ml) 1599 
10xDMEM 187.5 
NaOH 1M 30 
Matrigel GFR 1401 
volume 3000.0 
 
200 µl of collagen solution was added per well of 24 well plate and allowed to solidify in 
incubator for 1 h. Meanwhile, stable 22RV1 shFBXL4 PCa cells along with controls were 
tripsinised, spun down at 1200 rpm for 5 min, resuspended in 2% FCS DMEM and 
counted. 4000 cells were resuspended in 0.5 ml of 2% FCS DMEM with 2% Matrigel and 
added per well in triplicates. Plates then were placed in the incubator and cells allowed 
to invade collagen for 72 h. After 72 h cells with cellular extensions (pseudopodia) 
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3 Genome-wide alterations in PCa bone metastases 
3.1 Introduction 
The most common metastatic site of PCa is bone: around 90% of patients dying from 
this disease have skeletal metastases [193, 194]. Once tumours metastasize to bone, 
they are incurable and result in significant disease morbidity. Better understanding of 
bone metastases is needed in order to develop more efficient approaches and novel 
therapies to manage aggressive metastatic disease. It is well established that PCa has 
a genetic background and with abundance of prostatectomy specimens, there have been 
many genomic studies concentrating on genetic changes in primary PCa [165, 225-227], 
while difficulty in obtaining specimen from metastatic sites hindered genetic analysis of 
PCa metastases [139].  
Presence and extent of genomic changes in PCa bone metastases, the most common 
site of PCa spread is particularly understudied due to difficulty in obtaining good quality, 
high in tumour content samples. As PCa bone metastases are assessed by imaging 
methods, research samples usually come from autopsies [153, 167, 228, 229], unless 
as in recent studies, patients are specifically consented for bone biopsy [138, 230, 231]. 
As bone metastases result in significant disease morbidity with limited success of 
palliative treatment [232], better understanding of genomic changes in PCa bone 
metastases could lead to new bone-oriented treatment options, or identification of 
possible new predictive markers for metastatic cancer spread. Thanks to collaboration 
with The Robert Jones and Agnes Hunt Orthopaedic Hospital in Oswestry, Shropshire, 
we had a unique opportunity to look at genomic changes in PCa bone metastases from 
patients with advanced PCa who were treated there for pathological bone fractures 
caused by PCa.  
3.2 Results  
3.2.1 Sample and SNP 6.0 array data quality control 
Direct assessment of tumour purity in six fresh frozen samples of bone metastases prior 
to SNP analysis was impossible due to difficulty in sectioning of hard bone tissue. 
Therefore, FFPE samples (all decalcified with formic acid) from the same patients were 
H&E stained to indirectly estimate tumour cell content in fresh frozen specimens. 
Samples 2, 4, 5 and 6 showed very high tumour content of >80%. Samples 1 and 3 had 
less abundant tumour content of about 50% (Figure 12).  




FIGURE 12. CANCER PURITY IN FFPE DECALCIFIED PCA BONE METASTASES SAMPLES 
DERIVED FROM THE SAME PATIENTS AS FRESH FROZEN SPECIMENS. Samples 2, 4, 5 
and 6 show widespread tumour, while metastatic samples 1 and 3 are less tumour rich with more 
bone tissue present. Tumour content for each sample was assessed by a pathologist, Prof. Dan 
Berney. 
 
PCa bone metastases DNA quality was assessed by running 0.5-1 µg of DNA 
(dependent on sample availability) on 1% agarose gel (Figure 13A). Good quality DNA 
shows single high molecular size band on the gel with minimal smear of fragmented 
DNA. DNA integrity was reasonably good for samples 4, 5 and 6. The other three 
samples showed more degradation represented as a smear on the gel, while still 
displaying strong high molecular size band of intact DNA.  




FIGURE 13. AGAROSE GEL ELECTROPHORESIS BASED QUALITY CONTROL STEPS 
DURING SAMPLES PREPARATION FOR SNP 6 ARRAYS. (A), Good initial genomic DNA 
quality of six PCa bone metastases was confimed by the presence of a high molecular weight 
band of DNA with minimal low quality smear of DNA fragments. (B), Samples quality control 
(examples) after initial DNA fragmentation and fragments amplification by PCR. Fragmentation 
with both, Sty and Nsp enzymes resulted in DNA smears of expected 250-1100 bp size. (C), Last 
quality check (examples) after final DNA fragmentation. All samples show correct DNA fragment 
size below < 180 bp. 
 
All samples were processed for Affymetrix SNP 6.0 arrays according to manufacturer 
instructions (Affymetrix, Santa Clara, CA, US). Three quality checks were performed 
during samples preparation prior to hybridization on GeneChip arrays in order to exclude 
experimental errors. First check was to verify PCR product size by 2% agarose gel 
electrophoresis after initial genomic DNA restriction enzyme digestion, adaptor ligation 
and DNA fragments amplification by PCR. All samples were successfully amplified and 
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had correct DNA fragment size distribution within 250-1100 bp (example in Figure 13B). 
Next was the quantity check of the pooled and purified PCR products. PCR product 
concentration for all samples was verified by nanodrop and fell well within recommended 
range of 5.0 to 6.0 μg/μl. Third quality check was to confirm DNA fragments size by 2% 
agarose gel electrophoresis after final DNA fragmentation with DNase I. All samples 
were successfully fragmented with correct fragment size <180 bp (examples in Figure 
13C). Once the adequate quality of all samples was confirmed, they were hybridised 
onto GeneChips and data collected from processed SNP arrays was assessed for quality 
with Affymetrix Genotyping Console software (Affymetrix, Santa Clara, CA, US). An 
estimate of the overall quality for each individual sample was performed by calculation 
of QC Call Rate (QCR) for a default set of 3022 SNPs. This quality control step is used 
to identify poor quality samples. Two samples exhibited QC Call Rate slightly below 
recommended 86% cut off (sample 5 - 85.1% and sample 6 - 85.8%) while another four 
had good initial QC Call Rate between 90% and 95% (Table 37), confirming adequate 
quality for subsequent genotyping analysis with the genotype calling algorithm Birdseed 
v2 software (Affymetrix, Santa Clara, CA, US). The Birdseed algorithm performs a 
multiple-chip analysis to estimate signal intensity for each allele of each SNP and makes 
genotype calls (A-signal vs. B-signal). The Birdseed algorithm accurately determined the 
genotype calls of each PCa bone metastasis sample with overall call rate of over 95% 
(Table 37).  
TABLE 37 QUALITY CONTROL OF SNP ARRAY DATA GENERATED FOR THE PCA 
BONE METASTASES. 
Sample QC call rate (%) Birdseed v2 Call Rate (%) 
1 93.5 97.1 
2 90.5 96.4 
3 91.3 95.5 
4 90.3 95.1 
5 85.1 95.0 
6 85.8 95.5 
 
3.2.2 Genomic copy number changes detected in PCa bone metastases 
Generated SNP array data were analysed for copy number changes with GOLF v4.1 
software using combined set of 7 normal prostate samples as normal control, as 
CHAPTER 3   GENOME-WIDE ALTERATIONS IN PCA BONE METASTASES  
99 
 
described in materials and methods. Genomic copy number changes detected in the six 
fresh frozen tissues of PCa bone metastases are visualised in Figure 14.  
Surprisingly, many of detected genomic changes displayed very similar if not identical 
chromosomal breakpoints present in over half of the samples (Table 38) and included 
gains at 1p36.3, 1q32.1-32.2, 2q14.3, 3p26.1-24.3, 3p22.3, 3q29, 4p16, 5p15.33, 
5q35.2-35.3, 6p21.1, 6q27, 7p22.3-22.1, 7q11.23, 7q21.3-22.1, 7q32.1-32.2, 7q36.3, 
8q24.3, 9p13.3-13.1, 9q34.11-34.3, 11p15.5-15.4, 11p12-11.2, 11q12.3-14.1, 12p13.33-
q13.32, 12q13.11-14.1, 12q23.3-24.21, 12q24.23-24.31, 12q24.33, 13q32.2-32.3, 
13q34, 14q32.2-32.33, 15q14-21.1, 16p13.3, 16p12.1-11.2, 16q24.2-q24.3, 17q24.3-
25.3, 21q22.2-22.3, 22q11.21-11.22, 22q12.1-12.3,and 22q12.3-13.33, and losses at 
9q32-33.2, 10q25.1, 16q21, 17q21.33-q22, and 17q24.3.  
Another group of copy number changes detected in PCa bone metastases were more 
heterogeneous in location and chromosomal breakpoints. However, there were 
overlapping common regions shared by two or more samples (Table 39). The most 
common regions of copy number change in this group were losses at 6q14.1-23.1 (six 
cases), 8p23.3-q11.21 (four cases) and 17p13.3-12 (three cases), and gains at 
20q11.21-13.33 (three cases) and Xq11.1-28 (three cases), with minimal overlapping 
regions (MOR) at 6q16.1-16.2, 8p23.2-21.1, 17p13.1-12, 20q13.12-13.32 and Xq12-
13.1, respectively. Most regions of shared copy number changes were present in two 
cases with MOR at 3q21.2-q29, 4p14-13, 8q11.21-23.1, 8q23.3-24.3, 14q24.2-24.3 and 
20q13.12-13.32 for gains, and 2p13.1-11.1, 2q22.1-q23.3, 4q28.1, 5q14.3-22.1, 
10q23.31, 11q22.2-24.2, 13q13.2-31.1, 18q21.2-21.31, 18q21.33-22.3 and 20p12.3-
12.2 for losses. One sample had deletion at 21q22 between TMPRSS2 and ERG region. 
Examples of copy number changes are shown in Figure 15 - 19. Different size losses at 
6q14.1-23.1 found in all 6 cases with MOR at 6q16.1-16.2 are shown in Figure 15. 
Various size losses of most of the p arm of chromosome 8 with gains of 8q are displayed 
in Figure 16. Copy number gain at AR locus, Xq12 is depicted in Figure 17. Examples of 
recurrent copy number gains with very similar/identical breakpoints are depicted in 
Figure 18. Figure 19 shows identical chromosomal breakpoints at chromosome 16 in 
most of the samples.  




FIGURE 14. SUMMARY OF ALL REGIONS WITH COPY NUMBER CHANGES IN 6 PCA BONE 
METASTASES DETECTED BY SNP 6.0 ARRAY ANALYSIS. Each line on the right corresponds 
to an aberration in the associated chromosome regions. Red lines denote gains and green lines 
denote losses. Data is displayed with Genomic Recurrent Event ViEwer software 
(http://www.well.ox.ac.uk/GREVE/). * previously reported high frequent genomic alteration 
regions in mCRPC, including distant metastases [119, 121, 138, 150-153, 167, 228]. Double ** 
regions previously linked to liver and lymph node metastases [151]. 
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TABLE 38 COMMON COPY NUMBER CHANGES WITH THE SAME GENOMIC 




with copy number change 
(genes linked to PCa) 
No of cases 
Gains:   
1 1p36.3 6 
 1q32.1-32.2 6 
2 2q14.3 5 
3 3p26.1-24.3 5 
 3p22.3 6 
 3q29 6 
4 4p16 6 
5 5p15.33 6 
 5q35.2-35.3 6 
6 6p21.1 4 
 6q27 6 
7 7p22.3-22.1 6 
 7q11.23 6 
 7q21.3-22.1 (CDK6) 5 
 7q32.1-32.2 5 
 7q36.3 4 
8 8q24.3 4 
9 9p13.3-13.1 6 
 9q34.11-34.3 4 
11 11p15.5-15.4 5 
 11p12-11.2 5 
 11q12.3-14.1 (CCND1) 5 
12 12p13.33-13.32 5 
 12q13.11-14.1 (CDK2, CDK4) 6 
 12q23.3-24.21 6 
 12q24.23-24.31 5 
 12q24.33 6 
13 13q32.2-32.3 6 
 13q34 6 
14 14q32.2-32.33 5 
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15 15q14-21.1 5 
16 16p13.3 6 
 16p12.1-11.2 6 
 16q24.2-24.3 5 
17 17q24.3-25.3 6 
21 21q22.2-22.3 6 
22 22q11.21-11.22 4 
 22q12.1-12.3 4 
 22q12.3-13.33 4 
   







 17q24.3 6 
 
 
TABLE 39. COPY NUMBER CHANGES WITH DIFFERENT GENOMIC 
BREAKPOINTS IN PCA BONE METASTASES. 
Chromosome 
Minimum overlapping 
Region (genes linked to 
PCa) 
Altered genomic region 
Gains: 
  
3 3q21.2-29 (PIK3CA) 3q13.31-29 (sample 5) 
 
 3q21.2-29 (sample 2) 
8 8q11.21-23.1 (NCOA2) 8q11.21-23.1 (sample 6) 
8q11.21-24.3 (sample 3) 
 8q23.3-24.3 (MYC, PSCA) 8q11.21-24.3 (sample 3) 
  8q23.3-24.3 (sample 6) 
14 14q24.2-24.3 14q21.3-32.33 (sample 6) 
  14q24.2-24.3 (sample 4) 
20 20q13.12-13.32 20q11.22-13.32 (sample 6) 
  20q13.12-13.33 (sample 4) 
  20q11.21-13.33 (sample 5) 
X Xq12-13.1 (AR) Xq11.1-13.1 (sample 6) 
  Xq12-13.1 (sample 4) 
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  Xq11.1-28 (sample 5) 
Losses:   
2 2q22.1-23.3 2q22.1-32.1 (sample 2) 
 
 2q12.2-23.3 (sample 5) 
4 4q28.1 4q26-28.1 (sample 6) 
  4q28.1 (sample 5) 
5 5q14.3-22.1 (CHD1) 5q11.2-22.1 (sample 5) 
  5q14.3-23.1 (sample 3) 
6 6q16.1-16.2 (FBXL4) 6q14.1-22.32 (sample 6) 
  6q14.1-22.1 (sample 5) 
  6q14.1-16.2 (sample 3) 
  6q16.1-21 (sample 2) 
  6q15-21 (sample 1 and 4) 
8 8p23.2-21.1 (NKX3.1) 8p23.3-11.1 (sample 4) 
  8p23.3-q11.21 (sample 2, 3, 5) 
10 10q23.33 (PTEN) 10q23.33 (sample 4) 
  10q22.1-24.1 (sample 2) 
11 11q22.2-24.2 11q22.1-25 (sample 5) 
  11q22.2-24.2 (sample 6) 
13 13q13.2-31.1 (RB) 13q13.1-31.3 (sample 6) 
  13q13.2-31.1 (sample 2) 
17 17p13.1-12 (TP53) 17p13.3-p12 (sample 6) 
  17p13.2-11.2 (sample 2) 
  17p13.1-11.2 (sample 4) 
18 18q21.2-21.31 18q21.1-23 (sample 6) 
  18q21.2-21.31 (sample 4) 
 18q21.33-22.3 18q21.1-23 (sample 6) 
  18q21.33-22.3 (sample 4) 
20 20p12.3-12.2 20p12.3-12.2 (sample 2) 








FIGURE 15. COPY NUMBER LOSS AT 6Q PRESENT IN SIX PCA BONE METASTASES.  
Loss at 6q spans region between 6q14.1 and 6q22.32, depending on the sample (top). Minimum 
overlapping region for all six samples can be distinguished at 6q16.2 (98 – 99 kb, red box) and is 
magnified in the bottom panel with marked FBXL4 locus, a possible dirver for this alteration. 
Normal copy number is depicted in blue, loss in green and gain in red. 
 




FIGURE 16. COPY NUMBER CHANGES DETECTED ON CHROMOSOME 8 IN PCA BONE 
METASTASES.  Most of p arm was lost in four samples (samples 2-5) while one tumour displayed 
only small loss at p12 (sample 6) and another did not show loss of 8p (sample 1). Two tumours 
had 8q arm gain except for losses at q23 (sample 6) and q24.23 (sample 3). All samples displayed 
gain at q24.3. Lower panel shows magnified regions with NCOA2 and MYC loci, the two most 
commonly cited drivers for 8q gain in PCa. Normal copy number is depicted in blue, loss in green 
and gain in red. 
 




FIGURE 17. COPY NUMBER GAIN ON CHROMOSOME X AT AR LOCUS. Two samples 
display gains within AR locus located at Xq12, while one sample shows whole chromosome X 
gain. The magnified Xq12 gain region with marked AR locus is shown in lower panel. Normal copy 
number is depicted in blue, loss in green and gain in red. 
 




FIGURE 18. COPY NUMBER CHANGES PRESENT ON CHROMOSOME 11 IN PCA BONE 
METASTASES. All samples display gain at p15.5 and q13.1-14.1 while five samples also show 
gain at p11.2. Magnified region of q13.1-14.1 gain is displayed in lower panel and contains 
CCND1 oncogene, which we propose to be a potential driver for this genomic alteration. Normal 
copy number is depicted in blue, loss in green and gain in red.  
 




FIGURE 19 COPY NUMBER CHANGES AT CHROMOSOME 16.  All samples display almost 
identical pattern of copy number change (apart from sample 6 with most of q arm loss) with gains 
at 16p13.3, 16p12.1-11.2 and losses at 16q21-22.2 and 16q24.2-24.3. Gains at 16p13.3-p11.2 
and losses at 16q11.2-q21 are the 3rd most common gains and losses in metastatic PCa and 2-
3 times more frequent in metastatic than in primary PCa [121]. No driver genes for this regions 
were found. Normal copy number is depicted in blue, loss in green and gain in red. 
 
3.2.3 Confirmation of copy number changes in six fresh frozen bone metastases 
Two regions with copy number alterations shared by all PCa bone metastases were 
selected for copy number change confirmation using qPCR method. TaqMan genomic 
Copy Number Assays directed at CCND1 and FBXL4 genes were chosen to confirm 
copy number gain at 11q13 and loss at 6q16.3, respectively. Relative DNA copy number 
was analysed with CopyCaller Software v2.0 (Applied Biosystems, UK) using normal 
male DNA as 2n copy number control and RNase P TaqMan Copy Number Reference 
Assay located at 14q11.2 as endogenous control (Figure 20). Copy number analysis by 
qPCR at 6q16 correlated with SNP 6.0 results in all six PCa bone metastases. Copy 
number at FBXL4 locus varied from 1.0 – 1.2 (samples 4, 5 and 6) through 1.4 (samples 
2 and 3) to 1.9 (sample 1). Copy number analysis by qPCR at CCND1 locus correlated 
with SNP 6.0 results in 3/6 samples. Samples 5 and 6 showed CCND1 copy number 
around 3, while sample 2 had only slightly elevated copy number of 2.4. Samples 1, 3 
and 5 showed neutral copy number at CCND1 locus.  




FIGURE 20. RELATIVE COPY NUMBER CONFIRMATION AT 11Q13 AND 6Q16 USING 
QPCR. Copy number was analysed with CopyCaller Software v2.0 (Applied Biosystems, UK) and 
normalised to commercial healthy male DNA. RPPH1 (Rnase P) Copy Number Reference Assay 
located at 14q11.2 was used as endogenous control. 
 
3.3 Discussion  
Genomic alterations in metastatic PCa might reveal important biological insights into this 
lethal stage of PCa. Metastatic tumours often share common genomic alterations with 
primary tumours but display them at higher frequency [115, 150, 151]. These common 
genetic changes together with subsequently acquired novel genetic alterations may 
confer a selective advantageous phenotype, which allows the subset of cancer cells to 
disseminate from primary site and/or successfully establish distant metastases [169, 
172]. Identification of genetic changes that facilitate tumour progression to metastatic 
stage, as well as metastatic site-specific alterations could help with patient stratification 
into treatment groups or help to predict patient outcome.  
3.3.1 The common regions with copy number changes with same chromosomal 
breakpoints 
In the current study we performed genome-wide analysis of six PCa bone metastases 
obtained from sites of pathological bone fractures occurred due to prostate tumour 
spread. Subsequent data analysis with ‘in house’ developed GOLF software uncovered 
widely spread genetic changes in all metastatic samples. Many of detected genomic 
changes displayed very similar if not identical chromosomal breakpoints present in over 
half of the samples (Table 38) and included gains at 1p36.3, 1q32.1-32.2, 2q14.3, 
3p26.1-24.3, 3p22.3, 3q29, 4p16, 5p15.33, 5q35.2-35.3, 6p21.1, 6q27, 7p22.3-22.1, 
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7q11.23, 7q21.3-22.1, 7q32.1-32.2, 7q36.3, 8q24.3, 9p13.3-13.1, 9q34.11-34.3, 
11p15.5-15.4, 11p12-11.2, 11q12.3-14.1, 12p13.33-q13.32, 12q13.11-14.1, 12q23.3-
24.21, 12q24.23-24.31, 12q24.33, 13q32.2-32.3, 13q34, 14q32.2-32.33, 15q14-21.1, 
16p13.3, 16p12.1-11.2, 16q24.2-q24.3, 17q24.3-25.3, 21q22.2-22.3, 22q11.21-11.22, 
22q12.1-12.3,and 22q12.3-13.33, and losses at 9q32-33.2, 10q25.1, 16q21, 17q21.33-
q22, and 17q24.3. Presence of so many genomic changes with the same breakpoints in 
most cases suggests that they may be artefacts caused by technical error, as it is unlikely 
that all metastatic cases studied show such high similarity of genomic alterations. These 
artefact changes described above may cover true genomic regions of reccurent copy 
number gains or losses existing in these six samples. The source of the error is not clear 
but it could originate from the arrays processing or DNA quality. Error from arrays 
processing was tested by processing one primary PCa sample, which was previously 
analysed in our laboratory by SNP array, and comparing generated genomic profile to 
the profile acquired previously. New genomic profile of primary PCa sample was very 
similar to the one generated previously and different from profiles generated for 
metastatic samples. This result suggests that array processing might not be the main 
source of observed artificial genomic changes. Starting DNA quality will also have an 
impact on downstream sample processing. Additionally, as all samples were collected 
from sites of bone fracture, they may be contaminated with necrotic and apoptotic cells 
containing fragmented DNA [233, 234]. The fragmented and partially digested DNA from 
necrotic tissue may have over-representation of more digestion resistant DNA fragments 
whose presence could artificially enrich copy number of certain parts of genomic 
sequence.  
These described above potential artefacts make the evaluation of detected genomic 
changes with the same breakpoints less reliable. However, previous reports on genomic 
rearrangements associated with advanced PCa included several copy number changes 
falling in these regions (Table 38). For example, gains at 5q35.2-35.3, 11q13.2, 16p13.3 
and 6p21.1 were reported in liver and lymph node PCa metastases [151]. Interestingly, 
located within 6p21.1 gain VEGF oncogene has been reported to promote osteoblastic 
lesion formation at PCa bone metastatic sites [235]. Gain at 11q13.2 contained CCND1 
oncogene, which is commonly gained/amplified in mCRPC [138, 167]. Gains at 1q32 
and 7q22.1 were also frequently found in mCRPC [150, 152, 153]. Gain of 1q32 was one 
of the most common alterations found in disseminated tumour cells from patients with 
metastatic PCa (45%), and was detected in 50% of the deadly metastatic PCa [150]. 
Frequent gains at chromosome 7 and gains at 9q34.11, 12q24.31, 16p13.3 or 16p12.2-
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11.1 observed in our bone metastases were also previously reported to be significantly 
more common in soft tissue metastases (40-55% and >30%, respectively) from deadly 
mCRPCs than in localised PCa [151]. Validation of these highly similar genomic changes 
with different method is required to definitively assess their prevalence in PCa bone 
metastases. 
3.3.2 The common regions with copy number changes with different 
chromosomal breakpoints 
Another group of genomic changes detected in PCa bone metastases consists of 
variable size copy number alterations sharing overlapping region between two or more 
samples. Particularly interesting within this group were minimal overlapping regions 
shared by at least half of the samples and included losses at 6q16.1-16.2 (6 cases), 
8p23.2-21.1 (4 cases) and 17p13.1-12 (3 cases), and gain at 20q13.12-13.32 (3 cases) 
and Xq12-13.1 (3 cases). Detection of various size copy number loss at 6q14-22, present 
in all 6 metastatic samples is in agreement with several reports of frequent deletion within 
6q13-q22 in advanced mCRPC [119, 150, 151, 236]. Minimal overlapping region at 6q16 
could play an important role in metastatic cancer progression, as LOH at 6q16 was 
previously mentioned as the only LOH region showing a tendency towards higher degree 
of copy loss in metastatic and low differentiated tumours [226]. Therefore 6q16 loss was 
chosen for further analysis.  
Frequent loss of 8p (4/6) and recurrent gain of 8q (2/6) found in our metastatic samples 
correspond closely to other reports on PCa, as these alterations are most commonly 
detected in PCa, especially in metastatic disease [138, 167, 237-239]. Simultaneous 8p 
loss and 8q gain was also found more frequently in circulating tumour cells (CTC) from 
patients with metastatic than localised disease [150]. The 8p21 region was previously 
reported as the most frequent site of LOH in PCa and PIN [115]. Loss of 8p21 together 
with loss of PTEN at 10q23.33 (found in 2/6 of our bone metastases) are most commonly 
reported events involved in progression from PIN to PCa [141]. PTEN loss is very 
common in primary and metastatic PCa (40% of cases) [115, 138, 153, 228, 230]. As an 
early event in PCa progression, loss of PTEN is considered as one of the drivers of 
tumorigenesis [167, 230]. However, based on mouse models PTEN loss alone does not 
induce development of invasive tumours [240]. Interesting study on mice single and 
double knockout for PTEN and SMAD4 genes revealed that mice with both genes 
knockout develop highly aggressive invasive PCa and die within 32 weeks [241]. 
Therefore, it is possible that PTEN loss can lead to advanced metastatic disease when 
combined with concomitant deregulation of other genes such as SMAD4. SMAD4 is 
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consistently downregulated in PCa [241] and the region of 18q21.2, which harbours 
SMAD4, was found deleted in 30% of 17 soft tissue metastases [242]. We did not detect 
SMAD4 copy number loss in our 6 bone samples; however, we cannot exclude gene 
downregulation by post-transcriptional mechanisms. 
Copy number loss at 17p13.3-11.2 found in half of bone metastases (minimal 
overlapping region 17p13.1-12) was also commonly detected in 14 deadly metastatic 
PCa [151]. Letouze et al [152] used SNP 6.0 data from 14 PCa patients with multiple 
metastatic sites to reconstruct the tumour progression tree in each patient and to find a 
signature copy number pattern of the common precursor clone for each sample. 
Interestingly, most frequently detected changes in the precursor clones were also 
frequent in our samples, including loss of 8p21, 17p13-11 and 6q14-21, and gain of 8q24. 
As precursor clones would onset the metastasis, these recurrent abbreviations may play 
a role in metastatic progression. 
Taylor et al [115] based on copy number alterations analysis of 181 primary tumours and 
37 metastases distinguished two separate subgroups of tumours: those with minimal 
copy number alterations (clusters 1-4), mainly containing primary tumours, and those 
with substantial copy number alterations (clusters 5 and 6), that included most of the 
metastatic samples analysed. Cluster 5 contained 6/8 bone metastases studied and was 
characterised by presence of common genomic alterations, such as loss of 6q, 13q, 16q 
and 18q. Our bone metastases also displayed variable size losses within 6q14.1–q22.32 
(all cases), 13q13.1-q31.1 (2/6), 16q12.1-q24.3 (2/6) and 18q21.1-q23 (2/6). In Taylor et 
al study cluster 5 tumours had an extremely unfavourable prognosis. Together with 8p 
losses and 8q gains, losses at 13q, 16q and 18q are most commonly found in mCRPCs, 
as reported in a study of 150 samples of mCRPC collected from different metastatic sites 
(lymph nodes, bones, liver, soft tissue) [138] and another cohort of 54 metastatic 
samples (including bone metastases) from 10 mCRPC patients [167]. 
Gain of AR at Xq12 is usually linked to progression from localised to metastatic disease 
[141], with focal amplifications of AR restricted to mCRPC [115, 138, 167, 230]. 
Unsurprisingly, two of our bone metastases had gain within Xq12-13.1 and one sample 
had a whole chromosome X gain.  
Copy number loss at common TSG loci was also present in our PCa bone metastases. 
Loss of 17p13.1-12 (TP53 at 17p13.1) was found in 3/6 (sample 2, 4, and 6), 13q13-31 
(RB1 at 13q14.1) in 2/6 (sample 2 and 6), and 12p13.31-13.1 (CDKN1B at 12p13.1, 
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coding p27) and 9p24.2-21.1 (CDKN2 at 9p21.3, coding p16) were present in a single 
tumour (sample 5). Taylor et al [115] in his subset of primary and metastatic tumours 
found peaks of deletion in regions targeting RB1 (13q14.2), TP53 (17p13.1), and broader 
deletions at 12p13.31-p12.3, containing CDKN1B (12p13.1). They found RB1 loss in 
37% of metastatic PCa versus 5% of primary PCa and loss of CDKN1B in 47% of 
metastatic PCa versus 24% of primary tumours. Holcomb et al [151] reported loss of 
RB1 locus in 79% of soft metastases from mCRPC patients and Liu et al [228] found 
homozygous deletions at CDKN2A locus in single PCa metastatic sample. However, in 
recent NGS-based study, Robinson et al [138] found RB, CDKN1B and CDKN2A 
loss/mutations at lower frequencies of 21%, 4% and 2.7% in 150 PCa metastatic 
samples. As those genes are involved in one pathway, inactivation of any of them will 
lead to pathway disruption. Functional inactivation of p16 and Rb tumour suppressor 
proteins is generally mutually exclusive in human cancers [243, 244], which is also the 
case in our samples. Moreover, overexpression of cyclin D1, e.g. as a result of CCND1 
copy number gain, would have the same effect on cell proliferation (unrestrained) as loss 
of p16 and Rb [244, 245]. Interestingly, we confirmed copy number gain at CCND1 locus 
in exactly same three PCa bone metastases that had loss of CDKN2 or RB1. It is possible 
that in those samples additional gain of CCND1 was necessary to efficiently stimulate 
cell cycle progression. In lung cancer cyclin D1 overexpression coexist with loss of Rb 
or p16 and it has been suggested that overexpression of cyclin D1 may be an early event 
in this cancer, followed either by Rb loss, as occurs in SCLC, or by loss of p16 
expression, a common event in NSCLC [246]. Cyclin D1 overexpression followed by Rb 
loss has also been proposed for parathyroid cancer progression [247].  
One bone metastasis displayed deletion at 21q22.2-22.3 locus between ERG and 
TMPRSS2 genes, an event commonly found in PCa [122, 151, 228]. TMPRSS2-ERG 
rearrangement is considered as an early event in PCa carcinogenesis and its status in 
primary tumours is carried over to the metastatic sites, but is not acquired de novo at 
metastatic site, suggesting that is not necessary for PCa progression [228]. Currently, 
the significance of the TMPRSS2-ERG rearrangement in PCa is not clear, as 
associations with both poor [128] and good prognosis [131] have been reported. 
3.3.3 Copy number confirmation at CCND1 and FBXL4 locus 
Copy number analysis of FBXL4 locus by qPCR confirmed loss of the region in all 6 
samples analysed by SNP array but only 3/6 of PCa bone metastases with copy number 
gain at 11q13 detected by SNP array showed gain at CCND1 locus with TaqMan 
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CNAssay. Lack of copy number gain detection in the other 3 cases could be due to 
specificity of a relative quantification method used for copy number analysis. The qPCR 
method is widely used for copy number confirmation. However, as qPCR compares 
threshold cycles (Ct) between the target gene (target CNAssay) and a reference 
sequence (reference CNAssay) to generate ΔCt values, which are used for copy number 
variation (CNV) calculation, it highly relies on the assumption that amplification efficiency 
of both assays that are competing in a single reaction is equal. Differences in 
amplification efficiencies between target and reference amplicons would cause 
variations in ΔCt that can result in artifactual copy number assignments. It has been 
shown that as little as a 4% change in amplification efficiency could result in an error of 
up to 400% in ΔCt calculation [248, 249]. Unfortunately, at present, there is no accepted 
procedure to evaluate PCR efficiency from a single run, hence some methods can 
overestimate and others underestimate the true PCR efficiency [249]. qPCR methods 
are also prone to false copy number assignments if DNA concentration and quality are 
not optimal and inhibitory components from insufficiently purified DNA may also cause 
significant reduction in the sensitivity of qPCR assays [248, 249]. Most importantly, the 
analysis assumes that substitutional mismatches at either the test or reference locus 
primer binding sites do not lead to ‘drop-out’ of one or more copies. Any genetic changes 
within regions where primers and probe attach (e.g. polymorphism or point mutations) 
could affect qPCR efficiency and lead to failure of polymorphic copy to amplify, therefore 
reducing amount of PCR product [250, 251]. CCND1 sequence is particularly rich in 
polymorphic sites (over 100 SNPs identified) [252], and unfortunately, they could not be 
avoided in TaqMan assay used in this study.  
There is also the possibility of some sample or SNP array processing error which could 
potentially cover the true genetic alteration as this particular copy number gain is one of 
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4 Analysis of 11q13 gain/ CCND1 gene in PCa 
4.1 Introduction 
4.1.1 The 11q13-14 gain and potential driver genes 
One of the common genetic changes detected in all PCa bone metastases analysed was 
gain of 11q13-14. Gains within 11q12-24 region were previously found at higher 
frequency in more advanced/metastatic PCa than in localised tumours [150, 151, 226]. 
The smaller 11q13 region is especially frequently gained in a variety of tumours, 
including breast [253], ovarian [254], HNSCC [255, 256], bladder [257] and oral [258]. 
The common 11q13-14 gain detected in our 6 bone metastases spans over 15 Mbs and 
contains more than 300 genes. For such kind of gene rich region, it is always difficult to 
assess which of these genes is a potential driver for observed genomic alteration [259]. 
However, based on previous reports, the most frequently named potential candidate 
drivers within 11q13 gain are: CCND1, EMSY, FGF3 and FGF4 [255, 258].  
EMSY gene is located at 11q13.5 and has been found amplified in sporadic breast 
cancer (13%) and higher-grade ovarian cancer (17%), where it was associated with 
worse survival, particularly in node-negative breast cancer [254]. EMSY encodes a 
protein that binds to and inhibits the activity of BRCA2, suggesting its involvement in 
DNA repair in non-hereditary breast and ovarian cancers [254]. However in vitro study 
showed lack of benefit from EMSY amplification when considering cells sensitivity to 
agents targeting cells with defective homologous recombination [260]. Interestingly, 
EMSY genetic variants were reported to contribute to PCa predisposition [261, 262]. 
Other potential candidate drivers, FGF3 and FGF4, are frequently amplified together with 
CCND1 in many cancers, including bladder, breast and squamous cell carcinoma of the 
lung and head and neck [257, 263]. In recent NGS study they were found amplified in in 
22 of 391 cancer patients (5.6%) [264]. In breast cancer, FGF3 amplification was found 
to be a good indicator of prognosis in the subgroup of progesterone-receptor-negative 
patients [253]. However in PCa FGF3 amplification is rare or absent [265, 266], therefore 
it is unlikely to be involved in PCa carcinogenesis. Based on mouse model FGF3 
overexpression may lead to benign epithelial hyperplasia. Transgenic mice, which carry 
the FGF3 gene driven by the MMTV promoter/enhancer develop pronounced mammary 
gland hyperplasia (female) or benign epithelial hyperplasia similar to BPH [267].  
Based on widespread evidence of CCND1 oncogene involvement in human cancer, it 
seems to be most likely target gene of 11q13 gain/amplification [268]. Copy number 
gain/amplification specifically at CCND1 locus was recently commonly found at different 
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metastatic sites (including bone) in mCRPC [138, 167] and several metastatic PCa cell 
lines including PC3, DU145 and VCaP are known to have 11q copy number gain [218]. 
Chromosomal rearrangement, amplification and mutation of the CCND1 gene have been 
reported in many types of human cancers, including mantle cell lymphomas, parathyroid 
adenomas, breast, prostate, colon, lung, bladder and liver adenocarcinomas, squamous 
carcinomas of the esophagus and head and neck [252, 269]. Tissue culture-based 
experiments showed that cyclin D1, a CCND1 gene product, acts as a collaborative 
oncogene that enhances oncogenic transformation of other oncogenes (i.e. Ras, Src, 
E1A) in cultured cells [270]. Cyclin D1 was indicated in acquisition of invasive phenotype 
by breast cancer cells and their local invasion to surrounding tissue [271]. Cyclin D1 
deficient mice were resistant to breast cancer induced by the HER2 or Ras oncogenes 
[269]. Cyclin D1 overexpression also contributes to the resistance of tumour cells to 
chemotherapeutic agents such as cisplatin [272]. In PCa cell lines cyclin D1 inhibits 
FOXO-mediated anoikis (programmed cell death induced by detachment of anchorage-
dependent cells from the surrounding extracellular matrix) and therefore may contribute 
to tumourigenesis by promoting anchorage-independent cell survival [273].  
4.1.2 Cellular function of CCND1 product, cyclin D1 
CCND1 gene is located at chromosome 11q13.3 (Figure 21).  
 
 
FIGURE 21. CCND1 LOCATION ON CHROMOSOME 11Q13.  Red line marks CCND1 position. 
Adopted from www.genecards.org.  
 
Cyclin D1 belongs to conserved cyclin family, which function as regulatory subunits for 
the cyclin-dependent kinases (CDKs). 29 cyclins and more than 20 CDKs have been 
identified in mammalian cells [274]. All cyclins share a conserved domain of 150 amino 
acid residues called the “cyclin box”, which mediates binding to CDKs. D, E, A, and B-
type cyclins in complexes with relevant CDKs are known to directly regulate the cell 
cycle: through phosphorylation of different substrates they trigger transition to distinct 
cell cycle phases [275]. D-type cyclins (D1, D2, and D3) are G1-specific cyclins that 
associate with CDK4 or CDK6, and promote cell cycle progression during G1 phase. 
Unlike other cyclins, expression and accumulation of D-cyclins are strongly dependent 
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on extracellular mitogenic signals, therefore they are regarded as mitogenic sensors that 
transmit signals from the extracellular environment to the cell cycle machinery [276, 277]. 
The ability of Cyclin D1 to activate CDK4/6 is the most extensively documented 
mechanism for its oncogenic action. Activation of CDK4/6 leads to phosphorylation and 
inactivation of the tumour suppressor protein Rb. Rb serves as a gatekeeper of the G1 
phase and its inactivation by cyclin D1/CDK4/6 results in release of E2F transcription 
factors and activation of genes that are essential for advances into the late G1 and S 
phases [278] (Figure 22). Upregulation of cyclin D1 expression and CDK4/6 activation 
would therefore lead to mitogen independent cell proliferation and overriding checkpoints 
controlling genomic integrity and stability [268]. In normal cells, cyclin D1 levels are tightly 
controlled at transcriptional, posttranscriptional and protein levels [279]. Cyclin D1 
degradation is triggered by phosphorylation of its Thre286 residue through glycogen 
synthase kinase 3β (GSK3β). Under normal conditions, phosphorylation of cyclin D1 
leads to nuclear export and subsequent rapid ubiquitin-dependent proteolysis [279].  
 
FIGURE 22. CYCLIN D1 FUNCTION.  pRb is phosphorylated by G1 phase cyclins, cyclin D1 and 
cyclin E, which leads to its inactivation and release of E2F transcription factors. Adapted from 
Knudsen et al [252]. 
 
Cyclin D1 localisation and stability can also be altered by mRNA splicing due to 
polymorphism (G/A870) of the CCND1 locus, which has been reported to associate with 
increased cancer risk or poor prognosis for a number of cancers, including prostate [280]. 
The G/A870 polymorphism alters a splice donor site at the exon 4-intron 4 boundary 
(introduces a premature stop codon within intron 4) and the A allele predispose for the 
production of an alternative transcript b, which lacks exon 5. The C-terminus of cyclin 
D1b lacks located within exon 5 PEST domain, involved in protein destabilisation, and a 
phosphorylation site Thre286, regulating nuclear export and cyclin D1 turnover possibly 
leading to increased cyclin D1b stability and inability to be exported from the nucleus 
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(Figure 23) [252]. Cyclin D1b expression was confirmed to be largely nuclear, but didn’t 
show increased stability and as oppose to full variant (cyclin D1a), was found to be a 
poor activator of CDK4-dependent Rb phosphorylation [281]. Nonetheless, cyclin D1b 
seems to have enhanced oncogenic capacity compared to full-size cyclin D1a, possibly 
due to other functions than Rb inactivation. The cyclin D1b transcript is present in multiple 
cancers, including Ewing's sarcoma, mantle cell lymphoma, oesophageal, colon and 
breast cancers [282]. Based on mouse fibroblast models, cyclin D1b (but not cyclin D1a) 
induced tumour formation and anchorage independence, and in breast cancer cells 
induced resistance to therapeutic intervention [282].  
 
 
FIGURE 23. DIFFERENCE IN DOMAIN STRUCTURE OF CYCLIN D1 AND D1B.  Adopted from 
Knudsen et al [252]. 
 
In prostate, expression of full length cyclin D1a transcript increases in response to 
androgen stimulation of AR, which leads to subsequent CDK4 protein activation 
necessary for cell-cycle progression [283]. Prostate cancers require AR for survival and 
progression and androgen withdrawal therapy is the common treatment for PCa. 
Interestingly, accumulated cyclin D1a induces a negative feedback loop by directly 
binding to and inhibiting AR transcriptional activity, thus regulating the strength and 
duration of AR signalling and limiting further cellular proliferation [284]. Cyclin D1b fails 
to control AR activity: is deficient in its ability to regulate AR-dependent transcription and 
lost the ability to attenuate androgen-dependent proliferation. At the same time it can 
promote cell cycle progression in AR-dependent PCa [252, 285].  
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4.2 Results  
4.2.1 FISH analysis of 11q13/CCND1 gain in larger cohort of metastatic and 
primary PCa samples  
I performed FISH analysis of CCND1 locus in 43 bone metastases and 152 primary 
cancers to determine its copy number status. BPH TMAs (55 cases) were used as a non-
neoplastic control for FISH signal evaluation and counting. FISH analysis of 
11q13/CCND1 region was successfully performed in all BPH cases, 22/43 of PCa bone 
metastases. 142/152 cases showed good quality FISH signal at 11q13/CCND1 and 10 
(7%) of them had copy number gain at this locus. Overall, there was a significant 
difference in frequency of copy number change at 11q13/CCND1 locus between primary 
tumours and bone metastases (p<0.0001, Chi-square test) with more frequent copy 
number change in bone metastases (Table 40). Examples of copy number gain are 
shown in Figure 24. 
TABLE 40 FREQUENCY OF CCND1 GAIN DETECTED BY FISH IN PRIMARY AND 
METASTATIC PCA 
PCa type 
11q13 copy number gain 
p value 
positive negative 
Primary PCa 10/142 (7%) 132/142 (93%) <0.0001 
Bone metastases 12/22 (54.5%) 10/22 (45.5%)  
 




FIGURE 24. REPRESENTATIVE FISH IMAGES OF COPY NUMBER CHANGES AT 11Q13 IN 
PROSTATE SAMPLES. (A) CCND1 copy number gain in bone metastasis; (B), CCND1 gain in 
primary PCa; (C), BPH with neutral copy number at CCND1 locus. Red, CCND1 locus; green, 
control locus; blue, nuclei (DAPI). A minimum of 100 nuclei (cells) with clear hybridization signals 
were counted per tissue sample. Nuclei with same number of red and green signals were 
considered as no copy number change. Nuclei with more red than green signal were considered 
as positive for CCND1 copy number gain. Lower panel shows enlarged single nuclei (depicted in 
yellow dotted line) from the top pictures (yellow boxes) to illustrate copy number assessement for 
each exemplar nucleus. The percentage of nuclei with more red signals than green signals were 
determined per sample and the widely accepted cutoff calculated as the mean of false-positive 
findings in ten non-malignant controls (BPH samples) plus three times the standard deviation 
(mean % ± 3SD) was used for CCND1 copy number status evaluation in each sample. 
 
4.2.2 Cyclin D1 protein immunoexpression in FFPE PCa samples  
IHC for cyclin D1 was successfully performed in all 43 bone metastases and 152 primary 
PCa (staining examples shown in Figure 25 and Figure 26). Cyclin D1 staining was 
observed mainly in nuclei, however some degree of cytoplasmic expression was also 
noted. Only nuclear expression was used for analysis [286] and both: staining intensity 
as well as percentage of stained nuclei were assessed in each sample.  
Forty of 43 (90%) bone metastases showed various levels of cyclin D1 
immunoexpression with remaining three cases negative for cyclin D1 staining. Most of 
the cases positive for cyclin D1 were strongly stained (23/40, 57.5%; intensity score 3, 
e.g. sample 4, Figure 25) with only 6 tumours showing low staining intensity (6/40, 15%; 
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intensity score 1, e.g. sample 3, Figure 25). Mean percentage of stained nuclei was 
21.2% with most of the tumours expressing cyclin D1 in 10-30% of cells (29/40, 72.5%). 
 
FIGURE 25. EXAMPLES OF CYCLIN D1 IHC IN BONE METASTASES. Matched FFPE samples 
to six fresh frozen bone metastases showed wide range of cyclin D1 staining, with staining 
intensity from weak (sample 3) to strong (samples 4) in 10% (sample 1, 2, 3) to 70% of nuclei 
(sample 4). 
 
For the six bone metastases with available SNP array data, cyclin D1 expression was 
analysed in context of genetic alterations in CCND1/RB/CDKN2A and TP53/CDKN1A 
pathways (Table 41). All three cases with confirmed CCND1 copy number gain by qPCR 
had loss of TP53. Two of these cases had also loss of RB, while Sample 5 which was 
negative for RB loss had instead CDKN2A loss. All three cases showed medium cyclin 
D1 staining intensity with 10-40% positively stained nuclei. Two of the three samples 
negative for CCND1 gain had weak cyclin D1 expression in 10-20% of nuclei suggesting 
low activation of this pathway while the third sample (Sample 4) had strong cyclin D1 
expression in 70% of nuclei indicating strong pathway activation. All these three cases 
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TABLE 41. CYCLIN D1 EXPRESSION ON THE BACKGROUND OF GENETIC 














(p21) loss Int % 
Sample 1 - 1 20 - - - - 
Sample 2 + 2 10 + - + - 
Sample 3 - 1 10 - - - - 
Sample 4 - 3 70 - - - - 
Sample 5 + 2 20 - + + - 
Sample 6 + 2 40 + - + - 
 
Of 152 primary PCa, 130 were positive for cyclin D1 expression (85.5%). Most of the 
cyclin D1 positive primary tumours showed moderate (53/130, 40.8%; intensity score 2) 
to strong staining intensity (49/130, 37.7%; intensity score 3) with only 28/130 (21.5%) 
cases displaying weak staining (intensity score 1). Majority of the tumours had cyclin D1 
expression in 10-30% of nuclei (112/130, 86.1%) with only 12 cases having cyclin D1 
expression in more than 30% of nuclei (9.2%), including two tumours with all cells stained 
for cyclin D1 (Figure 26, last in top panel). There was no correlation between cyclin D1 
staining intensity (cut off ≥2) and Gleason score (41 tumours with GS<7, 46 with 
GS=3+4, 31 with GS=4+3 and 24 with GS>7; p=0.2276, X2 test) or with tumour stage 
(T1+T2 (2+51 tumours) vs T3 (19 tumours); p=0.7626, Fisher exact test). 
BPH samples used as non-malignant control also commonly stained for cyclin D1 (33/44, 
78.6%) but to lesser extent than tumour tissue (median staining intensity = 1 and median 
% of stained nuclei = 10%, Figure 26, bottom panel). Staining was often focal with only 
some of the glands stained. 




FIGURE 26. EXAMPLES OF CYCLIN D1 IHC IN PRIMARY PCA AND BPH. Top panel: 
representative range of cyclin D1 staining intensity in PCa with mostly low percentage of stained 
nuclei. One of two cases with all nuclei strongly stained is also shown (PCa strong). Bottom panel: 
BPH samples were also mostly positive for cyclin D1 but stained weak to moderate with most 
cases showing focal stain in ≤20% of nuclei.  
 
Cyclin D1 staining intensity had a tendency to be stronger in bone metastases than in 
primary tumours. Median staining intensity of bone metastases was higher than primary 
tumours (3 versus 2, p= 0.0152, two sided Mann-Whitney U test). 34/43 (79.1%) of bone 
metastases and 102/152 (67.1%) of primary tumours had intensity score ≥ 2 (Chi-square 
test, p=0.1869) but only 32.2% (49/152) of primary tumours expressed very strong 
staining intensity (score 3) compared to 53.5% (23/43) of bone metastases (Chi-square 
test, p=0.015, Figure 27A and B). The percentage of stained nuclei was similar in both 
groups with median and average values around 20% (p=0.270, two sided Mann-Whitney 
U test, Figure 27C and D, Table 42). For both, bone metastases and primary tumours, 
most of the cases had cyclin D1 expression present in 10-30% of nuclei with minority of 
cases expressing cyclin D1 in more than 30% of nuclei and two tumours (both primary 
PCa) showing 100% cyclin D1 positivity (Figure 27C). 




FIGURE 27. COMPARISON OF CYCLIN D1 IMMUNOEXPRESSION IN PRIMARY AND 
METASTATIC PCA SAMPLES. Bone metastases show higher intensity of cyclin D1 expression 
than primary tumours (A) with significantly higher mean cyclin D1 staining intensity than primary 
PCa (B). However, bone metastases show similar percentage of stained nuclei to primary tumours 
(C) with no difference in mean percentage of stained nuclei between those two groups (D). 
 
TABLE 42 MEDIAN AND AVERAGE CYCLIN D1 IMMUNOEXPRESSION IN PRIMARY 
PCA AND BONE METASTASES.  
Samples Score type Median Mean (SD) 
Primary PCa 
intensity 
2 1.85 (1.0) 
Bone metastases 3 2.26 (1.0) 
Primary PCa 
% of stained nuclei 
20 18.49 (15.9) 
Bone metastases 20 21.16 (15.9) 
 
4.2.3 Correlation between cyclin D1 expression and 11q13/CCND1 copy number 
gain 
Cyclin D1 expression measured by IHC and 11q13/CCND1 copy number gain assessed 
by FISH were both available for 164 cases, including 22 bone metastases and 142 
primary PCa. Twelve PCa bone metastases and 10 primary tumours were positive for 
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11q13/CCND1 copy number gain with average number of affected nuclei 53% and 43%, 
respectively. All samples with gain were positive for cyclin D1 staining. Correlations 
between cyclin D1 expression and 11q13/CCND1 copy number gain were calculated 
with two sided Mann-Whitney U test. Bone metastases positive for 11q13/CCND1 gain 
showed either moderate or strong cyclin D1 staining intensity. Tumours with 
11q13/CCND1 neutral copy number displayed similar staining intensity to samples with 
11q13/CCND1 gain, apart from two cases with weak staining. Most of the cases with 
11q13/CCND1 gain had cyclin D1 expression present in 30% of nuclei (7/12), while 
tumours without gain showed cyclin D1 IHC mostly in 10% or 20% of nuclei (5/10 and 
3/10, respectively). However, there was no significant difference in cyclin D1 IHC 
between those two groups (p=0.599 for staining intensity and 0.334 for percentage of 
stained nuclei). 
All primary tumours with 11q13/CCND1 gain, similar to bone metastases, showed either 
medium or strong cyclin D1 staining intensity, while 34.8% (46/132) of tumours with 
neutral copy number had weak or no cyclin D1 expression (p=0.002). Half of the tumours 
with 11q13/CCND1 gain showed cyclin D1 expression in 30% of cell nuclei, while cases 
with neutral copy number at 11q13/CCND1 had mostly cyclin D1 expression present in 
10% of cells (p=0.01). 
When primary and metastatic tumours were grouped together based on 11q13/CCND1 
copy number status, cases with 11q13/CCND1 gain had stronger cyclin D1 median 
staining intensity than cases with 11q13/CCND1 neutral copy number (p<0.0001, Figure 
28A and B). Tumours with 11q13/CCND1 gain also showed staining in more cell nuclei 
than cases without gain (p=0.003, Figure 28C and D). 
 




FIGURE 28. PCA WITH 11Q13 GAIN SHOW SIGNIFICANTLY STRONGER CYCLIN D1 
IMMUNOEXPRESSION AND IN MORE CELL NUCLEI THAN CASES WITH NEUTRAL COPY 
NUMBER AT CCDN1 LOCUS. (A), staining intensity distribution; (B), significant difference in 
median staining intensity; (C), percentage of stained nuclei score and (D), significant difference 
in median percentage of stained nuclei between the two groups.  
 
4.2.4  Cyclin D1 transcripts expression in prostate samples  
qPCR for full length cyclin D1a transcript was performed with TaqMan expression assay 
located at exon 4-5 junction, present only in transcript a. Cyclin D1b transcript was 
quantified with specifically designed primers targeting junction of exon 3 and 4 (forward) 
and beginning of intron 4 (reverse) and SYBR Green assay.  
Both cyclin D1 transcripts expression was tested in prostate cell lines. All prostate cell 
lines analysed expressed both transcripts, except for VCaP, which had highest levels of 
cyclin D1b but had undetectable levels of cyclin D1a. 22RV1 highly expressed both 
transcripts, followed by PC3, DU145 and LNCaP cells. PNT1A and PNT2 cell lines 
derived from normal PCa epithelium had lowest cyclin D1a and b RNA expression 
(Figure 29). As the CCND1 A/G status at 870 polymorphic site is already known for 
prostate cell lines, the relation between polymorphism and cyclin D1 transcripts 
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expression was analysed. Cyclin D1a and b transcripts expression levels did not 
correlate with A/G870 polymorphism and they also did not correlate with CCND1 copy 
number status. 22RV1 (A/A870, no CCND1 gain) and VCaP (CCND1 gain) showed 
higher cyclin D1 expression than PC3 (A/G870, CCND1 gain), DU145 (A/A870, no 
CCND1 gain) or LnCaP (A/G870, no CCND1 gain), which had similar but much lower 
levels of cyclin D1 transcripts.  
 
FIGURE 29. RNA EXPRESSION OF FULL LENGTH CYCLIN D1A AND ITS ALTERNATIVE 
SPLICE VARIANT, CYCLIN D1B IN PROSTATE CELL LINES.  
 
For clinical samples qPCR quantification was possible in 5/6 bone metastases (samples 
2 to 6), 4 primary tumours (WX samples) and 5 BPH samples. One metastatic sample 
(sample 1) was excluded from analysis due to poor RNA quality (no product was detected 
with cyclin D1 or β-actin primers after 40 cycles of qPCR).  
Both cyclin D1 transcripts were detected in most of bone metastases, primary tumours, 
and all BPH samples (Figure 30). 5/9 cancer samples and 2/5 BPH samples expressed 
more cyclin D1b than cyclin D1a transcript (Figure 30, red boxes). Cyclin D1a transcript 
levels varied widely across the samples while Cyclin D1b levels were more consistent 
(Figure 31A). There was no correlation between cyclin D1a and cyclin D1b levels across 
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FIGURE 30. CYCLIN D1 TRANSCRIPTS EXPRESSION IN PROSTATE CLINICAL SAMPLES 
BY QPCR. Samples in red boxes express more cyclin D1b transcript. PCa bone metastases are 
positioned left (sample 2-6), primary tumours in the middle (WX cases), and BPH samples on the 




FIGURE 31. CYCLIN D1 TRANSCRIPTS EXPRESSION ACROSS PROSTATE CLINICAL 
SAMPLES BY QPCR. (A), mean transcript expression in all clinical prostate samples tested. (B), 
no correlation between cyclin D1a and b transcripts in the same patient set. 
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4.3 Discussion  
4.3.1 11q13/CCND1 gain is more prevalent in metastatic than primary PCa  
MOR of copy number gain at 11q13-14 found in all analysed bone metastases falls within 
11q12-24 region, which was previously found at higher frequency in more advanced/ 
metastatic PCa than localised tumours [150, 151, 226]. CCND1 oncogene coding for 
cyclin D1 protein is the best candidate driver gene for this gained chromosomal region, 
as cyclin D1 overexpression is commonly involved in human cancer. Recent study found 
frequent CCND1 gain/amplification at various metastatic sites (including bone) of 
mCRPC, implicating cyclin D1 involvement in advanced metastatic disease [138]. 
Further investigation of FFPE samples by FISH showed significantly higher prevalence 
of CCND1 gain in bone metastasis (54.5%, 12/22) than in primary tumours (7%, 10/142; 
p<0.0001). Enrichment of metastatic samples in CCND1 gain suggests its involvement 
in PCa tumour progression and metastasis. Similar to our study, Das et al [287] reported 
gain of 11q13 at CCND1 locus to be more common in patients with bone metastasis 
(67%, 4/6) than in those without distant metastasis (23%, 9/40); unfortunately they had 
very limited number of bone samples. Additionally, they found significant association of 
11q13 gain with higher Gleason score (Gleason 8-10, 50% versus 5-7, 12%). Another 
study looked at high level of CCND1 amplification (≥ 3 fold) and considered it as a rare 
event in PCa, present in 2/172 (1.2%) of the primary tumours, 3/38 (7.9%) of local 
recurrences, and in 2/43 (4.7%) of the metastases (other than bone) [288]. We too, rarely 
saw high amplification of CCND1 - only in 2 bone metastases and in none of the primary 
PCa. Presence of low copy number gain was unfortunately not included in their report. 
Recent study of 150 mCRPC biopsies from different metastatic sites, including 43 bone 
samples, found 11q13-14 region commonly gained in those samples, with CCND1 
amplification present in 9% of metastatic cases [138].  
4.3.2  Cyclin D1 IHC staining intensity is stronger in bone metastases than in 
primary tumours  
Following FISH analysis of 11q13/CCND1 locus, cyclin D1 expression with IHC was 
examined in the same set of prostate samples. BPH samples commonly expressed 
cyclin D1 (33/43; 78.6%) but at low intensity and in a small proportion of nuclei (mean 
staining intensity = 1 and % of stained nuclei = 10%). Common but often focal cyclin D1 
expression in our non-malignant samples is in agreement with other reports [289, 290], 
with recent study finding 72.2% (13/18) of BPH cases positive for cyclin D1 [290]. The 
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staining probably reflects the benign growth and enlargement of prostate glands seen in 
BPH condition. Cyclin D1 expression was more pronounced in cancer samples. Staining 
intensity had a tendency to be stronger in bone metastases than in primary tumours 
(median staining intensity 3 versus 2, p=0.015), with 53.5% (23/43) of bone metastases 
and only 32.2% (49/152) of primary tumours (p=0.018) expressing very strong staining 
intensity (score 3). In contrast, the percentage of stained nuclei was similar in both 
groups with cyclin D1 expression in 30% or less nuclei in majority of cases. Taken 
together, the results suggest, that similar proportion of cells express cyclin D1 in primary 
and metastatic tumours but with higher protein levels in bone metastases. It is possible 
that cyclin D1 staining positivity/intensity was affected in our FFPE bone metastatic 
samples by formic acid–based bone decalcification. Immunohistochemistry tests are 
commonly and successfully performed on decalcified bone marrow trephine biopsies 
obtained for bone marrow diseases. Still, suboptimal IHC results are not uncommon with 
weaker staining or high background leading to misinterpretation of the staining pattern 
[291]. Bigger excision samples are more problematic as they need to be decalcified for 
days and prolonged formic acid treatment was reported to reduce staining intensity [292]. 
As about half of our bone metastases were excision specimens, it is possible that cyclin 
D1 expression in those samples is underestimated due to extension of formic acid 
treatment. 
Comparison of cyclin D1 IHC between studies is challenging due to use of different 
antibodies and variety of scoring systems [289, 293, 294]. Many of those antibodies 
exhibit limited sensitivity and specificity, and cyclin D1 IHC in pathology practice was 
reported as difficult, erratic, technically challenging and therefore not routinely used 
[286]. Reports on cyclin D1 expression in primary prostate tumours differ widely, ranging 
from as high as 63% (n=238) [289] - 71% (n=187) [293] to substantially lower; 11.6% 
(n=86) [295] - 22% (n=140) [294]. In our cohort, 85.5% (130/150) of primary PCa 
expressed cyclin D1, which is similar to recent study (same antibody) reporting 75.4% 
(64/85, cutoff >5%) primary tumours positive for cyclin D1 [296]. High grade PCa were 
reported to be more cyclin D1 positive than low grade tumours (18/64, 28% versus 13/76, 
17%) [294] and one study found frequency of positive cyclin D1 immunoexpression (cut 
off ≥ 20%) significantly higher in PCa bone metastases (15/22, 68.2%) than localised 
tumours (10/86, 11.6%) [295]. There is an evidence, that increased cyclin D1 expression 
in advanced tumours can promote cancer cell migration and invasion. Fibroblasts, 
epithelial cells and macrophages have increased adhesion and reduced migration in the 
absence of cyclin D1 and cyclin D1 was reported to regulate transcription of genes that 
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promote migration and invasion (e.g. the Rho effector ROCK2) [268]. Furthermore, cyclin 
D1 may play a role in the maintenance of VEGF expression as administration of 
antisense to cyclin D1 in mouse models inhibited the growth of HCT116 and DLD1 
xenografts. This direct anti-tumour effect of antisense to cyclin D1 was due to significant 
inhibition of tumour vessel formation accompanied by a significant reduction in VEGF 
expression [297]. Regardless of multiple studies confirming cyclin D1 role in 
tumorigenesis, its prognostic value in PCa is not currently clear. Early studies reported 
lack of independent prognostic value of cyclin D1 expression in PCa [294, 298]. In our 
study we looked at cyclin D1 staining intensity in relation to Gleason score and did not 
find correlation between these two (p=0.2276) despite using the most validated antibody 
(rabbit monoclonal, clone SP4), which was proven to provide results that are more 
consistent than those obtained with other antibodies [286]. Other studies using the same 
antibody also found no correlation between cyclin D1 expression and Gleason score or 
time to recurrence [299-301]. Lack of direct correlation of cyclin D1 with clinical features 
can be due to its often cooperative role in carcinogenesis with other oncogenes. Cyclin 
D1 is known to collaborate with HER2 or Ras oncogene to transform mammary gland 
epithelial cells or with c-MYC to induce B cell lymphomas in transgenic mice [278]. 
Indeed, in PCa cyclin D1 also seem to collaborate with other oncogenes to drive cancer 
progression and cyclin D1 expression was included in four gene signature (which 
involves inactivation of PTEN and SMAD4 and activation of CCND1 and SPP1), which 
was shown to be prognostic of PSA biochemical recurrence and to enhance the 
prognostic accuracy of the Gleason score in predicting metastatic lethal outcome [241]. 
Similarly, cyclin D1–regulated gene expression was recently associated with biochemical 
recurrence and poor prognosis in human PCa [302].  
4.3.3 PCa samples with 11q13/CCND1 gain show stronger cyclin D1 median 
staining intensity than cases with 11q13/CCND1 neutral copy number  
All samples with 11q13/CCND1 copy number gain expressed cyclin D1. When we 
correlated 11q13/CCND1 copy number status with cyclin D1 IHC, we found that bone 
metastases, as oppose to primary tumours, did not show correlation between cyclin D1 
immunoexpression and 11q13/CCND1 copy number status. However, when we grouped 
tumours based on 11q13/CCND1 copy number status, cases with 11q13/CCND1 gain 
had stronger cyclin D1 median staining intensity and showed staining in more cell nuclei 
than cases with 11q13/CCND1 neutral copy number (p<0.0001 and 0.003, respectively), 
confirming correlation between 11q13/CCND1 copy number gain and increased cyclin 
D1 immunoexpression. The small sample size of metastatic tumours could be the reason 
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for these discrepancies. It is well known that overexpression of cyclin D1 is generally 
much more common in cancer than can be explained by copy number gain or mutations 
[268]. As cyclin D1 is a key regulator of cell proliferation its expression is regulated by a 
variety of signalling pathways at the transcriptional level as well as post-transcriptionally, 
through mentioned above modulation of RNA splicing, nucleocytoplasmic transport, 
protein stability and degradation [279, 303]. Many factors, including mitogens such as 
growth factors, can induce cyclin D1 expression in cells without genetic alterations of 
CCND1 locus, which would make a correlation between protein expression and gene 
copy number more difficult to detect. It is important to note, that although we chose the 
best validated antibody for cyclin D1 commercially available [286], this antibody was 
raised against part of C-terminus of cyclin D1 protein positioned within exon 5 of CCND1 
gene and therefore can only detect full length cyclin D1 (cyclin D1a) and not a truncated 
cyclin D1b protein, devoided of exon 5 [304]. 
Cyclin D1 overexpression in cancer is linked to cell cycle progression and increased cell 
proliferation [268]. Cyclin D1 induces cell cycle progression through inactivation of RB 
protein. Rb inactivation leads to accumulation of p16 which in turn blocks cyclin D1/CDK4 
activity eventually causing cell cycle arrest [244]. Increased cell proliferation is 
additionally blocked by activation of p53 which leads to elevated levels of p21 and cell 
cycle arrest [245]. Therefore alterations within any of the genes in CCND1/RB/CDKN2A 
and TP53/CDKN1A pathways would impact cell proliferation. Three of the six bone 
metastases analysed by SNP arrays had confirmed copy number gain of CCND1 and 
they all had medium cyclin D1 expression present in 10-20% of nuclei. Two of these 
cases had also loss of RB, while the other sample negative for RB loss displayed 
CDKN2A loss which is in agreement with general observation that inactivation of p16 
and Rb TSGs is mutually exclusive in human cancers [244, 245]. These results imply 
that cancer cells rely on more than one mechanism to inactivate common pathway. 
Cyclin D1 overexpression coexist with loss of Rb or p16 in other cancers and is proposed 
as an early event, followed either by Rb loss, e.g. in SCLC [246] and parathyroid cancer 
[247] or p16 loss, e.g. in NSCLC [246]. Furthermore, all three cases with CCND1 gain 
had also TP53 deletion which would protect the proliferating cells from cell cycle arrest 
caused by p53 dependent p21 overexpression.  
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4.3.4 Cyclin D1a and cyclin D1b transcript levels do not correlate with PCa 
progression. 
Prostate cell lines including DU145, 22RV1, LAPC4, LnCaP and PC3 are known to 
express both cyclin D1a and D1b transcripts [285]. We also found both transcripts in 
most of the tested PCa cell lines, including DU145, 22RV1, LnCaP and PC3, and 2 
immortalised epithelial cell lines PNT1A and PNT2. Only VCaP cells expressed high 
levels of cyclin D1b but had no cyclin D1a transcript. Similar to previous report [285] 
cyclin D1 transcripts expression levels did not correlate with A/G870 polymorphism and 
they also did not correlate with CCND1 copy number status. It is plausible that in addition 
to genetic changes at CCND1 locus different regulatory mechanisms as well as phase 
of cell cycle the cells are in are affecting cyclin D1 expression levels in PCa cells. Same 
can be true for our limited set of fresh-frozen clinical samples, where we also saw no 
relation with cyclin D1 transcripts levels and CCND1 copy number status (known in PCa 
bone metastases) or cancer progression. All samples: BPH, primary PCa and bone 
metastases displayed cyclin D1b at similar levels and most also expressed cyclin D1a 
transcript but the levels varied widely across the samples. Burd et al [285] detected cyclin 
D1b in all 5 samples tested with lower levels in two matched normal tissues but higher 
expression in other two PIN samples compared to matched tumours. The single lymph 
node metastasis tested also expressed cyclin D1b. They further showed that in contrary 
to cyclin D1a, cyclin D1b was compromised for regulation of multiple AR target genes 
(including PSA), and whereas cyclin D1a significantly attenuated androgen-dependent 
proliferation in AR positive LnCaP cells, cyclin D1b promoted cell-cycle progression. In 
AR negative PC3 cells ectopic expression of either transcript did not affect cell 
proliferation. Therefore, they concluded that cyclin D1b expression may yield a significant 
growth advantage in AR-positive PCa cells. Three of our bone metastases (sample 4, 5, 
and 6) had copy number gain at AR locus, implying increase in AR pathway and they did 
not show higher cyclin D1b levels. They also seem to have less cyclin D1a transcript 
than cases without AR gain. However, we cannot exclude that tumours without AR gain 
have AR pathway activated by other means e.g. activating mutations in AR locus as they 
are very common in advanced PCa.  
Assessment of cyclin D1b protein levels is currently hampered by lack of commercially 
available antibody. Comstock et al [282] used non-commercial cyclin D1b antibody to 
assess by IHC cyclin D1b expression in a cohort of microarrayed human prostate 
specimens (1,626 cores), containing non-neoplastic tissue, PIN lesions, and 
adenocarcinomas. They found that cyclin D1a and D1b showed distinct profiles in PCa, 
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with significant subset of tumours expressing cyclin D1b. Mean cyclin D1a levels were 
similar in non-neoplastic tissue, PIN or adenocarcinomas while cyclin D1b expression 
was elevated in tumours compared with non-neoplastic tissue (p<0.004), suggesting that 
cyclin D1b isoform may be specifically induced in PCa [282].  
Persistent expression of cyclin D1 in primary and metastatic PCa tumours suggests that 
cancer cells requires cyclin D1 expression for their tumourigenic potential. Significantly 
higher frequency of CCND1 gain in metastatic than primary tumours indicates that 
acquirement of ‘genetic fix’ allowing continuous cyclin D1 expression is advantageous 
for PCa cell survival and sustained metastatic growth in bone microenvironment. Further 
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5  Analysis of 6q16/FBXL4 loss in PCa 
5.1 Introduction 
Copy number losses within the 6q14-22 region were present in all 6 bone metastases 
with minimal overlapping region at 6q16.2. The 6q12-22 deletion is one of the most 
common deletions in PCa with the frequency of 22–62% [115, 119, 305]. Loss of 6q13-
q22 is widely present in advanced mCRPC [119, 150, 151, 236, 306]. Genes located at 
6q16 could play an important role in metastatic cancer progression as among six major 
loss of heterozygosity (LOH) regions in PCa (6q14-16, 8p23-11, 10q23, 13q13-21, 
16q21-24 and 21q22.2), LOH at 6q14-16 was reported as the only LOH region showing 
a tendency towards a higher degree of copy number loss in metastatic and low 
differentiated tumours [226]. 
Only two known genes are located within 6q16.2 minimal overlapping region: POU3F2 
and FBXL4. POU3F2 codes for Brn2, a member of the mammalian class III POU 
transcription factor family (includes Brn1, Brn2, and Oct6), which is widely expressed in 
the developing mammalian central nervous system and involved in cortical neural 
migration and neurogenesis [307, 308]. Brn2 expression is also present in melanocytes 
(originating from melanoblasts, a sub-population of neural crest cells), where is involved 
in the determination of melanocytic phenotype [309]. In melanoma lesions, cells 
expressing high levels of Brn2 show enhanced proliferation [310] and invasive and 
metastatic capacity [311]. Therefore, POU3F2 is regarded as a proto-oncogene involved 
in melanocytic growth and tumourigenesis [312]. Small cell lung cancers (SCLC) are 
neuroendocrine tumours and similar to melanoma cell lines also overexpress Brn2, 
which is involved in accelerating cell proliferation and plays important roles in maintaining 
characteristic biological behaviour of SCLC [313]. Considering that POU3F2 seems to 
be expressed only in cells of neural origin where it behaves as an oncogene, it is unlikely 
that this gene is a driver for 6q16 loss.  
There is little known about FBXL4 function. FBXL4 gene product belongs to a large F-
box protein family. F-box proteins are part of E3 ubiquitin protein ligase complex called 
the SKP1-CUL1-F-box (SCF) complex, which orchestrates phosphorylation dependent 
protein ubiquitination and degradation [314]. Through substrate downregulation, F‑box 
proteins regulate diverse biological pathways that control cell growth, division, 
development and differentiation, signalling responses, cell survival and death [315]. 
Therefore, it is not surprising, that more and more evidence emerges about deregulation 
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of F-box proteins in human cancer and its impact on cancer development, progression 
and metastasis [316-318]. Several F-box proteins are known TSGs and are 
downregulated in cancer e.g. due to mutations (FBXW7 in endometrial, colorectal, 
stomach cancer; FBXO4 in oesophageal cancer) or deletions (FBXO18 in melanoma), 
while others act as oncogenes and are overexpressed in several cancers (SKP2 in 
lymphoma, prostate, colorectal, melanoma, pancreatic, breast cancer) [318]. It is 
possible that FBXL4 acts as a TSG in PCa and therefore is a target gene for 6q16 loss.  
5.2 Results  
5.2.1 FISH analysis of FFPE samples finds 6q16/FBXL4 loss in half of PCa bone 
metastases and in a small subset of primary tumours 
Due to limited numbers of fresh samples available for array analysis, we used the FISH 
method to study FBXL4 copy number in a larger cohort of FFPE samples, including 43 
bone metastases, 152 primary tumours and 55 non-malignant BPH samples, which were 
used as controls. FISH analysis of FBXL4 locus was successfully performed in 23/43 of 
PCa bone metastases, 145/152 of primary tumours and all BPH samples. The FBXL4 
region was lost in 11/23 (47.8%) of bone metastases and in 20/145 (13.8%) of primary 
tumours. None of the BPH samples harboured FBXL4 loss. Overall, there was a 
significant difference in the frequency of FBXL4 copy number loss between primary 
tumours and bone metastases (p<0.0001, Chi-square test) with more frequent FBXL4 
loss in bone metastases (Table 43). Examples of FBXL4 copy number loss are shown in 
Figure 32. 
TABLE 43 FREQUENCY OF FBXL4 LOSS DETECTED BY FISH IN PRIMARY AND 
METASTATIC PCA. 
PCa types  FBXL4 copy number loss p value 
(X2 test) positive negative 
Primary 20/145 (13.8%) 125/145 (86.2%) 0.0003 
Bone metastases  11/23 (47.8%) 12/23 (52.2%)  




FIGURE 32. REPRESENTATIVE FISH IMAGES OF COPY NUMBER CHANGES AT FBXL4 IN 
PROSTATE SAMPLES. (A) and (B) respectively: FBXL4 loss in PCa bone metastasis and 
primary PCa; (C), BPH with neutral copy number at FBXL4 locus. Red, 6q16 locus; green, control 
locus; blue, nuclei (DAPI). A minimum of 100 nuclei (cells) with clear hybridization signals were 
counted per tissue sample. Nuclei with same number of red and green signals were considered 
as no copy number change. Nuclei with less red than green signal were considered as positive 
for FBXL4 copy number loss. Lower panel shows enlarged single nuclei (depicted in yellow dotted 
line) from the top pictures (yellow boxes) to illustrate copy number assessement for each 
exemplar nucleus. The percentage of nuclei with less red than green signals were determined 
per sample and the widely accepted cutoff calculated as the mean of false-positive findings in ten 
non-malignant controls (BPH samples) plus three times the standard deviation (mean % ± 3SD) 
was used for FBXL4 copy number status evaluation in each sample. 
 
5.2.2 FBXL4 copy number loss in conservatively managed localised PCa 
correlates with cancer progression 
FBXL4 copy number status was then investigated in a large cohort of conservatively 
managed localised PCas diagnosed by TURP, in order to assess FBXL4 loss as a 
potential cancer prognostic marker. FBXL4 loss was present in 77/447 (17%) cases 
successfully analysed by FISH. FBXL4 loss strongly correlated with high Gleason score 
and clinical stage (p=0.000002 and 0.0005, respectively, Table 44) as well as with PSA 
levels and extent of disease (p=0.00015 and 0.000049, respectively). Loss of FBXL4 
was also significantly associated with poor patient survival (HR 1.738, p=0.009; Figure 
33) by univariate analysis. However, since loss of FBXL4 was strongly correlated with 
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other poor prognosis factors such as PSA, the correlation with poor patient outcome lost 
significance in multivariate analysis when Gleason score, baseline PSA and extent of the 
disease were simultaneously included in the analysis model (Table 45). Therefore, 
although loss of FBXL4 significantly correlates with advanced disease, it cannot be used 
as an independent prognostic factor for PCa survival. 
TABLE 44. CORRELATION OF FBXL4 LOSS WITH GLEASON SCORES AND 
CLINICAL STAGES. 
Parameter No FBXL4 loss FBXL4 loss p value (X2 test) 
Gleason score <7  197 20 0.000003 
Gleason score =7 97 22  
Gleason score >7 76 35  
Clinical stage T1 104 10 0.0005 
Clinical stage T2 83 32  
Clinical stage T3 40 16  
Clinical stage Tx 63 11  
 
 
FIGURE 33. FBXL4 LOSS IS SIGNIFICANTLY ASSOCIATED WITH DECREASED PCA 
SPECIFIC SURVIVAL. Kaplan–Meier survival curves represent conservatively managed 
localised prostate cancers with or without FBXL4 loss (HR 1.74, p=0.009). 
 
No FBXL4 loss 
FBXL4 loss 
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TABLE 45. MULTIVARIATE ANALYSIS OF CLINICOPATHOLOGICAL 
PARAMETERS. 
Parameter HR (95% CI) P value 
FBXL4 loss 0.750 0.225 
Gleason score <7 vs. =7 0.750 0.253 
Gleason score >7 5.579 0.000002 
PSA 1.366 0.007 
Clinical stage T1 0.702 0.339 
Clinical stage T2 0.964 0.901 
Clinical stage T3 0.961 0.890 
Extent of the disease 3.876 0.0001 
 
5.2.3 FBXL4 expression  
5.2.3.1 FBXL4 RNA expression is reduced in PCa 
After confirmation of common FBXL4 loss in PCa, I looked at FBXL4 RNA expression in 
fresh-frozen samples from bone metastases, primary PCa and BPH. Relative FBXL4 
expression levels of all bone metastases and 3/4 primary PCa (WX samples) analysed 
were lower than in 6 BPH samples (Figure 34, Table 46) and the difference was 
statistically significant between the 3 groups (p=0.0079, Kruskal-Wallis test). Prostate 
cell lines also had low expression levels of FBXL4. 22RV1, LNCaP and VCaP cell lines 
with no FBXL4 copy number loss had relatively higher FBXL4 levels than PC3 and 
DU145 cell lines, which are positive for FBXL4 loss. Surprisingly, normal epithelial cell 
lines immortalised with SV40, PNT1A and PNT2 displayed the lowest FBXL4 expression 
(Figure 35). 
 




FIGURE 34 FBXL4 EXPRESSION LEVELS IN PROSTATE CLINICAL SAMPLES MEASURED 
BY Q-RT-PCR. PCa bone metastases are positioned left (Sample 2-6), primary tumours in the 
middle (WX cases), and BPH samples on the right. RQ values presented here were calibrated to 
expression levels in 22RV1 cell line. 
 
 
TABLE 46 DIFFERENCE IN FBXL4 TRANSCRIPT EXPRESSION BETWEEN PCA 
BONE METASTASES, PRIMARY TUMOURS AND BPH SAMPLES. 
Sample 
FBXL4  p value  
(Kruskal-Wallis test) Median Mean SE 
PCa bone metastases 3.8 6.1 2.37 0.0079 
Primary PCa 12.8 18.5 7.27  

















FIGURE 35 FBXL4 EXPRESSION IN PROSTATE CELL LINES MEASURED BY QPCR. 
LNCaP, VCaP and 22RV1 PCa cell lines without FBXL4 loss show higher FBXL4 expression than 
PC3 and DU145 cells positive for FBXL4 loss. Normal immortalised prostate epithelial cells PNT2 
and PNT1A also have low FBXL4 expression levels. FBXL4 expression was measured by relative 
quantification method with GAPDH as endogenous control and 22RV1 cell line as a calibrator 
sample. 
 
5.2.3.2 FBXL4 protein expression  
5.2.3.2.1 Anti-FBXL4 antibody testing using inducible protein expression in 
HEK293 cells 
The predicted size of FBXL4 protein is 70.1 kDa. Based on RNA expression analysis, 
endogenous levels of FBXL4 are low in PCa cell lines, which make it difficult to test anti-
FBXL4 antibodies. There are several commercially available anti-FBXL4 antibodies, 
however all published data is based on tagged FBXL4 protein overexpression models, 
implying low specificity/sensitivity of available antibodies [319-321]. Tetracycline-
Regulated Expression System for Mammalian Cells (T-Rex-293 System) was used for 
anti-FBXL4 antibody testing. We generated stable single clones of T-Rex-293 cells 
containing expression vector with FBXL4 cDNA tagged at C-terminus with flag, which 
highly overexpressed FBXL4 from the vector upon tetracycline treatment, ensuring 
easier protein detection. Addition of flag tag allowed for easy monitoring of FBXL4 protein 
overexpression and identification of FBXL4-specific band on WB. FBXL4 overexpression 
upon tetracycline treatment was confirmed at RNA level by qRT-PCR (Figure 36). Of five 
anti-FBXL4 antibodies tested by WB and IHC, only two were specific: rabbit polyclonal 
from Abcam (ab153812) and mouse monoclonal antibody from Santa Cruz (sc-81270). 
On WB, both antibodies produced a band at 70 kDa (FBXL4 protein size) only in protein 
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better and producing stronger band under less exposure time, than mouse antibody sc-
81270 (Figure 37A and B). Specificity of the observed band was confirmed by two 
different anti-flag antibodies, which also detected the same bands in protein lysates from 
FBXL4 overexpressing cells, at the same time confirming FBXL4 overexpression from 
the vector (Figure 37C and D). Testing the antibodies for IHC showed increased staining 
in FBXL4 overexpressing cells for both antibodies when compared to control cells (Figure 
38), proving that they are both able to detect FBXL4 protein. However, in terms of 
staining quality the antibodies produced opposite results to WB. Mouse antibody sc-
81270 produced superior results to rabbit antibody ab153812, with sharper and much 
stronger staining in FBXL4 overexpressing cells (Figure 38A and B). Based on these 
data, all further assessment of FBXL4 protein expression by WB was done with rabbit 
antibody ab153812, while IHC analysis was performed with mouse antibody sc-81270. 
 
 
FIGURE 36. CONFIRMATION OF FBXL4 RNA OVEREXPRESSION IN HEK293 CELLS. EV, 
control cells with empty expression vector; FBXL4, HEK293 cells transfected with expression 
vector containing FBXL4-Flag. ‘-‘, no tetracycline treatment; ‘+’, 1µg/ml tetracycline treatment. 
Error bars indicate SD; n = 3. 




FIGURE 37. ANTI-FBXL4 ANTIBODIES SPECIFICITY IN HEK293 C-FLAG FBXL4 
OVEREXPRESSION SYSTEM BY WB. Both anti-FBXL4 antibodies; rabbit ab153812 (A) and 
mouse sc-81270 (B) produced bands at 70 kDa (size of FBXL4 protein) in protein lysates from 
FBXL4 overexpressing cells treated with 1µg/ml tetracycline over 48 h. Specificity of supposed 
FBXL4 bands was confirmed with two anti-Flag antibodies (C) and (D), both producing same 
bands as anti-FBXL4 antibodies in FBXL4 overexpressing cell lysates. EV, control cells with 
empty expression vector; FBXL4, HEK293 cells transfected with expression vector containing 
FBXL4-Flag. ‘-‘, no tetracycline treatment; ‘+’, 1µg/ml tetracycline treatment. Protein load: 100 µg. 
 




FIGURE 38. CONFIRMATION OF FBXL4 PROTEIN DETECTION BY IHC WITH ANTI-FBXL4 
ANTIBODIES IN HEK293 CELLS OVEREXPRESSING FBXL4. FBXL4 protein staining in FBXL4 
overexpressing cells shows that mouse anti-FBXL4 sc-81270 antibody (A) produces stronger 
staining than rabbit ab153812 (B). Both antibodies also seem to detect endogenous levels of 
FBXL4 in control cells. EV, control cells with empty expression vector; FBXL4, HEK293 cells 
transfected with expression vector containing FBXL4-Flag. ‘-‘, no tetracycline treatment; ‘+’, 
1µg/ml tetracycline treatment. 
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5.2.3.2.2 FBXL4 overexpression is lost in PCa cell lines upon selection for stable 
clones 
Stable PCa cell lines transfected with C-flag FBXL4 expression vector were generated 
upon antibiotic selection for 3 weeks. As DU145 and PC3 cells have FBXL4 loss and 
express relatively lower FBXL4 RNA levels than cells without FBXL4 copy loss such as 
22RV1, we used a constitutive gene expression system to generate stable cells. In case 
of 22RV1 cells, which already have reasonably high FBXL4 expression we used a 
tetracycline inducible system to avoid potential toxicity from too high levels of TSG. Initial 
FBXL4 overexpression was confirmed at RNA levels by qRT-PCR and was very strong 
24 h post-transfection/tetracycline treatment. However, it was substantially reduced 
within the next 48 h, especially in DU145 and 22RV1 cells (Figure 39A). After continuous 
selection with antibiotics over 3 weeks for stable cell population a substantial decrease 
in RNA levels of FBXL4 was noticed in all transfected cell lines. PC3 cells on average 
expressed only five times more FBXL4 RNA than transfection control (Figure 39B). 
DU145 cells completely lost initial FBXL4 overexpression and returned to FBXL4 levels 
seen in non-transfected cells (Figure 39C). Inducible expression system used for 22RV1 
cells also produced only minor, four-fold increase in FBXL4 levels when compared to 
transfection control (Figure 39D). About one fold leakage was observed in cells 
transfected with C-Flag FBXL4 vector without tetracycline treatment. FBXL4 protein 
analysis by WB generally showed very weak FBXL4 bands and no increase in FBXL4 
band size in FBXL4 overexpressing cells when compared to control cells (Figure 40). 
Reduction of FBXL4 expression levels upon continuous antibiotic selection could be 
explained by the death of the cell population with FBXL4 expression vector and 
remaining untransfected cells acquiring resistance to antibiotic. Therefore, presence of 
FBXL4 expression vector was tested by PCR in stable cell populations using a forward 
primer located within the C-terminus of FBXL4 sequence and a reverse primer located 
within the vector backbone sequence. All stable cell populations transfected with FBXL4 
expression vector still contained the vector, and therefore, capacity to express FBXL4 
(Figure 41A).  
Unsuccessful attempts to overexpress FBXL4 in three different PCa cell lines led us to 
test constitutive FBXL4 overexpression over a prolonged period of time in T-Rex-293 
cells in order to see if the FBXL4 overexpression would also disappear over time. As T-
Rex-293 is a tetracycline-inducible system, we continuously treated the cells with 
tetracycline over a six week-period, mimicking constitutive FBXL4 expression system 
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used in PC3 and DU145 cells. In contrary to PCa cells, constant induction of FBXL4 
expression in HEK293 cells led to continuous and relatively stable FBXL4 
overexpression (Figure 41B). The presence of FBXL4 expression vector in HEK293 over 
a period of time was confirmed with PCR (Figure 41C). 
 
FIGURE 39. PCA CELL LINES FAIL TO STABLY EXPRESS HIGH LEVELS OF FBXL4 
PROTEIN. Initial cell transfection with C-flag FBXL4 led to high levels of FBXL4 RNA in all 3 cell 
lines tested (A). However, upon 2 weeks of antibiotic selection for stable cell population, FBXL4 
expression levels dropped dramatically with PC3 cells having FBXL4 expression only 5 times 
higher than in transfection control (B), and DU145 FBXL4 RNA expression returning to 
endogenous levels (C). 22RV1 cells showed similar levels of FBXL4 RNA to PC3 cells upon 24, 
48 and 72 h of 1µg/ml tetracycline treatment after two weeks of selection (D). CTR, untreated 
cells; EV, control cells with empty expression vector; FBXL4, cells transfected with expression 
vector containing C-Flag FBXL4. Error bars, SD. 
 




FIGURE 40. LACK OF FBXL4 PROTEIN OVEREXPRESSION IN STABLE PCA CELL LINES. 
Neither constitutive expression system (DU145 and PC3) nor tetracycline inducible system 




FIGURE 41. STABLE CELL POPULATIONS RETAIN FBXL4 EXPRESSION VECTOR. All PCa 
stable cell lines were positive for presence of FBXL4 expression vector (A). HEK293 stable clones 
(two with FBXL4 expression vector and two controls) continuously overexpressed FBXL4 over 42 
days of tetracycline treatment (B). Presence of FBXL4 expression vector was confirmed with PCR 
(C). EV, control cells with empty vector; FBXL4, cells with FBXL4 expression vector. 
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5.2.3.2.3 Anti-FBXL4 antibody testing using protein downregulation models 
FBXL4 knockdown was performed with siRNA and shRNA. Transient FBXL4 knockdown 
with siRNA led to 60-70% reduction in FBXL4 RNA levels in all three cell lines tested 
(Figure 42A-C). Stable FBXL4 knockdown performed with shRNA in 22RV1 cells 
produced the best results for single clone 19 and 26, with FBXL4 RNA reduction of 60% 
(Figure 42D). 
 
FIGURE 42. FBXL4 KNOCKDOWN IN PCA CELL LINES. FBXL4 was successfully knockdown 
by siRNA in DU145 (A), PC3 (B) and 22RV1 (C) cells. NT, cells transfected with non-targeting 
siRNA smartpool; siFBXL4, cells transfected with anti-FBXL4 siRNA smartpool. Stable FBXL4 
knockdown in 22RV1 cells with shRNA (D). FBXL4 RNA levels are normalised to mock-transfectd 
cells. CTR, mock-transfected cells; NT, cells transfected with non-targetting siRNA/shRNA; 
siFBXL4/shFBXL4, cells transfected with anti-FBXL4 siRNA/shRNA; c, single clone; MIX, mixed 
stable cell population. Error bars, SD. 
 
If the observed good FBXL4 knockdown at RNA level translates into downregulation of 
FBXL4 protein, it should be detectable with anti-FBXL4 antibody by WB. In general, 
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endogenous FBXL4 protein levels were difficult to detect with tested antibody, as it 
produced weak FBXL4 bands (Figure 43) and in PC3 cells the bands were hardly visible 
at all. Longer exposure resulted in background bands becoming so strong that they 
obscured FBXL4-specific bands. Transient FBXL4 knockdown in 22RV1 and DU145 cell 
lines was undetectable on WB, with FBXL4 bands size and intensity similar in control 
and knockdown cells (Figure 43A). Stable FBXL4 knockdown in 22RV1 was tested in 
protein lysates from uniform single clone cell populations, however the antibody still 
could not detect differences in FBXL4 expression between FBXL4 knockdown and 
control clones (Figure 43B), suggesting that anti-FBXL4 antibody was not 
sensitive/specific enough to detect FBXL4 protein reduction beyond endogenous levels 
or possibly there was no reduction in FBXL4 protein levels. Testing the IHC-specific anti-
FBXL4 antibody in 22RV1 cells with stable (Figure 44A) or transient (Figure 44B) FBXL4 
knockdown also produced similar results. IHC staining was reasonably strong with 
uniform cytoplasmic pattern but no reduction in staining intensity was present in FBXL4 
knockdown cells. 
 
FIGURE 43. FBXL4 KNOCKDOWN IN PCA CELL LINES IS UNDETECTABLE AT PROTEIN 
LEVELS BY WB. (A) FBXL4 protein levels after knockdown with siRNA in 22RV1 and DU145 
cells. (B) FBXL4 protein levels after knockdown with shRNA in 22RV1 cells. CTR, mock-
transfected cells; NT, cells transfected with non-targetting siRNA/shRNA; siFBXL4/shFBXL4, 
cells transfected with anti-FBXL4 siRNA/shRNA; c, single clone; MIX, mixed stable cell 
population. Protein load: 100 µg. 
 




FIGURE 44. ANTI-FBXL4 ANTIBODY FAILS TO DETECT FBXL4 DOWNREDULATION BY 
IMMUNOHISTOCHEMISTRY IN 22RV1 CELLS. 22RV1 cells show similar staining intensity for 
FBXL4, regardless of treatment with anti-FBXL4 siRNA (A) or shRNA (B). NT, cells transfected 
with control non-targeting siRNA/shRNA; siFBXL4/shFBXL4, cells transfected with anti-FBXL4 
siRNA/shRNA. 
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5.2.3.2.4 FBXL4 protein immunoexpression in FFPE PCa samples  
IHC for FBXL4 was successfully performed in 43 bone metastases, 120 primary PCa 
and 20 BPH non-malignant controls (staining examples shown in Figure 45). FBXL4 
staining pattern was cytoplasmic and scored based on staining intensity (score from 0 to 
3).  
Thirty-five of 43 (81.4%) bone metastases showed various levels of FBXL4 
immunoexpression with remaining eight samples (18.6%) negative for FBXL4 staining. 
Most of the cases positive for FBXL4 were weakly or moderately stained (22/35, 62.9%). 
Slightly more primary tumours stained for FBXL4 (113/120, 94%) with majority 
expressing FBXL4 at low or medium levels (100/113, 88.5%). Similar proportion of non-
malignant BPH tissues stained for FBXL4 (19/20, 95%), however most cases showed 
moderate (9/20, 45%) and strong (10/20, 50%) FBXL4 expression (Figure 46A, Table 
47). There was a significant difference in FBXL4 staining intensity between those 3 
groups (p=0.0005, Kruskal-Wallis test, Figure 46B and Table 47). Further group analysis 
using Mann-Whitney U test (significance levels corrected with Bonferroni correction to 
0.05/3=0.017) showed that a significant difference in FBXL4 expression is present 
between bone metastases and BPH (p=0.0097), and primary PCa and BPH (p<0.0001) 
but not between bone metastases and primary PCa (p=0.490).  
 




FIGURE 45. EXAMPLES OF FBXL4 IHC IN PROSTATE CLINICAL SAMPLES. Top panel: 
representative range of FBXL4 staining intensity in BPH samples and strong FBXL4 expression 
in positive control (pancreas). Middle panel: weak to strong FBXL4 expression in primary PCa 
and lack of staining in a negative control (no primary antibody). Bottom panel: range of FBXL4 




FIGURE 46. COMPARISON OF FBXL4 IMMUNOEXPRESSION IN PRIMARY AND 
METASTATIC PCA SAMPLES. Bone metastases and primary PCa show lower intensity of 
FBXL4 expression than BPH samples (A) and the difference in median FBXL4 expression 
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TABLE 47 MEDIAN AND AVERAGE FBXL4 IMMUNOEXPRESSION IN PROSTATE 
CLINICAL SAMPLES. 
Samples Median Mean (SD) 
Primary PCa 2 1.7 (1.1) 
Bone metastases 2 1.6 (0.8) 
BPH 2.5 2.5 (0.6) 
 
FBXL4 expression measured by IHC and 6q16 copy number loss assessed by FISH 
were both available for 163 cases, which include 23 bone metastases, 120 primary PCa 
and 20 BPH. Eleven PCa bone metastases and 22 primary tumours were positive for 
6q16 copy number loss while all BPH had neutral FBXL4 copy number at 6q16. Three 
of these 11 (27.3%) bone metastases and 14/22 (63.6%) of primary tumours had no or 
low FBXL4 expression. Together, half (17/33, 51.5%) of samples with FBXL4 copy 
number loss had also low or no FBXL4 protein expression while only 43/110 (39.1%) of 
samples with neutral FBXL4 copy number showed low or absent FBXL4 expression 
(Figure 47). However, the difference was not statistically significant (p=0.614).  
 
FIGURE 47. NO SIGNIFICANT DIFFERENCE IN FBXL4 IMMUNOEXPRESSION BETWEEN 
PCAS WITH AND WITHOUT FBXL4 COPY NUMBER LOSS. (A), staining intensity distribution; 
(B), no significant difference in median staining intensity.  
 
5.3 Discussion  
5.3.1 FBXL4 loss is more prevalent in metastatic PCa tumours and correlated 
with cancer progression and poor patient outcome 
All PCa bone metastases analysed by DNA microarrays displayed large deletions within 
the 6q14.1-22.32 region. Copy number loss at 6q14-22 is a common feature of PCa and 
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is especially enriched in advanced tumours [119, 150, 151]. A recent meta-analysis of 
PCa somatic copy number alterations from 11 aCGH and SNP microarray publications, 
which included 546 primary and 116 advanced tumours placed 6q12–q22.33 deletion as 
the fourth most deleted region in PCa after 8p, 13q and 16q, with a frequency of 46.7% 
[121]. According to this meta-analysis, the frequency of 6q loss almost doubled in 
advanced tumours when compared to primary PCa (74.1% versus 40.8%), however, due 
to large size of the region, the exact drivers for this deletion could not be specified. Our 
initial focus specifically on PCa bone metastases led us to the detection of a very small 
region at 6q16 locus, whose loss was shared by all samples. Of the two known genes 
located within this deletion we concentrated on FBXL4, a member of F-box protein family, 
from which several other members are well known to be involved in cancer [316]. Our 
further investigation of FBXL4 copy number status by FISH in a larger cohort of FFPE 
PCa bone metastases, primary tumours and BPH samples revealed that FBXL4 loss is 
indeed commonly present in bone metastases but also found in a small subset of primary 
tumours (14%). Detection of 6q16 loss in half of the bone metastases correlates well with 
Holcomb et al [151] report of 6q13-q22.31 deletions in 43% (23/54) of their soft tissue 
metastases retrieved from autopsies of 14 patients who died from PCa. They also found 
this loss in 37% (4/11) of disseminated tumour cells retrieved from bone marrow 
aspirates collected from patients with metastatic PCa [150]. Alers et al [322] found loss 
of 6q (with minimal overlapping region at 6q15-q16) specifically enriched in the distant 
metastases (11/15, 73%) compared to the regional lymph nodes (4/18, 22%). Taylor et 
al [115] performed unsupervised hierarchical clustering of copy-number alterations in 
194 PCa, including 37 metastases and found the majority of metastases in clusters 5 
and 6, both of which showed substantial CNAs, with cluster 5 tumours having especially 
many genome-wide alterations, including 6q deletions, and an extremely unfavourable 
prognosis. Similarly, 6q loss was commonly found in a recent next generation 
sequencing study of 150 biopsies from distant metastases, including 43 (28.7%) bone 
metastases [138]. Based on results from all these studies, FBXL4 seems to be generally 
associated with more advanced disease. In our study we also found reduction of FBXL4 
gene expression at the RNA level in a limited number of fresh frozen primary and bone 
metastatic tumours when compared to non-malignant BPH samples, which further 
indicates the downregulation of FBXL4 in PCa. High frequency of FBXL4 loss in our 
metastatic tumours suggests a possible tumour suppressor role for FBXL4 in PCa. 
Presence of a cell population with FBXL4 deletion in limited number of primary tumours 
could be indicative of FBXL4 loss being an early event in carcinogenesis and promoting 
cancer spread and invasiveness. We confirmed this hypothesis when we analysed 
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FBXL4 loss in in a large cohort of conservatively managed localised PCa diagnosed by 
TURP [216]. Loss of FBXL4 in these early cancers positively correlated with all PCa 
prognostic markers, including high Gleason score, clinical stage, PSA and extent of 
disease. It also associated with death from PCa, which further implicates the importance 
of FBXL4 loss in aggressive disease. Recent comprehensive molecular analysis of 333 
primary PCa identified seven distinct subtypes defined by ETS fusions or mutations in 
SPOP, FOXA1, and IDH1 genes [323]. Interestingly, subtypes with SPOP, FOXA1, and 
IDH1 mutations and not with ETS fusions were enriched in 6q deletion, similar to 26% of 
cancers with wide range of genomic alterations, for which no obvious genetic drivers 
could be found. We did not correlate ETS fusion status with FBXL4 loss in our cohort of 
early tumours, but only one of our six bone metastases with FBXL4 loss had deletion at 
21q22.2-22.3, indicative of ERG and TMPRSS2 genes rearrangement. The majority of 
primary tumours from the above study were locally advanced with limited follow up data 
(2 years only), rendering the possibility of assessing the association of molecular PCa 
subtypes with cancer progression by the authors unfeasible. In fact, not many reports 
looked specifically at 6q loss in very early PCa. Lu et al [324] analysed LOH at 6q16–22 
in Japanese patients in 53 premalignant lesions of high-grade prostatic intraepithelial 
neoplasia and 145 primary PCa, including 38 very early tumours (low tumour volume, 
<100 mm3; low PSA levels of 0–3.9 ng/ml) detected incidentally in cystoprostatectomy 
specimens. Similar to our benign samples they did not detect 6q loss in premalignant 
cases but found it in primary PCa, including the early cases, which led them to conclusion 
that 6q16–22 deletion is likely involved in the initiation and/or progression of PCa. 
However, they found no correlation between 6q16–22 loss and PCa progression. Other 
small studies of 6q loss in primary PCa also found no relation of 6q loss with PCa 
progression [306, 325]. Interestingly, Strohmeyer et al [326] used CGH to analyse 57 
primary PCa, including 51 localised tumours and found that loss of 6q, as well as loss of 
13q and gain of 7q correlated with cancer progression (biochemical or clinical). The 
differences between the studies are probably due to a small number of samples 
analysed. In our cohort loss of FBXL4 correlated with all PCa progression markers in 
univariate analysis, however it was not independent prognostic marker in multivariate 
analysis. Still, FBXL4 loss detected at the early stage could be indicative of more 
aggressive tumours, which are likely to progress to a metastatic stage.  
5.3.2 Challenges in assessing FBXL4 protein levels  
FBXL4 gene is not well studied and despite a range of commercial antibodies offered by 
different companies, none have been used in published reports. Common copy number 
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loss of FBXL4 in PCa suggests downregulation of FBXL4 signalling, which can be 
confirmed at protein levels with anti-FBXL4 antibodies. We tested 5 different antibodies 
by WB and IHC using inducible C-Flag FBXL4 expression system in HEK293 cells, which 
provided us with an abundance of FBXL4 protein for easy detection while addition of 
Flag tag allowed for confirmation of FBXL4-specific band on WB. Similar overexpression 
systems were previously successfully used for FBXL4 expression analysis of a tagged 
protein [319-321]. Based on comparison to expression of tagged protein, two tested 
antibodies produced specific results but with significant background especially visible on 
WB. Some of the observed multiple bands could still potentially represent FBXL4 protein 
with different post-translational modification status, breakdown products, or splice 
variants, however the majority are most likely unspecific [327]. When used for IHC, both 
antibodies exclusively produced a cytoplasmic staining pattern, which is in agreement 
with the general function of F-box proteins and with reports of FBXL4 co-localisation with 
mitochondria [319, 320]. Of the two specific anti-FBXL4 antibodies one performed better 
in WB while another was more suitable for IHC, which is not surprising considering 
different protein preparation for these two methods. While WB identifies denatured, linear 
proteins, IHC stains proteins in their native 3-D structure, therefore epitopes accessible 
to antibodies on linear peptide may be hidden inside the native protein structure, covered 
by posttranslational modifications or distorted due to formalin fixation and antigen 
retrieval prior to IHC [327]. Both antibodies were raised against synthetic peptides, which 
do not necessarily recapitulate the 3-D structure or post-translational modifications of the 
native protein, hence their different specificity/sensitivity for different applications. 
Regardless of the application, both antibodies showed low sensitivity and did not perform 
well when challenged with more subtle changes in FBXL4 expression as in FBXL4 
knockdown cell models. Clearly, there is a need for more specific and sensitive anti-
FBXL4 antibody, able to detect endogenous levels of the protein especially in systems 
with low FBXL4 expression such as PCa cell lines. 
Initially we attempted to test the anti-FBXL4 antibodies directly in PCa cell models, 
however our trials to generate stable PCa cell lines for FBXL4 overexpression failed 
regardless of the cell line used. We observed an initial strong FBXL4 overexpression in 
all cells, which then was reduced to insignificant levels under antibiotic selection despite 
continuous presence of FBXL4 expression vector. It is possible that FBXL4 
overexpression led to some unfavourable phenotypic changes within cells such as 
reduced proliferation or survival. Consequently, within mixed population of transfected 
cells, cells overexpressing FBXL4 would eventually die off or be outgrown by cells with 
CHAPTER 5            ANALYSIS OF 6Q16/FBXL4 LOSS IN PCA 
159 
 
lower FBXL4 expression. Changes in proliferation/ survival could potentially explain lack 
of gene overexpression in PC3 and DU145 cells with constitutive FBXL4 transgene 
expression but this seems to be a less likely reason for the loss of expression in 22RV1 
cells with tetracycline - inducible FBXL4 expression. Nonetheless, the twofold leakage 
noticed in untreated cells with FBXL4 transgene could also affect cell phenotype. Another 
explanation for lack of FBXL4 overexpression could be gene repression. Foreign DNA 
integrated into eukaryotic genomes is often rapidly silenced after a transient state of 
activity [328, 329]. Rapid silencing of a stably integrated transgene expression is 
frequently a result of de novo DNA methylation. De novo DNA methylation in mammalian 
cells gradually spreads across the integrated viral genomes with increasing passage 
numbers of cells in culture until the genome is strongly methylated [329]. The methylation 
is especially common when the vector DNA integrates at the region where surrounding 
endogenous chromatin structure is already repressed [330]. Contrary to PCa cells, we 
did not encounter any problems when we overexpressed FBXL4 in HEK293 cells, even 
when we continuously induced FBXL4 expression over 10 weeks. This is probably not 
surprising as HEK293 cells are commonly used as a model for studying the 
transforming/oncogenic properties of cancer-associated genes precisely because they 
are easy to transfect, permitting the expression of a wide range of proteins from many 
sources [331].  
5.3.3 FBXL4 protein expression is reduced in PCa cancer but do not correlate 
with FBXL4 copy number status.  
Being aware of the anti-FBXL4 antibody limitations, we used it to analyse FBXL4 protein 
expression in our cohort of FFPE clinical samples. Based on RNA expression in fresh 
frozen samples, tumours seemed to have fairly lower (4-20 times) FBXL4 levels than 
non-malignant BPH cases, a difference which if reflected in protein levels should be 
sufficient for detection by IHC. Indeed, we were able to detect significantly lower FBXL4 
protein expression in bone metastases and primary tumours than in BPH samples, which 
is consistent with observed FBXL4 copy number loss and reduction in RNA expression 
in tumour samples when compared to BPH. However, despite difference in FBXL4 copy 
number loss frequency between bone metastases and primary tumours, no significant 
difference in FBXL4 protein expression was seen between these two groups, which could 
be due to the low sensitivity of the antibody. Additionally, antibody performance in bone 
samples could be further compromised by prolonged tissue decalcification with formic 
acid, which is known to reduce staining intensity and/or increase background [292]. Apart 
from general reasons such as antibody specificity/sensitivity and protein quality/epitope 
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availability after fixation, decalcification and antigen retrieval, lack of correlation between 
FBXL4 copy number status and protein expression can be explained by other 
mechanisms of FBXL4 expression regulation. Other F-box proteins acting as TSGs like 
FBXW7 are known to be downregulated in cancer at the RNA level by a variety of 
oncogenic miRNAs [332]. Predicted post-translational modifications for FBXL4 protein, 
such as phosphorylation, ubiquitination, sumoylation and methylation 
(http://sumosp.biocuckoo.org, http://cplm.biocuckoo.org, http://bioinfo.ncu.edu.cn, 
http://www.jci-bioinfo.cn/UbiResultBySeqs) can also potentially regulate FBXL4 protein 
localisation, stability and activity [333]. Therefore, it is possible that in PCa cases without 
FBXL4 copy number loss, the protein expression is downregulated by some of these 
non-genetic mechanisms, similar to other TSGs. 
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6  FBXL4 function in PCa 
6.1 Introduction 
As mentioned in the previous chapter, the FBXL4 gene product belongs to a large F-box 
protein family, which are the component of E3 ubiquitin protein ligase complex called the 
SKP1-CUL1-F-box (SCF) [334]. Within SCF, cullin 1 protein functions as a scaffold with 
N-terminus occupied by SKP1 adaptor protein and C-terminus bound to a RING finger 
protein, RBX1. RBX1 recruits ubiquitin-conjugating enzyme E2 and SKP1 is a docking 
site for substrate-bound F-box proteins. F-box proteins are responsible for substrate 
recognition and delivery to the core of the ligase. They are the variable component of 
SCF E3 ligase and bind to SKP1 through their conserved F-box domain. Once the 
substrate is delivered to the E3 core, it undergoes ubiquitination by ubiquitin charged E2 
enzyme (Figure 48) [334, 335]. Consequently, as a part of the ubiquitin proteasome 
system, E3 ligases together with ubiquitin-activating enzyme E1 and ubiquitin-
conjugating enzyme E2 catalyse the ubiquitination of a variety of protein substrates for 
targeted degradation through the 26S proteasome [336].  
 
FIGURE 48. THE SKP1-CUL1-F-BOX (SCF) COMPLEX. Adapted from Harper et al [335]. 
F‑box proteins are divided into three families based on substrate binding domain: WD40 
domain (FBXW) proteins (12 proteins), Leucine-rich repeat (FBXL) proteins (21 proteins) 
or other domains (FBXO) proteins (38 members) [315, 334]. In response to various 
stimuli, F-box proteins selectively bind target proteins based on unique, short 
degradation peptidic signature (degron) present in their substrates [315, 337]. Through 
substrate downregulation, F‑box proteins regulate diverse biological pathways that 
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control cell growth, division, development and differentiation, signalling responses, and 
cell survival and death [315].  
FBXL4 protein belongs to Leucine-rich repeat group of F-box proteins with 9 Leucine-
rich repeats present within its target binding domain (Figure 49) [320]. The exact function 
of FBXL4 is presently unknown. Recent studies found FBXL4 protein to co-localise with 
mitochondria and linked recessive loss-of-function and splice mutations in this protein 
with severe respiratory chain deficiency mitochondrial disease [319, 320, 338]. 
 
FIGURE 49. THREE-DIMENSIONAL STRUCTURAL MODELLING OF FBXL4 PROTEIN.  
Bioinformatically determined mitochondrial localisation sequence (mt) is visible at N-terminus, 
followed by conserved F-box domain and nine leucine-rich repeats located at the C-terminus. 
Adapted from Bonnen et al [320]. 
 
Proteomics based approach, aiming at the identification of candidate substrates and 
stably interacting proteins for a range of F-box family members led to the detection of 
several proteins potentially interacting with FBXL4 [321], which were mostly located in 
endoplasmic reticulum (ER) (Endoplasmic Reticulum Lectin 1 - ERLEC1, SEL1L, 
Calmegin - CLGN, p58) [339-341] and mitochondria (Translocase Of Outer Mitochondrial 
Membrane 70 Homolog A -TOMM70A, Heat Shock Proteins 90kDa-HSP90AA4P and 
HSP90AB4P), where they are involved in the unfolded protein response (UPR) during 
cellular stress [342, 343]. The UPR was first discovered in ER and involves 
transcriptional induction of molecular chaperones in response to ER stress and is 
triggered by accumulation of misfolded proteins. As a result, misfolded proteins are 
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retrotranslocated to the cytoplasm, where they are polyubiquitinated and degraded by 
the proteasome in a process called ER-associated Protein Degradation (ERAD). ERAD 
is essential for maintaining ER homeostasis and cell survival under stress, and disruption 
of ERAD leads to ER stress-induced apoptosis [344]. Increasing evidence suggests the 
presence of a mitochondria-associated degradation (MAD) pathway that regulates 
mitochondrial protein quality control, with multiple E3 ubiquitin ligases residing at the 
outer mitochondrial membrane where misfolded proteins are ubiqitinated and 
subsequently degraded by proteasomes [345-347]. Additionally, recent evidence shows 
that ER and mitochondria form physical contacts and collaborate in response to stress 
[348-351].  
Interestingly, ERLEC1 was confirmed as FBXL4 binding target by IP/WB method [321]. 
ERLEC1, a luminal resident protein of the endoplasmic reticulum, is member of a protein 
family containing mannose 6-phosphate receptor homology (MRH) domains involved in 
N-glycan binding [352]. ERLEC1 is a molecular chaperone that plays a role in the 
recognition of terminally misfolded proteins and the extraction of these proteins to the 
cytoplasm for proteasomal degradation [353]. Specifically, ERLEC1 binds to misfolded 
glycoproteins in the ER lumen and delivers them to ER membrane bound HRD1 E3 
ligase through binding to transmembrane receptor, SEL1L. Ubiquitinated by HRD1 
misfolded proteins are subsequently degraded by the cytosolic ubiquitin–proteasome 
system [340, 353]. Interestingly, ERLEC1 was identified in lung cancer as a novel cancer 
invasion and metastasis-related gene controlling the response to hypoxia and ER stress 
[354]. Ectopic expression of ERLEC1 in lung cancer cells increased their tolerance to 
hypoxia through reduced degradation and consequently accumulation of a hypoxia-
inducible factor, HIF-1α. Stabilisation of HIF-1α activates the transcription of genes 
involved in cell survival, angiogenesis, dedifferentiation, and invasion [355]. ERLEC1 
was also found to activate the UPR pathway and therefore increasing cellular tolerance 
to ER stress. If ERLEC1 is indeed downregulated by FBXL4, then FBXL4 loss in PCa 
would lead to stabilisation of ERLEC1 protein and therefore contribute to tumour 
progression by protecting cancer cells from apoptosis under hypoxia and ER-stress; 
conditions which are often encountered by growing tumours [356]. 
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6.2 Results  
6.2.1 FBXL4 knockdown leads to increased PCa cell migration and invasion 
without affecting cell viability 
As mentioned in the previous chapter, FBXL4 knockdown with siRNA led to a 60-70% 
reduction in FBXL4 RNA levels in all three PCa cell lines analysed (DU145, 22RV1 and 
PC3, Figure 50A). FBXL4 downregulation did not affect cell viability (Figure 50B) but led 
to significant increase in cell migration and invasion (Figure 51, 52 and Table 48). FBXL4 
knockdown in PC3 (Figure 51A) and DU145 (Figure 51B) cells, which already have 
heterozygous FBXL4 DNA copy number loss, led to around a 30% increase in cell 
migration while in 22RV1 cells exibiting normal FBXL4 DNA copy number, FBXL4 
knockdown increased their migration by 46% (Figure 51C and Table 48). Stable single 
clone 22RV1 cells with FBXL4 knockdown showed an even higher two fold increase in 
cell migration when compared to control (Figure 51D). 
The effect of FBXL4 downregulation on cell invasion was tested using basement 
membrane (Matrigel) and stromal/interstitial type of extracellular matrices (collagen and 
mixed collagen/Matrigel). Matrigel matrix, a reconstituted basement membrane extracted 
from the Engelbreth-Holm-Swarm mouse sarcoma containing of 60% laminin, 30% 
collagen IV, and 8% entactin (https://www.corning.com/) was used to mimic cellular 
penetration of a basement membrane layer [357-359]. For single cell invasion into 
stromal/interstitial matrices, which form the majority of the body connective tissue and 
mainly contain fibrillar collagen I, the solution of 2 mg/ml type I collagen [223, 358-361] 
and mixed 50:50% collagen/matrigel [224] gels were used. FBXL4 knockdown 
significantly increased PCa cells invasion through the Matrigel (Figure 52A and Table 
48), with increase ranging from 33% in PC3 cells through to 55% in DU145 to 75% in 
22RV1 cells. Further analysis of PCa cells motility/invasion was performed by seeding 
PCa cells as a single cell suspension on top of collagen gels (2 mg/ml type I collagen) 
[223, 360, 362]. The invading cells as oppose to non-motile cells, produce cellular 
protrusions readily visible under the microscope (Figure 52B) and only cells with these 
protrusions were counted as invading cells. Modest but significant increases in collagen-
based cell migration/invasion were seen in cells with FBXL4 siRNA knockdown 
compared to cells transfected with non-targeting siRNA in all three cell lines tested 
(Figure 52B and Table 48). The results were confirmed with stable 22RV1 FBXL4 
knockdown cells seeded as a single cell suspension on collagen/Matrigel gels (1.6 mg/ml 
collagen, 50% Matrigel) (Figure 53) [224]. These cells also showed 9.2% increase in 
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motility/invasion when compared to 22RV1 cells transfected with non-targeting shRNA 
(p=0.01, Figure 53). The above results suggest that FBXL4 knockdown leads to a modest 
but consistent increase in cell invasion into collagen. 
 
FIGURE 50. THE EFFECT OF FBXL4 KNOCKDOWN ON PCA CELLS VIABILITY. (A) 
Confirmation of FBXL4 knockdown at mRNA level in DU145, 22RV1 and PC3 cells. (B) FBXL4 
knockdown does not affect PCa cell viability in DU145, 22RV1 and PC3 cells compared to non-
targeting siRNA. Cell viability was measured by MTS assay at 48 and 72 h post FBXL4 siRNA 
transfection. CTR, non-transfected control cells; NT, cells transfected with non-targeting siRNA; 
siFBXL4, cells transfected with FBXL4 siRNA. Error bars indicate SD; n = 3. 
 




FIGURE 51. FBXL4 KNOCKDOWN INCREASES PCA CELL MIGRATION. FBXL4 siRNA 
knockdown increased cell migration by about 30-40% in PC3 (A), DU145 (B), and 22RV1 (C). 
22RV1 single clones with stable reduction of FBXL4 showed even higher (two fold) increase in 
cell migration (D). NT, cells transfected with non-targeting siRNA/shRNA; siFBXL4/shFBXL4, 
cells transfected with FBXL4 siRNA/shRNA. Error bars: SD; n=3. *: p<0.05, **: p<0.01. 
 
 
FIGURE 52. FBXL4 KNOCKDOWN LEADS TO INCREASED PCA CELL INVASION. (A) PCa 
cell invasion through Matrigel increases from over 30% (PC3) to 70% (22RV1) in FBXL4 
knockdown cells. Scale bar: 300 µm. (B) PCa cell migration/invasion on collagen increases by 
10% (PC3) – 15% (DU145) after FBXL4 knockdown. Single cell suspensions were seeded onto 
collagen (2mg/ml) and after 24 h cells with cellular protrusions were considered as 
migrating/invading cells and counted. NT, cells transfected with non-targeting siRNA; siFBXL4, 
cells transfected with FBXL4 siRNA. Error bars: SD; n=3. *: p<0.05, **: p<0.01 and *** p<0.001. 
Scale bar: 50 µm. 
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TABLE 48. PCA CELL MIGRATION AND INVASION INCREASES AFTER FBXL4 
KNOCKDOWN. 
PCa  Migration  Invasion 
cell line 
Statistics %,   %, Matrigel %, Collagen 
 t-test siFBXL4  siFBXL4 siFBXL4 
DU145 mean 127.6  155.2 15.3 
 SD 10.4  14.3 3.0 
 p value 0.04  0.001 0.01 
22RV1 mean 146.5  175.8 13.5 
 SD 10.2  30.4 2.4 
 p value 0.02  0.0498 0.01 
PC3 mean 132.3  133.3 9.8 
 SD 9.3  5.1 2.9 





FIGURE 53. FBXL4 KNOCKDOWN INCREASES 22RV1 CELL MIGRATION/INVASION ON 
COLLAGEN/MATRIGEL 3D CULTURE. 22RV1 single cell suspension was seeded onto gels 
(1.6 mg/ml collagen, 50% Matrigel) and allowed migration/invasion for 72 h. Cells with cellular 
protrusions were considered as migrating/invading cells and counted. NT, stable 22RV1 cells 
transfected with non-targeting shRNA; shFBXL4, stable 22RV1 cells transfected with FBXL4 
shRNA. Error bars indicate SD; n = 3. 
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6.2.2 FBXL4 overexpression leads to reduced cell migration 
To confirm that FBXL4 expression levels affect cell migration, we used stable HEK293 
cells with tetracycline-inducible FBXL4 expression from the vector. As shown in Chapter 
5.2.3.2.1, FBXL4 overexpression in these cells was confirmed at both, RNA and protein 
levels (Figure 36, Figure 37, and Figure 38). Overexpression of FBXL4 had no effect on 
cell viability (Figure 54A) but as expected led to significant (54.4%) reduction in cell 
migration when compared to control cells transfected with an empty vector (p=0.00004, 
Figure 54B).  
 
 
FIGURE 54. FBXL4 OVEREXPRESSION LEADS TO REDUCED HEK293 CELL MIGRATION 
WITHOUT AFFECTING CELLS VIABILITY. (A) 72 h induction of FBXL4 overexpression with 
1µg/ml tetracycline does not affect HEK293 cell viability when compared to control HEK293 cells 
containing empty vector. (B) HEK293 cells overexpressing FBXL4 show reduced migration when 
compared with control HEK293 cells. EV, control cells with empty expression vector; FBXL4, 
HEK293 cells transfected with expression vector containing FBXL4. ‘-‘, no tetracycline treatment; 
‘+’, 1µg/ml tetracycline treatment for 72 h. Error bars: SD; n=3. 
 
6.2.3  FBXL4 co-localises with mitochondria. 
Based on previous reports using overexpression systems, FBXL4 protein was found to 
co-express with mitochondria [319, 320]. Using stable HEK293 cells with induced FBXL4 
overexpression and anti-Flag antibody we found by IF that FBXL4 indeed co-localises 
with mitochondria stained with mitotracker in most of the cells (Figure 55, top panel). 
HEK293 control cells did not stain for Flag, confirming specificity of the Flag antibody. 
FBXL4 staining using anti-FBXL4 antibody confirmed co-localisation of FBXL4 with 
mitochondria but also produced diffused cytoplasmic stain throughout the cells (Figure 
55, bottom panel).  




FIGURE 55. FBXL4 PROTEIN CO-LOCALISES WITH MITOCHONDRIA IN HEK293 
OVEREXPRESSING FBXL4. FBXL4 protein stained with anti-Flag antibody mainly co-localises 
with mitochondria (top panel), while IF with anti-FBXL4 antibody gives some additional 
cytoplasmic staining (bottom panel). FBXL4 overexpression is clearly visible with both antibodies. 
FBXL4 expression (green) correlates with mitochondria distribution. EV, empty vector control; 
FBXL4, cells with FBXL4 expression vector; +, tetracycline treatment (1µg/ml, 3 days). Blue, 
DAPI; green, anti-Flag-FBXL4 or FBXL4 antibody; red, mitotracker.  
 
6.2.4  FBXL4 does not regulate epithelial to mesenchymal transition (EMT) 
related proteins  
As the acquisition of a motile and invading phenotype is linked to EMT, we investigated 
the levels of several proteins linked to EMT and cell movement, including mesenchymal 
markers – vimentin and N-cadherin; epithelial marker E-cadherin as well as F-actin and 
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focal adhesion kinase (FAK). WB analysis showed no difference in the expression of 
EMT markers in HEK293 cells overexpressing FBXL4, with all HEK293 cells strongly 
expressing vimentin and N-cadherin but equally lacking E-cadherin expression (Figure 
56A). Similar, no difference in the expression of E- and N-cadherins was found in stable 
22RV1 cells with FBXL4 downregulation when compared to control cells (Figure 56B). 
All 22RV1 cells were negative for vimentin expression. No difference in total and 
activated, phosphorylated FAK was seen by WB. These results suggest that FBXL4 does 
not regulate expression of these proteins. 
 
FIGURE 56. FBXL4 DOES NOT REGULATE EMT MARKERS EXPRESSION. (A), all stable 
HEK293 including cells overexpressing FBXL4 had equally strong expression of mesenchymal 
N-cadherin and vimentin markers, and low levels of activated FAK. (B), similar lack of difference 
in EMT markers N- and E-cadherins and very low levels of FAK were visible in all 22RV1 cells, 
including control cells (NT c4) and cells with FBXL4 downregulation shFBXL4 c26). Protein load, 
50µg. wt, wild type, EV, empty vector control; FBXL4 cells with FBXL4 expression plasmid; +, 1 
µg/ml tetracycline treatment to induce FBXL4 expression.  
 
6.2.5 ERLEC1 protein as a potential downstream target of FBXL4  
6.2.5.1 Anti-ERLEC1 antibody validation  
Polyclonal rabbit anti-ERLEC1 antibody (ab102046) was purchased from Abcam, UK 
and tested by WB, IF and IHC. ERLEC1 knockdown in HEK293 cells with anti-ERLEC1 
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siRNA produced substantial reduction in ERLEC1 protein expression by WB (Figure 
57A), proving antibody suitability for use in WB. However, IF staining of the cells from 
the same experiment produced mostly nuclear rather than the well documented ER 
staining [354, 363] with similar intensity in control and knockdown cells, showing lack of 
specificity of the antibody for use in IF (Figure 57B). Testing the antibody for IHC using 
PCa bone metastases, primary tumours and BPH also produced mostly nuclear stain 
(Figure 58) not previously reported for this protein. 
 
FIGURE 57. ANTI-ERLEC1 ANTIBODY TESTING IN HEK293 CELLS. (A) WB shows ERLEC1 
protein reduction by 63.4% (48h) - 78.7% (72h) after knockdown when compared to non-targeting 
control. (B) There is no difference in IF FBXL4 expression between knockdown and control cells. 
CTR, control mock-transfected cells; NT, cells transfected with non-targeting siRNA; siERLEC1, 
cells transfected with anti-ERLEC1 siRNA smartpool. 
 
 




FIGURE 58. ANTI-ERLEC1 ANTIBODY TESTED IN FFPE CLINICAL SAMPLES BY IHC. The 
anti-ERLEC1 antibody produced mostly nuclear stain. 
 
6.2.5.2 Relation between FBXL4 and ERLEC1 expression levels using in vitro cell 
line models. 
The relationship between ERLEC1 and FBXL4 proteins was tested in vitro by 
manipulating FBXL4 expression levels in cell lines. First, endogenous levels of ERLEC1 
expression were assessed in prostate cell lines. All PCa cell lines (PC3, DU145, 22RV1 
and LnCaP) as well as immortalised normal prostate epithelial cells (PNT1 and PNT2) 
showed abundant expression of ERLEC1 protein (Figure 59). Transient knockdown of 
FBXL4 in 22RV1 and DU145 PCa cell lines did not result in a visible change in ERLEC1 
protein expression (Figure 60A). However, stable 22RV1 shFBXL4 clones had increased 
ERLEC1 expression from 24% in shFBXL4 c42 clone through to 57% in shFBXL4 c26 
to 95% in shFBXL4 c19 (Figure 60B) when compared to control clone.  








FIGURE 60. ERLEC1 PROTEIN EXPRESSION IN PCA CELL LINES WITH FBXL4 
KNOCKDOWN. (A) No visible change in ERLEC1 protein levels after FBXL4 knockdown with 
siRNA in 22RV1 and DU145 cells. CTR, mock-transfected cells; NT, cells transfected with non-
targetting siRNA smartpool; siFBXL4, cells transfected with anti-FBXL4 siRNA smartpool. (B) 
Increased levels of ERLEC1 protein are detected in stable 22RV1 FBXL4 knockdown clones 
when compared to 22RV1 transfected with non-targeting shRNA. Top graph – confirmation of 
FBXL4 downregulation at RNA level. Bottom graph-relative quantification of ERLEC1 protein 
levels detected on WB. NT, cells transfected with control non-targeting shRNA; shFBXL4, cells 
transfected with anti-FBXL4 shRNA; c, single clone; MIX, mixed stable cell population. Protein 
load: 100 µg. 
 
In opposition to FBXL4 downregulation in PCa cells, FBXL4 overexpression in stable 
HEK293 led to a reduction in ERLEC1 expression ( ~20%) when measured by WB 
CHAPTER 6                 FBXL4 FUNCTION IN PCA 
175 
 
(Figure 61A). IHC for ERLEC1, similair to previous results, showed nuclear staining and 
no visible reduction in ERLEC1 expression was visible in HEK293 cells overexpressing 
FBXL4 (Figure 61B).  
 
FIGURE 61. ERLEC1 PROTEIN EXPRESSION IN HEK293 CELLS OVEREXPRESSING 
FBXL4. (A) ERLEC1 protein is downregulated in cells overexpressing FBXL4. ERLEC1 and 
FBXL4 protein lysates were collected after 48 h treatment with/without 1µg/ml tetracycline. (B) 
ERLEC1 IHC expression is nuclear and similar in all HEK293 cells, regardless of FBXL4 status. 
EV, control cells with empty expression vector; FBXL4, HEK293 cells transfected with expression 
vector. ‘-‘, no tetracycline treatment; ‘+’, 1µg/ml tetracycline treatment. Protein load: 100 µg. 
 
6.3 Discussion  
6.3.1 FBXL4 regulates cell migration and invasion without affecting proliferation. 
The association of FBXL4 loss with advanced bone metastatic PCa and worse patient 
survival strongly suggests FBXL4 role as a TSG. Using in vitro experiments, we were 
able to establish that FBXL4 exerts its possible tumour suppressor function by regulation 
of cell motility and invasiveness. FBXL4 downregulation led to an increase in PCa cell 
migration and invasion, which was even more pronounced in 22RV1 cells with normal 
FBXL4 DNA copy number status than in PC3 and DU145 cells with heterozygous FBXL4 
loss. Considering that PC3 and DU145 cell lines already had lower FBXL4 RNA 
expression, additional reduction in FBXL4 levels would have a lesser effect on cell 
migration and invasion when compared to 22RV1, explaining the observed difference 
between the cell lines. As expected, overexpression of FBXL4 had the opposite effect 
on cell migration, confirming the role of FBXL4 in the regulation of cell motility. The 
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capability for invasion is one of the hallmarks of cancer and enables cancer cells to 
spread beyond the primary tumour and colonise new sites, where nutrients and space 
are not limiting [81]. Overexpression of oncogenes or downregulation of tumour 
suppressors in cancer often results in increased cell proliferation, survival, migration and 
invasion [364]. Several F-box proteins are known TSGs regulating cell motility and 
invasion, and similar to FBXL4 are found downregulated in human cancer. The best 
studied is FBXW7, which exerts its tumour suppressor role by promoting the degradation 
of various oncoproteins and is often inactivated in cancer by mutations or copy number 
loss [365, 366]. Like FBXL4, FBXW7 can regulate cell migration and invasion and its 
inactivation increases cell aggressiveness [367]. FBXO11 is another F-box TSG 
regulating cell migration and invasiveness and is deleted or mutated in a subset of 
human B-cell lymphomas [368]. Interestingly, the deletions/mutations found in FBXO11 
are largely monoallelic, indicating haplo-insufficiency of FBXO11 TSG, similar to FBXL4 
loss. FBXL5 is one more potential F-box TSG, whose expression is significantly 
decreased in gastric cancer, especially in metastatic tumours leading to increased 
cancer invasion and metastasis [369]. Despite similar end effects, these F-box proteins 
exert their action through downregulation of different targets and currently the targets for 
FBXL4 are not clear.  
Based on observed FBXL4 co-localisation with mitochondria and on recent reports, 
linking rare recessive loss of function FBXL4 mutants with a form of encephalomyopathic 
mitochondrial DNA depletion and mitochondrial network fragmentation, it is possible that 
FBXL4 may play a role in mitochondria maintenance [319, 320, 338, 370]. Mitochondria 
form in cells dynamic network regulated by fusion and fission (mitochondria 
fragmentation) events, important for the morphology, function and distribution of 
mitochondria. Fusion allows the exchange of proteins, DNA, and metabolites between 
neighbouring mitochondria, rescuing mildly damaged mitochondria. Fission is necessary 
for efficient mitochondrial transport to the subcellular regions with high energy demands 
and for separation and removal of damaged mitochondria, therefore maintaining a 
healthy mitochondrial population [371, 372]. Recent evidence shows that mitochondrial 
dynamics is involved in migration and invasion of epithelial cells, with fission being 
necessary for efficient relocation of mitochondria, and upregulation/downregulation of 
fission/fusion promoting proteins is often observed in invasive cancer cells, including 
breast and prostate cancer cells [373-375]. Increased mitochondrial network 
fragmentation was observed in highly invasive metastatic breast cancer cells when 
compared with non-metastatic cells, and manipulation of mitochondria dynamics by 
CHAPTER 6                 FBXL4 FUNCTION IN PCA 
177 
 
increasing fusion or fission significantly suppressed or enhanced metastatic abilities of 
breast cancer cells [373]. Mitochondrial fission also promotes formation of lamellipodia, 
the leading edge of migrating cells necessary for cancer cell migration and invasion, 
while mitochondrial fusion suppresses lamellipodia formation in breast cancer cells [373]. 
Mitochondria localisation in motile cells further affects their migration, with anterior 
localisation of mitochondria, in between the nucleus and the leading edge correlating 
with faster migration. Inhibition of the mitochondrial network fragmentation or stimulation 
of mitochondria fusion significantly reduces the number of cells with anterior localisation 
of mitochondria and significantly decreases the speed of migrating cells [374].  
Based on these reports, we looked at FBXL4 localisation in cells and we confirmed that 
FBXL4 protein colocalises with mitochondria. However we were not able to assess levels 
of mitochondrial network fragmentation in cells with overexpression or downregulation of 
FBXL4 due to too low resolution of our images. To properly study mitochondrial network, 
laser-scanning confocal microscopy has to be used with high magnification lense (63x 
or 100x) and multiple image planes acquisition along the Z-axis [376, 377]. Acquired 
images need to be analysed with image processing program, e.g. ImageJ (U.S. National 
Institutes of Health, Bethesda, MD, USA) in order to identify and count mitochondrial 
segments and continuous mitochondrial structures [378, 379]. Such careful examination 
of mitochondrial network in cells with overexpression or downregulation of FBXL4 is 
crucial to definitively establish the relationship between FBXL4 levels, mitochondrial 
network fragmentation and cell migration.  
Several F-box proteins with tumour suppressor function such as FBXW7, FBXL5, 
FBXO45 and FBXL14 are involved in downregulation of the core EMT regulators such 
as Zeb1/2, Snai1/2 and Twist1 [369, 380-382]. EMT plays a critical role in the 
development of tumour metastases by enhancing migration and invasion of cancer cells, 
therefore it could be potentially affected by FBXL4 [383]. The change from an epithelial 
to a mesenchymal phenotype is characterized by loss of cell apical-basal polarity, cell-
cell adhesion, cell adhesion to basement membranes and the acquisition of an invasive, 
mesenchymal phenotype [383-385]. A critical molecular feature of EMT is a ‘‘cadherin 
switch’’; a downregulation of epithelial cell adhesion molecule E-cadherin and increased 
mesenchymal N-cadherin expression, induced by mentioned above transcription factors 
and resulting in the aggressiveness, de-differentiation and metastasis of many 
carcinomas [386-388]. Cadherins associate with the cytoskeleton including actin 
microfilaments and intermediate filaments (e.g. keratin and vimentin) to provide 
mechanical strength at points of adhesion and scaffolds for proteins involved in cell 
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signalling [389]. During EMT, intermediate filament composition changes with increase 
in vimentin filaments expression enabling cell motility, possibly due to the interaction of 
vimentin with motor proteins [383, 390, 391]. ‘‘Cadherin switch’’ was reported as an 
independent prognostic factor for PCa progression and cancer-specific death [392] while 
vimentin overexpression was found to contribute to PCa invasion and metastasis [393]. 
Our analysis of EMT markers using in vitro cell line models showed no changes in their 
expression upon manipulation of FBXL4 levels suggesting that FBXL4 does not regulate 
cell migration directly through EMT. No changes in vimentin and N-cadherin protein were 
seen in HEK293 upon FBXL4 overexpression while E-cadherin levels were undetectable 
in these cells, which is surprising assuming they are epithelial cells. Low or undetectable 
E-cadherin expression frequently reported in HEK293 cells [394-396] could be explained 
by their origin from the adrenal gland rather than the embryonic kidney epithelium, which 
was suggested in recent detailed study on genetic and expression profiles of HEK293 
cells [397]. And indeed, adrenal gland cells do not express E-cadherin at detectable 
levels [398]. Regardless of HEK293 origin, they still expressed abundance of vimentin 
and N-cadherin and overexpression of FBXL4 did not lead to the expected decrease in 
levels of any of these proteins. Similarly, we saw no decrease in expression of E-cadherin 
or increased N-cadherin expression in 22RV1 cells with stable FBXL4 downregulation, 
making FBXL4 involvement in EMT regulation unlikely.  
The crucial player in cell movement is filamentous actin (F-actin) cytoskeleton, which is 
responsible for morphological changes and physical forces that occur during migration, 
such as formation of protruding cellular structures at the front of migrating cells (filopodia 
and lamellipodia) [399]. F-actin cytoskeleton is linked to focal adhesion complexes, which 
are the points of adhesion between cell and extracellular matrix (ECM). Turnover of focal 
adhesions is essential for cell migration and requires coordination between focal 
adhesion and actin cytoskeleton. A key trigger for adhesion turnover is a non-receptor 
protein tyrosine kinase, FAK [399-401]. FAK phosphorylation and activation is dependent 
on its localization to focal contacts, where it promotes integrin-stimulated cell motility 
through activation of small GTPases RhoA and Rac1 [399], which in turn regulate actin 
polymerization, and consequently adhesion dynamics and cell movement [399, 402]. 
FAK-dependent regulation of cycles of focal contact formation and disassembly is 
required for efficient cell movement [400] and increased FAK expression and activation 
correlates with tumour progression and metastasis [402]. We analysed F-actin 
cytoskeleton network and FAK status in our in vitro cell models and we did not observe 
significant changes in expression intensity or distribution of F-actin or FAK proteins upon 
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manipulation of FBXL4 expression levels, suggesting that FBXL4 regulates cell migration 
through yet unknown pathways.  
6.3.2 ERLEC1 protein levels are regulated by FBXL4 
Previous reports studying ERLEC1 expression, including association with FBXL4 [321] 
were based on tagged protein [352, 353] or custom-made antibodies [363] as there were 
no available anti-ERLEC1 antibodies. Only more recent reports used, in addition to anti-
tag, commercial anti-ERLEC1 antibodies for assessment of endogenous protein by WB 
[403]. We tested a commercial polyclonal rabbit anti-ERLEC1 antibody (ab102046, 
Abcam, UK) by WB, IF and IHC. We proved antibody specificity for WB, but not for IF or 
IHC applications, where instead of well documented ER expression [352-354, 363] we 
obtained mostly nuclear staining. Using WB we found abundant ERLEC1 expression in 
all tested prostate cell lines, which seems to be in agreement with a previous report 
indicating common ERLEC1 RNA expression in a range of human adult tissues, 
including testis, skeletal muscle, pancreas and prostate [354].  
Using proteomics based approach to identify candidate substrates and stably interacting 
proteins for a range of F-box family members, Tan et al [321] found ERLEC1 to interact 
with FBXL4, which was confirmed by co-immunoprecipitation. In their study, ERLEC1 
was enriched in lysates from cells treated with either the proteasome inhibitor Bortezomib 
or CRL E3 inhibitor MLN4924. These agents increase the abundance of CRL (including 
SCF E3 ligases) and proteasomal substrates consistent with the assumption that 
ERLEC1 is a target for ubiquitination and proteasome degradation. Confirming ERLEC1 
as a degradation target of FBXL4 proved difficult in cell line models with transient FBXL4 
knockdown. This could be due to strong ERLEC1 expression from untransfected cells, 
which would make it hard to see further increase in ERLEC1 levels from FBXL4 
knockdown cells in whole cell lysates. Indeed, when ERLEC1 was tested in monoclonal 
cell populations with stable FBXL4 knockdown or overexpression, we could confirm that 
FBXL4 targets ERLEC1 for degradation as cells with reduced FBXL4 had increased 
levels of ERLEC1 protein while the cells overexpressing FBXL4 showed reduction in 
ERLEC1 protein expression. ERLEC1 is a luminal ER protein, while FBXL4 mostly co-
localises with mitochondria [319, 320], which we confirmed in stable HEK293 cells. It is 
not clear how these two proteins interact. Based on the study from Tan et al [321], FBXL4 
targets several ER proteins, with many involved in stress induced unfolded protein 
response. 
CHAPTER 6                 FBXL4 FUNCTION IN PCA 
180 
 
Most of ER proteins marked for degradation are dislocated from the ER into the 
cytoplasm, often with the help of luminal chaperons such as ERLEC1 and OS-9, which 
deliver them to membrane bound non-SCF E3 ligases, e.g. HRD1. These E3 ligases 
ubiquitinate misfolded proteins on the cytoplasmic site of the ER membrane, after their 
dislocation from the ER. Ubiquitinated proteins are then released from the ER membrane 
and delivered to the proteasome for degradation [340, 404-406]. Mitochondrial proteins 
are mostly degraded by mitochondrial proteases and only some of them are considered 
to be degraded by outer mitochondrial membrane-bound non-SCF E3 ligases in a similar 
way to ER proteins [407].  
There is little known about F-box E3 ligases involved in the degradation of ER or 
mitochondrial proteins. A limited number of cytoplasmic SCF E3 ligases, including these 
linked to FBXO2, FBXO6, FBXO17, FBXO27, and FBXO44 F-box proteins seem to be 
capable of recognising and ubiquitinating glycosylated proteins translocated from the ER 
[408-412]. Even less is known about F-box proteins linked to mitochondrial protein 
degradation. Global analysis of human proteins for mitochondria targeted sequence 
predicts mitochondrial association of several components of cytoplasmic ubiquitin 
proteosome system, including several F-box proteins such as FBXO17, FBXO21, 
FBXO38, FBXW5, FBXL12 and FBXL4 [407, 413]. FBXL4 capability to bind ER proteins 
may come from close interactions between ER and mitochondria. Recent evidence 
shows that ER and mitochondria form physical contacts, which facilitate transfer of 
metabolites, such as lipids and Ca2+, necessary for the regulation of lipid homeostasis, 
mitochondrial metabolism and the regulation of apoptotic signalling [348, 349]. 
Mitochondria sense and respond to ER stress by increasing contact with ER, promoting 
Ca2+ transfer and enhancing metabolism and ATP synthesis, which is then used to mount 
an adaptive response, protecting cells from stress-induced apoptosis [350, 351]. This 
stress induced response is regulated by parkin, another E3 ubiquitin ligase involved in 
mitochondria maintenance [414, 415]. Proximity of these two organelles and their 
increased contact upon stress would allow mitochondria-bound FBXL4 to interact with 
both, mitochondrial and ER proteins. This would explain why several of the proposed 
downstream targets of FBXL4 are involved in response to ER stress [321]. Further 
studies are necessary to determine where and how exactly FBXL4 interacts with 
ERLEC1 and leads to its degradation. 
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7 Final discussion and future plans  
7.1 Final discussion  
7.1.1 Genomic copy number changes in prostate cancer revealed by genome-
wide analysis  
Studies of advanced metastatic PCa are hampered by the lack of routine pathological 
specimen. While there is abundance of primary PCa tissue from radical prostatectomies, 
no routine biopsies are performed for metastases, due to their skeletal location. Imaging 
techniques are used instead to confirm presence and excess of metastatic disease [416]. 
We have a unique set of PCa bone metastases collected from PCa patients, who were 
treated for pathological bone fractures caused by tumour metastases. Using genome-
wide approach, these samples gave us the opportunity to look at the landscape of 
genomic changes specifically at PCa bone metastatic sites. Until recently the few 
published studies on genomic changes in metastatic PCa, which included limited number 
of bone metastases came from autopsies [153, 167, 228, 229], while more recent reports 
published during the course of our study, specifically consented advanced PCa patients 
for bone biopsy [138, 230, 231].  
Our array-based genome-wide analysis of CNAs in PCa bone metastases found 
abundance of genomic changes, which is a common feature of advanced PCa [242]. 
Large losses of 6q, 13q, 16q and 18q as well gains of 8q, 7pq and Xq, which were present 
in 2-6 (33%-100%) of our six bone metastasis samples are the most frequent genomic 
changes reported in metastatic PCa and linked to bad prognosis [115, 219, 322, 417]. 
Many of these CNAs contained well-known PCa associated genes, including TSGs 
within losses (PTEN on 10q23.31, RB1 on 13q14.2, TP53 on 17p13.1) and oncogenes 
in gained regions (AR on Xq12, MYC on 8q24.21, NCOA2 on 8q13.3 or CCND1 on 
11q13) [115, 164, 417]. Genetic changes within these genes are much more frequent in 
metastatic than localised cancers [121] and loss/inactivation of TP53 and gain/activating 
mutations of AR specifically associate with PCa metastases [138]. We did not detect 
genomic changes specific in these bone metastasis samples, which is in agreement with 
current understanding that metastatic PCas display similar genomic changes to primary 
tumours but with higher frequency [121, 138]. 
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7.1.2  11q13/CCND1 copy number gain and cyclin D1 expression in PCa  
The 11q13-14 gain detected in our 6 bone metastases is one of the most frequent gains 
in metastatic PCa, with CCND1 oncogene commonly considered as a potential driver for 
this alteration [138]. Our genome-wide analysis showed that samples with confirmed 
CCND1 copy number gain had also additional genomic changes within common 
CCND1/RB/CDKN2A and TP53/CDKN1A pathways controlling cell cycle progression, 
including losses within RB, CDKN2A (p16) and TP53 tumour suppressor genes. These 
multiple alterations within the same pathway would all result in increased cell proliferation 
highlighting their importance in PCa progression. Our further analysis of CCND1 copy 
number by FISH in larger cohorts of bone metastases as well as primary tumours 
revealed presence of CCND1 gain in over half of PCa bone metastases but also in a 
small number of primary tumours, suggesting that CCND1 gain can be an early event in 
PCa progression, which then becomes enriched in advanced tumours [138, 167].  
Immunostaining for cyclin D1 protein in these two cohorts showed common presence of 
a small subset of cells (around 20%) positive for cyclin D1, with stronger staining intensity 
in tumours with CCND1 gain and in bone metastases than primary tumours, confirming 
higher cyclin D1 activation in metastatic PCa [138]. Regardless of common cyclin D1 
overexpression and multiple studies confirming its role in tumorigenesis, we found no 
correlation between cyclin D1 immunoexpression and Gleason score, which is the main 
prognostic factor for PCa. Our results are in agreement with other studies [299-301] and 
could possibly be explained by the fact that cyclin D1 often plays a cooperative role in 
carcinogenesis with other oncogenes, e.g. MYC or Ras [269, 270]. Additionally, cyclin 
D1 is a known feedback inhibitor of the AR, leading to repression of androgen-dependent 
proliferation [268, 284, 285, 418]. Considering that PCa is driven by activation of AR 
pathway, there is now more evidence that cyclin D1b, an alternatively spliced variant of 
cyclin D1 compromised for AR regulation, is more oncogenic than full size cyclin D1a 
and associated with PCa progression and poor outcome [282, 419]. 
We did not observe the same trend in our limited number of fresh-frozen prostate tissues 
and found low levels of cyclin D1b expressed along cyclin D1a across all samples, 
including BPHs, primary tumours and bone metastases. Recent in vivo study suggests 
that simply the presence of cyclin D1b can promote tumour formation without need for 
its elevated levels [419]. Unfortunately proper analysis of cyclin D1b expression in clinical 
samples is currently hampered by lack of commercially available antibodies. 
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7.1.3 Role of FBXL4 loss in PCa  
Loss of 6q13-q22 is a common feature of PCa and is especially frequent in advanced 
mCRPC [119, 150, 151, 236, 306]. However, due to large size of deleted region it is 
difficult to identify the potential driver of this alteration. Here, using genome-wide 
approach, we managed to narrow down the location of the driver to a small deletion 
within 6q16, the only deleted region shared by all six bone metastases analysed and 
located within, FBXL4 gene.  
FBXL4 is a member of F-box protein family involved in protein ubiquitination and 
degradation although it hasn’t been widely studied and there are no reports linking it to 
cancer [314]. Here, for the first time we propose for FBXL4 to be a possible TSG in PCa. 
We found FBXL4 copy number loss a common feature of PCa bone metastases, which 
was also present at low frequency in primary tumours suggesting that FBXL4 loss is an 
early event in PCa carcinogenesis. Further analysis of FBXL4 loss in a large cohort of 
early stage conservatively managed localised PCas [216] showed that FBXL4 loss was 
significantly associated with poor PCa prognostic features and PCa specific death, 
suggesting its involvement in PCa progression. However, FBXL4 loss was not 
independent prognostic factor in multivariate analysis. Analysis of FBXL4 protein 
expression in clinical samples is currently hindered by lack of good commercial 
antibodies. We tested several commercial anti-FBXL4 antibodies and only one showed 
good level of specificity but still was not sensitive to small differences in protein levels 
based on knockdown in vitro experiments. Additionally, to confirm a tumour suppressor 
role of FBXL4 in vivo study is necessary, where mice are injected with PCa cells, e.g. 
22RV1 with or without FBXL4 knockdown and size and number of tumours is counted. If 
FBXL4 is a TSG then mice injected with FBXL4 knockdown cells should have 
more/bigger tumours than control animals.  
Using in vitro cell line models we showed that FBXL4 regulates cell motility and invasion 
but not proliferation. FBXL4 downregulation in PCa cell lines consistently led to increased 
PCa cell migration and invasion and this increased cell aggressiveness is in agreement 
with observed correlation of FBXL4 loss with aggressive metastatic PCa. Currently, it is 
not known how exactly FBXL4 regulates cells invasiveness but it could be due to 
regulation of ERLEC1 protein levels. ERLEC1 was previously identified as a FBXL4 
binding protein [321]. Using in vitro cell line models we confirmed that ERLEC1 is a 
degradation target of FBXL4 as ERLEC1 protein expression inversely correlated with 
FBXL4 expression levels. ERLEC1 is an ER chaperone involved in degradation of 
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misfolded proteins, leading to release of cellular stress [352, 353, 363]. In lung cancer 
ERLEC1 was identified as a novel cancer invasion and metastasis-related gene involved 
in increased cells tolerance to stress and protection from apoptosis [354]. Therefore, 
downregulation of FBXL4 in PCa cells would lead to stabilisation of ERLEC1 allowing 
malignant cells to efficiently respond to encountered stress such as hypoxia. 
Considering that homozygous loss of function mutations in FBXL4 lead to severe 
impairment of mitochondrial function including fragmentation of mitochondrial network 
[319, 320, 338, 370], FBXL4 is probably involved in mitochondria maintenance. We 
confirmed that FBXL4 associates with mitochondria. Mitochondria are in constant 
contact with ER and ER is actively involved in their fission [420, 421]. Mitochondria are 
also responsive to ER stress, adapting their function towards stress attenuation [350, 
351]. Therefore, downregulation of ERLEC1 protein levels by FBXL4 could be linked to 
normal mitochondria-ER dynamics. Moreover, mitochondrial network organisation, 
specifically its fragmentation levels are important for cell motility, with more fragmented 
network promoting cell migration and invasion [373, 374]. The relation between FBXL4 
and ERLEC1, especially in contest of cellular stress such as hypoxia or ER stress needs 
to be studied further. Further in vitro studies involving manipulation of FBXL4 and 
ERLEC1 protein levels are necessary to uncover the interplay between these proteins 
and their impact on mitochondria network integrity, cell invasion abilities and survival 
under stressful conditions.  
7.1.4  Conclusions 
In this study, by analysing PCa bone metastases using high-density microarrays, I found 
many genomic alterations shared by advanced metastatic PCa. Further analysis of two 
of these regions, 11q13 gain at CCND1 locus and 6q16 loss at FBXL4 locus in larger 
FFPE tissue cohorts of primary PCa and bone metastases, confirmed enrichment of 
these alterations in metastatic samples. While full length cyclin D1a expression doesn’t 
seem to correlate with Gleason score, studies of the possibly more oncogenic splice 
variant, cyclin D1b are currently hampered by lack of commercially available antibodies.  
The FBXL4 gene, which until now was never reported to be involved in cancer, seems 
to be a possible tumour suppressor in PCa, as its loss can be detected in a subset of 
early stage primary cancers, where it correlates with all poor PCa prognostic features 
and worse patient survival. My study shows, that the FBXL4 loss may contribute to PCa 
progression through increased cancer cells motility and invasion. Impact of FBXL4 on 
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cell invasiveness could be linked to its role in downregulation of ERLEC1, a protein 
involved in pro-survival ERAD pathway activated in response to stress. Therfore, loss of 
FBXL4 could be one of the mechanisms to increase cancer cells efficiency to respond to 
stress and to increase their metastatic potential through stabilisation of ERLEC1. Further 
analysis of FBXL4-ERLEC1 interactions could potentially help to develop novel targeted 
therapies for aggressive disease harbouring FBXL4 abnormalities. My findings give new 
insights into PCa progression, raising the potential to develop a novel biomarker to 
monitor disease progression and novel therapeutic approaches for this subgroup of 
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